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Abstract 
The field of nanomedicine has witnessed an incredible expansion, from a total market 
value in 2003 of $500 million expected to rise to $160 billion by 2015 (Global Industry 
Analysts, Inc.). The nanomedicine industry is forecasted to grow and have a significant 
impact on the economy, with sectors such as biomaterials, diagnostics and drug 
delivery expected to play a major role. This thesis gives a detailed account of the 
synthesis and characterisation of molecularly imprinted nanogels for drug delivery. 
Their toxicity and potential use as a targeted carrier to cancerous cells is evaluated.  
Initially an overview of nanomaterials and their uses in many areas such as agriculture, 
energy storage and technology are discussed. The impact of nanomaterials on the life 
sciences is examined; in particular their application in drug delivery is focussed upon. 
Chapters 2, 3 and 4 make up the results and discussion of this work. Chapter 2 
focuses on developing the synthesis of the acrylamide based nanogels and, vitally, 
incorporating a suitable fluorescent tag in order to track the nanogels in vitro and in 
vivo. Fundamentally toxicity studies carried out on the nanogels, both in vitro and in 
vivo in Danio rerio (zebrafish) are reported in Chapter 3 to ensure the nanogels are 
biocompatible. Chapter 4 introduces an innovative approach, molecular imprinting, to 
incorporating a drug into the nanogels. The upload and release of Tamoxifen (a drug 
used to treat breast cancer) at reduced pH, was also analysed. Finally future 
development of the carrier is discussed and key issues that need to be addressed. 
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1 Introduction 
1.1 Nanotechnology and its impact on developments and 
applications, especially in the life sciences 
1.1.1 Nanotechnology 
There has been a growing interest in a relatively new area of technology defined as 
nanotechnology. This interest has grown since it was discovered that materials, which 
are just nanometers in size, display unusual and interesting properties that 
macromolecules do not exhibit. Nanotechnology is difficult to define, however most 
scientists agree that it is “the study and control of manmade materials that are between 
1 and 100 nm in length” and these nanoscale proportions give the materials special 
properties1.  
Nanotechnology has had and continues to have a significant impact on our lives, 
improving it in many ways. Computers, for example, in the last few years have 
developed from a standard desktop to one that can fit in the palm of the hand, with 
devises such as the iPhone. 
1.1.2 A brief history of nanotechnology 
1.1.2.1 Early manifestations 
Some of the earliest nanotechnologists were ancient Romans (30 BC-640 AD) 
although they did not realise this at the time. The Lycurgus Cup, seen in figure 1, is a 
famous artefact that was found from this period which appears green when lit from 
outside the cup, however when a light is placed inside the cup it turns red: this effect is 
due to the glass containing gold and silver nanoparticles2. Other artefacts, which seem 
to be failed attempts at recreating this effect have also been found from this period 
(and no other successful examples have been discovered) so the cup is believed to 
have been created by accident. Stained glass windows were produced throughout the 
medieval period (500-1450 AD) and are formed by metal nanoparticles being trapped 
in a glass matrix. Gold nanoparticles formed the red glass and silver nanoparticles 
formed the yellow glass. It is because the metals are in nanoparticulate form that they 
exhibit these colours and later it became known as just one of many differences in 
properties of metals between their macromolecular states. However it was Michael 
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Faraday who realised, in the mid 1800’s, that gold colloids, now known to be 
nanoparticles had special optical and electrical properties3.  
Figure 1 - The Lycurgus cup, A) is without a light inside and B) with a light inside, showing the 
special optical properties of the gold nanoparticles3. 
1.1.2.2  Nanotechnology consciously used 
It was not until 1959 that the concept of nanotechnology was originally thought of and 
consciously used. Richard Feynman was an American physicist who, with Julian 
Schwinger and Sin-Itiro Tomonaga, won the Nobel Prize in 1965 for their work on 
quantum electrodynamics.4 Feynman is famous for a lecture he gave entitled ‘There’s 
plenty of room at the bottom’, in which Feynman described the possibility of writing out 
the entire Britannica encyclopaedia on the head of a pin.5 He also described the 
possibility of miniaturising the computer (which at that time was as big as a room) using 
machines to control smaller machines to manipulate individual atoms and molecules. 
This idea only became a reality 30 years later, in 1990, when Don Eigler (who worked 
for IBM) discovered that he could use a scanning tunnelling microscope (STM) to move 
single atoms around to form the letters of his employer, an image of which can be seen 
in figure 2.6  
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Figure 2 - Image captured by Don Eigler when he moved single atoms around, using a 
scanning tunnelling microscope, to form the letters of his employer, IBM.7 
1.1.2.3 Nanotechnology formally defined 
Nanotechnology was not given its name until 1974 when Norio Taniguchi, a Science 
University Professor in Tokyo, defined the term ‘nanotechnology’ in a paper, he wrote: 
 “Nano-technology mainly consists of the processing of, separation, consolidation, and 
deformation of materials by one atom or molecule.”8  
This is still used as a basic definition of nanotechnology today although it has evolved 
over time, for example, to include materials up to 100 nm.8  
In November 1996 it was attempted to coordinate all work on the nanoscale as 
members of several agencies met regularly to discuss developments made. This group 
continued to meet informally until September 1998 when it was named officially as the 
Interagency Working Group on Nanotechnology (IWGN) under the National Science 
and Technology Council (NSTC). In August 1999 the group submitted the first draft of a 
plan of an initiative in nanotechnology to the President’s Council of Advisors for 
Science and Technology (PCAST) which ended in the group gaining substantial 
funding in its 2001 submission to congress and the Clinton administration raised the 
level of nanoscale science and technology to federal initiative.9 Since 2001 
nanotechnology has developed vastly in many areas, including life sciences, 
pharmaceuticals and drug delivery.  
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1.2 Applications of nanotechnology in different areas 
1.2.1 Nanotechnology in agriculture 
Nano science has benefited many areas of research and human life. One area of 
science that has benefited from the developments in nanotechnology is agriculture. 
When analysing the amount of published/patented research in agriculture, the majority 
of research has been on plant protection products rather than fertilizers, which 
accounted for less than a quarter of the research focus. Nanotechnology has helped 
plant protection by assisting with the dispersion, protection and controlling the release 
of actives as well as aiding photocatalysis.10 All these developments have had great 
effects on increasing output and maintaining the health of crops.11 However, this is just 
one small area of research. Another area of research that is seeing huge change, due 
to research at the nano scale, is energy. 
1.2.2 Nanotechnology and energy efficiency 
Energy, its storage and conversion from one form to another, is currently a very 
lucrative and seductive area of research and has benefited tremendously from the 
developments in nano science. Nanotechnology has been exploited in the conversion 
of solar energy to electricity.12, 13 This is because much of the solar energy, which hits a 
solar panel, is not absorbed. This can be due either to some photons having too little 
energy to allow absorbtion, or some with very high energy, being only partially 
absorbed meaning that some energy is therefore wasted. Nanomaterials are being 
developed to try to make the process more efficient and utilise as much of the energy 
as possible.13  
The finite resource of fossil fuels available is rapidly running out and therefore finding 
new ways of converting natural sources of energy and storing it is fundamental to 
sustaining and improving quality of life. It is here that nanomaterials, due to their small 
size and special characteristics, are enabling new, ever improved batteries that can last 
longer and store more energy, significantly enough to power electric cars.14 However 
batteries are merely one example of improvements in energy usage that have seen the 
benefit that nanomaterials can bring: technology in general has developed rapidly since 
developments in the nano world. 
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1.2.3 Nanotechnology and computer science 
Information technology and computing have completely changed our lives in the last 
couple of decades, enabling computers to be reduced from the size of a room to 
remarkably powerful hand-held phones, tablets and laptops.  
1.2.4 Moore’s Prediction 
It was Moore in 1965 who suggested that the size of features in devices would reduce 
by a factor of 0.7 every three years, which has turned out to be true with components 
decreasing in size in line with this prediction, as shown by the graph in figure 3, and 
companies use Moore’s exponential decrease as targets to keep up with competitors.15 
This appears to be tailing off due to lithography limitations. Lithography in electronics is 
where silicon wafers (used to make chips) are coated in a light-sensitive layer. Light is 
shined through a stencil, or mask, burning the photoresist away in undesired areas, 
after which they are etched away. However in order to do this a UV-light with 193 nm 
wavelength is required. Therefore the limit is imposed by the wavelength of the light 
and the size of the mask. A Dutch company is currently working on a technique they 
believe will be ready by 2015 on using 10 nm masks and an EUV light with a 
wavelength of 13.5 nm which will enable the trend to continue for a few more years.16  
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Figure 3 – A graph to show the trend in electronics conforming to Moore’s prediction in 196517. 
In turn, such advances in technology have indirectly benefited many other areas of our 
lives (including those of energy storage, agriculture). The trend towards smaller and 
smaller devices directly impact business practice and human life in the wider sense, as 
there are few jobs or activities that these days do not at one time or another require the 
use of information technology or a computer, even if it is just to communicate. 
Nanotechnology has demonstrably benefited human life in a variety of fields and one 
further very important area where its research and development has had a huge impact 
is that of health and the life sciences.  
 
1.2.5 Nanotechnology and its use in the life sciences 
The UK has one of the most successful Life Sciences industries viewed from the global 
perspective. Life Sciences includes everything from synthetic and industrial 
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biotechnology through pharmaceuticals to medical devices and diagnostics. The UK 
Life Sciences industry is growing faster than the UK economy in general, with an 
annual turnover of more than £50bn. In global terms, Life Sciences are having to 
change rapidly in direct response to lifestyle changes, extended life expectancy and 
contemporary rises in chronic conditions such as diabetes, obesity and dementia. To 
address these important issues, traditional methods are no longer suitable or sufficient.  
Advances in computing and rapid developments in genomics are opening up new and 
exciting areas for research in medicine. However, because these materials are 
required to be ever more sophisticated the research is becoming ever more expensive 
and time consuming. Older methods and research for ‘one drug fits all’ is no longer 
appropriate. The possibility of, and consequent need for, more cleverly tailored drugs 
and medicines to target specific genes and genetic characteristics are slowly becoming 
a reality. Due to these significant changes in approach, and with the new perspective 
offered by nanotechnological thinking, we are obtaining increasing knowledge on how 
different medications affect different people in different ways. This makes it ever more 
difficult to jump through all the necessary rules and regulations to actually get the 
medication to market and guarantee its safety. It now takes on average 20 years and 
$1bn to develop a new drug.18  
Nanotechnology and the special properties nanomaterials possess give great 
opportunities to accomplishing some of these tailored medicines. However introducing 
nanomaterials into the drug market raises several issues including the question of 
intellectual property rights. Traditionally pharmaceuticals would go through a 7 step 
model, presented in figure 4, and take approximately 9 years between identification of 
a drug and its large scale use in healthcare. 
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Figure 4 - 7 step diagram showing the development stages of a drug.19 
When nanomaterials are added into this model, it significantly increases the timeframe 
of getting the drug to market and therefore there is often only a year or two before the 
drug patent expires. This therefore greatly limits the profits made by the pharmaceutical 
company. One way in which the market is bypassing this problem is the formation of 
many SME’s dealing in nanotechnologies and them licensing their technology to larger 
pharmaceutical companies to get a drug to market, substantially reducing the time and 
cost incurred by the drug developer.20 The UK government is also aware that SME’s 
developing new diagnostics and treatments can be crippled by the cost of phase III 
clinical trials, meaning many, particularly personalised, therapies are never being put 
into use due to financial constraints. The government is working alongside the EU to 
support innovative materials and methods to treat, diagnose and prevent terminal or 
seriously debilitating diseases by fast-tracking these medicines through conditional 
authorisation or accelerated assessment of products where there are currently no 
effective therapies.18  
Not only are the government fast-tracking very promising research in the life sciences 
but they are also keen to pump money into SME’s in the early years when their main 
Identify theraputic agent 
Generate active molecule and patent 
Develop formulations and products 
Prove efficacy and saftey 
Licence the technology 
Market the product 
Build value through use and indictations of further work 
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focus is on research and development and therefore their income is limited. This period 
in a SME’s lifetime is often referred to as the ‘Valley of Death’ and means that 
numerous potential new therapies are ‘dead in the water’ before commercialisation is 
even a possibility. The government’s willingness to allocate millions of pounds to life 
sciences research shows just how important this research is, both for maintaining 
human life but also by stimulating the economy. Nanotechnology accounts for more 
and more of the life sciences sector. For example, in drug delivery alone 
Nanotechnology was forecasted in 2008 to account for 11% of the total market in 
201220 and the sector is still growing rapidly. 
Nanotechnology and its rapid development has had a huge effect on the life sciences 
and transitioning medicines from a ‘one for all’ mentality to personalised medicines. 
Nanotechnology has great potential for many applications in the life sciences, not just 
drug delivery, including cosmetics, imaging21, 22, sensors23, dentistry, and more. The 
development of nanotechnology over the last 30 years has seen huge benefit to the life 
sciences and human health and has been gathered together under a new term, 
nanomedicine. 
 
1.3 Applications of nanotechnology in medicine 
Nanomedicine is a relatively new term which covers the medical application of 
nanotechnology.24 Nanomedicine covers a variety of materials and structures, many of 
which existed before the term. Although some nanomedicines have been researched 
for the last three decades or more, and nanomedicines have rapidly developed in the 
last decade, many applications still have not made it to regular clinical use25 because 
there is a large concern surrounding the toxicity of nanomaterials both long term to the 
environment and also their effects in the body.    
There are 5 main areas of development in nanomedicine that are enabling the 
development of personalised treatments, biomarkers, miniature biochips and the 
development of nanomaterials for drug delivery, diagnostics and regenerative 
medicine. Research into biomarkers has been incredibly important to pinpoint signs the 
body gives off that a problem exists and therefore detection and treatment is occurring 
faster and earlier than ever before. 
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Biomarkers are biological molecules that are found in blood, fluids or tissues in the 
body that indicate that a particular condition or disease is absent/present or even just 
signals that a normal or abnormal process is occurring in the body. Biomarkers can be 
related, but not limited, to DNA, RNA, epigenetic changes, protein and antibody 
expression. These biomarkers are used in many ways for medical purposes: one 
important development in using biomarkers is detecting colon cancer by using a 
biomarker in the blood,26 as a new ‘simple’ blood test enhances the patient’s 
compliance over what would previously have involved complex and uncomfortable 
internal investigations. Biomarkers have also been established both in the blood and in 
serum both to indicate increased risk of developing cardiovascular disease and also as 
indicators that a blood vessel leading to the heart is blocked, since identifiable 
biomarkers are released in the blood.26 Blood markers for Alzheimer’s is also currently 
being researched to try to diagnose and treat the condition earlier and more 
efficiently.27 Research into biomarkers is facilitating faster and earlier diagnosis of 
many life threatening and life altering diseases helping to prolong life and to maintain a 
better quality of life for longer.28, 29,30 One big area of research for biomarkers is that 
related to cancer. A breakdown of patents currently filed, according to a report by John 
bates in 2008 can be seen in figure 5. 
 
Figure 5 - Biomarker patent filings according to type of cancer.31 
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Much research has also gone into the design and application of biochips. Biochips are 
essentially a microchip that is, often but not only, designed to work in a biological 
environment for example inside living organisms. Some of the most well-known 
biochips are those used to identify animals however, more recently biochips have been 
developed in medicine, for use in biosensing.32 One of the first biosensors was for 
glucose. In this case it was just the probe that was inserted into the body.33 More 
recent medical research is an investigation of the incorporation of entire sensors onto a 
biochip, which would then need to be coated in a biocompatible material in order to 
protect both the sensor and the person in which the sensor is to be inserted from 
degradation and leakage.32 
These developments in nanomedicine are highly significant in terms of the changes in 
approach, allowing treatments that, before the ‘discovery’ of nanotechnology, simply 
would not have been possible. The development of vast numbers of nanomaterials that 
has dramatically expanded research in nanomedicine, particularly in drug delivery, 
diagnostics and regenerative medicine.  
1.3.1 Drug delivery  
Nanotechnology potentially offers major benefits in drug delivery due to the unique 
properties of nanomaterials. However, due to the extensive testing and research 
needed to produce drugs, pharmaceutical companies are reluctant to then spend the 
same amount of time and money on a delivery device, in effect doubling the time and 
cost needed to produce the drug alone.19  Drug delivery methods are therefore very 
much seen as a secondary and conservative area of research.  However the delivery of 
a drug can be fundamental in whether the drug itself is useable and therefore could be 
the lifesaving ingredient in many cases. For example free drugs are often insoluble in 
water. This limitation can prevent a drug from being able to be administered altogether. 
Where the administration of some free drugs is possible the lack of bioavailability often 
hinders their ability to work to their full potential. Nanomaterials can help overcome 
both of these issues by making administration of otherwise resistant drugs possible, in 
addition to making target-specific drugs with controlled or directed delivery and hence 
improving their efficiency.  
1.3.1.1 Traditional delivery methods 
There are five major routes for drug delivery, parental injection, oral (absorption 
through the gastrointestinal tract), transdermal, transmucosal and pulmonary delivery. 
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Each has its advantages and disadvantages. Delivering drugs via injection, for 
example, is the most widely used administrative method. However, most of the time it 
needs to be done by a medical professional, it is not well liked by patients and can 
cause local damage to the skin and other tissues and runs a minor risk of infection at 
the administered site. Oral delivery is normally the preferred route for administration but 
preventing degradation of the drug in the gut/upper GI tract can be a problem when 
treating cancer of the colon. Oral administration is a preferred route of administration 
for patients over inserting a lower intestine suppository. Therefore if these degradation 
problems can be overcome and a delivery system can bypass these two sections 
without degradation and/or absorption of the drug and then, in addition to these two 
factors the drug is released directly and only in the colon itself, then there is great 
potential for application of the system.19  
Transdermal delivery, through the skin, has been available for the past couple of 
decades and patient compliance is high as it is painless and user-friendly. This method 
of delivery is also advantageous as it gives a slow steady release of a drug keeping 
concentrations in the blood consistent19. Limitations relating to skin permeation are a 
constraint and drug incorporation can itself be poor in patches and creams. If a high 
concentration of drug is required and required quickly an alternative administrative 
route would need to be used. Transmucosal delivery can overcome the permeability 
problems of the skin as buccal mucosa, which lines the inside cheeks, is 40000 times 
more permeable. Oral, nasal, rectal, vaginal and ocular cavities are all used as routes 
to deliver drugs and huge amounts of research has been put into each. Saliva is also 
highly useful for dissolving medications as humans produce between 0.5 and 2 litres 
every day, which is essentially water based and can be used to hydrate drugs 
administered through oral mucosa. The last area for drug delivery is directly into the 
lungs, pulmonary delivery, which have a huge surface area allowing for good drug 
absorption and drugs can be self administered. The major challenge in this delivery 
route is to avoid phagocytosis and other systems protecting the body from foreign 
bodies. Nanomaterials can be used to help deliver drugs in all of these routes, 
overcoming the associated issues.  
1.3.1.2 New, ‘nano’ delivery methods 
Nanotechnology has completely revolutionised drug delivery. For example if a drug 
was desired to be administered orally (which has the best patient compliance) and the 
drug was not water-soluble or it could not pass through the lining of the digestive 
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system, a drug, which had proven efficacy, would have been unusable since getting the 
drug to the required site was impossible using this administration route. With so much 
research now carried out at the nano scale, more and more drugs have become 
available for treatments because nanocarriers can deliver the drug to the target site 
faster and with pinpoint accuracy34. Not only this, such drug delivery devices can help 
reduce side effects, increase bioavailability by comparison with the free drug and 
enable more sophisticated treatments than ever before. Examples of nanomaterials 
and their use in drug delivery are described in section 1.5 of this chapter.  
1.3.2 Diagnostics 
Drug delivery is not the only application in which nanomaterials are used in medicine. 
Many nanomaterials are also used for sensing. Early-stage detection and diagnosis of 
disease-related biomarkers is an important area of research to help to preserve life and 
the development and functionalisation of nanomaterials is making this a possibility.35 
Biosensing has seen significant changes over the last decade due to the development 
and integration of nanomaterials. A biosensor is a device that couples the recognition 
element (a biological receptor) with a chemical or physical transducer, see figure 6. 
These two elements work together to give a concentration of a target analyte by 
measuring a biological response.36 As nanomaterials can be ‘tailor-made’ for size, 
shape, surface charge, physiochemical characteristics and even attach polymers or 
bioactive molecules such as antibodies, increasing their biocompatibility, they have 
become highly attractive for use in biosensing. Paper-based biosensors are of 
particular interest due to paper being so cheap and accessible. One of the first and 
most well-known paper based sensor is the pregnancy test, readily available to all and 
easy to use as a diagnostic tool, which detects human chorionic gonadotropin 
produced by a fertilised ovum.37  
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Figure 6 – A diagram to show the basic mechanism of  common biosensors. 
 
1.3.3 Tissue engineering and regenerative medicine 
Tissue engineering is a relatively new area of research, which essentially follows on 
from medical treatments such as skin grafts and can now mean like-for-like tissue can 
be used,38 speed up healing times39 and also help prevent tissue rejection.40 Tissue 
engineering was first given its name in the 1980’s but at the turn of the century another 
term, ‘regenerative medicine’ also became widespread.41, 42 Tissue engineering uses 
many different methods but the use of biomaterials as scaffolds to support and 
encourage tissue growth is commonly accepted as one of the most important of these.  
There are two man approaches to tissue engineering. The first is where tissue is 
harvested from the body and the cells are loaded onto biomaterials in vitro, allowed to 
grow and expand on the scaffold, after which the tissue is then replaced in the body 
and helps to speed up the healing process. The alternative method is to place the 
scaffold in the body at the site of required regeneration of cells in order to encourage 
growth at the damaged site. In both cases the biocompatible scaffold decomposes in 
the body over time, at which point it purpose has been served. The biomaterials used 
in tissue engineering and regenerative medicine are vast in number and have different 
characteristics according to the tissue that is in need of repair.43 In some instances 
differentiated cells are used that are identical to that of the target site, in others stem 
cells are used and manipulated to develop into the required tissue.44  
One area of tissue engineering which is notoriously difficult to achieve, is that of bone 
regeneration. Saiz et al discuss developments in bone regeneration which has been 
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Apply electrical current Measure the final current
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substrate present)
Substrate Product
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proven difficult to accomplish.  In the paper they demonstrate the need for a 
biocompatible scaffold, which in turn needs some signals, to promote cell growth and 
prevent scaffold rejection (often delivered by nanomaterials) before cells are, normally, 
injected into the scaffold, shown in figure 7.45  
 
Figure 7- The components required for successful cell growth and bone regeneration.45 
 
1.4 Advances in nanomaterials 
Nanomaterials are at the forefront of research in nanotechnology and are 
indispensable in biological and medical applications46 due to their size and properties. 
Nanomaterials are “materials (polymers, semiconductors, ceramics, oxides, metals, 
etc.) with particle sizes in the 1–100 nm range in at least one dimension”. 
Functionalised nanomaterials are completely transforming many areas of science. 
Indicative of this boom in nanoscience is the fact that between 1990 (when there were 
zero) and March 2012, 161 Journals covering research in the ‘nano’ area were 
created.47 There are many different nanomaterials that now exist, too many to cover all 
of them in the introduction of this thesis, however there are three main categories into 
which most nanomaterials fall, carbon-based, inorganic and polymeric-based 
nanomaterials. Many nanomaterials use combinations of these materials, and some fall 
outside of these categories. Here are just a few examples of some nanomaterials and 
their impact on life science. 
1.4.1 Carbon based nanomaterials 
Some of the first nanomaterials to be discovered were fullerenes. These were initially 
discovered by Prof. R.F. Curl, R.E. Smalley and Sir H. W. Kroto in 1985, for which they 
received the Nobel Prize in 1996.48 Fullerenes can be in the form of a sphere, ellipsoid 
or tube that are made wholly of carbon and are hollow. The spherical fullerenes are 
also known as ‘bucky balls’, both were named after Richard Buckminster Fuller, who 
was an American architect,49 due to their similarity to his geodesic domes. The C60 
spherical fullerene is of particular interest in medicine due several potential exploitable 
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features. One of these is the C60’s ability to fit inside the hydrophobic cavity of HIV 
proteases, which in turn blocks the catalytic enzyme site, inhibiting the substrate. 
Fullerenes also have the ability to carry genes/ drugs, used in diagnostics and are also 
able to cleave DNA due to their ability to produce singlet oxygen in the presence of 
light combined with direct electron transfer from the fullerene and DNA bases excited 
state. However their solubility is limited, methods such as encapsulation, suspension 
(using co-solvent methods) and chemical functionalisation have helped overcome this 
to a certain degree.48  
Carbon nanotubes were developed not long after the discovery of fullerenes, in 1991.50 
There are two types of carbon nanotubes – single walled carbon nanotubes (SWCNT) 
and multiwalled carbon nanotubes (MWCNT).51 SWCNTs are formed from a single 
graphite sheet rolled into a seamless cylinder and MWCNTs are made up of several 
graphite sheets each rolled into a cylinder inside one another with differing diameters 
up to 100nm. The length of the nanotubes can vary from a few nanometers to a few 
micrometers. Carbon nanotubes can be functionalised covalently and non-covalently to 
improve their solubility and also have the potential to be used in medical imaging.52, 53 
Carbon nanotubes also conduct electricity which gives them potential as conductive 
scaffolds, conducting electrical signals across tissue constructs enabling 
electrophysical functions in certain cells such as neurons and cardiac tissue.53 
Another carbon based nanomaterial are nanodiamonds. Nanodiamonds are diamond 
powders that have been formed by detonating diamonds to between 5-100 nm, they 
vary in their purity depending on how they are isolated from impurities after detonation. 
Nanodiamonds can be ground through milling and then dispersed in water to form a 
colloidal solution. Water can then be removed to a greater or lesser extent to form a gel 
of the required density. Even if almost all water is removed (down to 2-3% the 
nanodiamonds will readily redisperse in water,54 giving them ideal characteristics for 
medical applications, the process of formation is presented in figure 8. Nanodiamonds 
can also be oxidised and carboxylated in strong acid to make them hydrophilic. They 
can be further functionised either covalently or non-covalently to enable a drug to be 
adsorbed onto their surface.55 Nanodiamonds have been explored for use in drug 
delivery both for the delivery of small molecules such as doxorubicin56 for cancer 
therapies and also have shown protein release. Insulin is being investigated as a 
potential wound healing agent by way of promoting the formation of blood vessels. 
Insulin has been shown to be released from nanodiamonds at basic pH,57 which is 
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often observed when a wound becomes infected by bacteria. Nanodiamonds have also 
been explored for imaging purposes.58 Gd(III) is used as a contrast agent providing 
cells that are similar magnetically but have different histology in magnetic resonance 
imaging (MRI). When covalently bound to nanodiamonds Gd(III) has shown an almost 
10-fold increase in sensitivity over free Gd(III).59 
 
Figure 8 – formation of nanodiamonds and method to obtain a colloidal solution and soft or 
hard gels containg nanodiamonds.54  
 
Although carbon based nanomaterials have shown great potential for medical 
applications they can suffer from poor solubility and are often found to be quite toxic in 
vitro59 and are expensive and/or time consuming to obtain. Another set of 
nanomaterials with promising attributes for use in the life sciences is that of inorganic 
nanomaterials. 
1.4.2 Inorganic nanomaterials 
There are many different inorganic nanomaterials. One type which has shown great 
promise in advancing medicine is silicon-based nanoparticles. Silicon oxides are the 
main component of both sand and quartz and make up for 90 % of the earth’s crust. It’s 
high availability and therefore low cost along with the unique chemical and physical 
properties of silicon-based materials means it has been used in many applications from 
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construction and electrics to food and biomedical science.60 One example of how 
silicon has been exploited using nanotechnology is its use in NanoceuticalsTM 
Microbright tooth powder.  This commercial product contains nano-scaled molecular 
cages (1-5 nm in diameter) made of silica-mineral hydride that reduces acid that 
remains on the teeth from food and therefore helps to protect the enamel.60 
Mechanised mesoporous silica nanoparticles (MSNPs) have a high surface to volume 
ratio giving a higher surface functionalisation whilst having great porosity in which a 
significant amount of material can be carried whilst maintaining its stability.61 One way 
in which these NPs are formed is to use a cationic surfactant as a micellular template 
and then condense silica around the template before removing the template to give 
porous particles of between 50 nm and 2 µm. The NP’s can be functionalised during 
formation or surface functionalised afterwards. Drugs can be loaded into the porous 
structure and functionalisation of the MSNPs can allow targeted delivery of a drug.61 
However some studies have found some silica NPs to be toxic in vitro, with indications 
that the smaller the size and the higher the dose (up to 1 mg/ml was tested) the higher 
the cell mortality rate.62  
Another well established type of inorganic NPs are gold nanoparticles. Au NP’s have 
different properties at the nanoscale compared with bulk gold due to their size and 
shape. Metal NP’s in general exhibit unique electronic, catalytic or optical properties 
depending on the metal and size of the core. Gold is of particular interest due to its 
localised surface plasmon resonance (LSPR), which is where the conduction-band 
electrons in the metal coherently oscillate when exposed to an incident light. This 
results in strong absorbance and scattering of the light and in the case of gold the light 
is emitted in the visible region when the Au core is between 3 and 200 nm in size. This 
gives Au NP’s great potential in colorimetric sensing applications and as biological 
contrast agents. One example where Au NP’s have been used for DNA detection is 
where the gold NP’s have been functionalised with a single strand of oligonucleotide. 
These Au NP’s have shown to be an effective diagnostic for Escherichia coli present in 
human urine. The NP’s turn the solution red if it is present, and aggregate forming a 
purple solution if it is not, with a sensitivity of 54 ng.63 The LSPR of gold NP’s can also 
be tailed to the near-infrared region meaning they have potential application in in vivo 
imaging and photothermal treatments.47  
Some of the most reported inorganic nanoparticles are mainly composed of silica or 
alumina, although the core can contain metals, metal oxides and metal sulfides. Due to 
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all the possible variations (size, shape, porosity etc) in inorganic nanoparticles an 
immeasurable number of different nanoparticles can be formed which gives them great 
potential as drug delivery aids.  For example it has been shown that ibuprofen can be 
taken up by the mesoporous silica based molecular sieve MCM-41 (Mobile Crystalline 
Material 41) and released into body fluids after 3 days, controlling the drug’s release.64 
SEM and TEM images of these can be seen in figure 9. Inorganic nanoparticles tend to 
be very stable across a broad range of temperatures and pH, however they do not 
biodegrade and have slow dissolution rates which causes concern for long term 
administration.65 Some nanomaterials which have very rapid dissolution rates are 
polymeric-based nanomaterials formed via microemulsion.66 
 
Figure 9 – A SEM image of MCM-41 (a) and a TEM image of MCM-41 (b)61 
 
1.4.3 Polymeric-based nanomaterials for use in nanomedicine 
Polymeric nanomaterials formed via oil in water and/or water in oil microemulsions can 
contain lipids, polymers and/or surfactants and have been developed for many 
applications. One such nanomaterial are solid lipid nanomaterials (SLN) these can be 
formed by using a lipid with a low melting point and forming a warm oil in water 
emulsion. The lipid can be loaded with an ‘active’ (such as a drug or tracking agent) 
either throughout the matrix, shown in figure 10, or in the lipid core or shell depending 
on how the SLN is formed.66 Solid lipid nanoparticles can have a hydrophobic lipid core 
(which remains solid at both room and body temperature) with a monolayer of 
phospholipids surrounding them. These nanoparticles are prevented from aggregating 
by the addition of surfactants. The release profile of the active payload can be 
controlled by how much surfactant is incorporated into the nanoparticles when they are 
formed. Solid lipid nanoparticles biodegrade easily and are therefore less toxic than 
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some other nanoparticle formats.65 SLN have been used for different applications in 
nanomedicine, one of which is drug delivery. Shuhendler et al have also found that by 
using solid polymer-lipid nanoparticles to deliver cancer drugs, doxorubicin and 
mitomycin C, resulted in a 20-30 fold decrease of drug that was required in comparison 
to the free drugs.67 SLN’s have been shown to increase absorption of drug when 
administered orally, increase drug circulation time and also increase the amount of 
drug crossing the blood brain barrier (BBB).68 SNL have not only been used for drug 
delivery but have also been exploited in medical imaging. SLN’s were developed by 
Gasco et al for use in imaging, enabling contrast agents to cross the BBB that normally 
do not, allowing MRI scanning of the brain.69 
 
Figure 10 - A diagram of how a drug is incorporated into a solid lipid nanoparticle.70 
Micelles and vesicles are all self-assembling polymeric nanomaterials, which have 
been developed over several decades. Micelles are normally formed from block-
copolymers,71 which form a monolayer with a hydrophilic head in contact with water 
and the hydrophobic tail, which can incorporate a hydrophobic active, on the interior, 
demonstrated in figure 11.  An example of this are sterically stabilised micelles (SSM) 
which were developed to carry poorly soluble Camptothecin.72 Micelles which are 
formed from synthesized co-block polymers vary in size and shape depending on their 
structure and the method used to form the aggregates.73 Micelles have been evaluated 
for their use as permeable membranes, where co-block polymers have previously 
shown great potential in gas permeation and fuel cells amongst other applications. 
More recently micellula membranes have been formed which have acute pore size 
distribution and can respond to pH and temperature changes.74 Other applications of 
micelles include 2D/3D coatings,75 detection,76 imaging77, 78 and of course drug 
delivery.77, 79-81 
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Figure 11 – Structure of a micelle and a liposome. 
Liposomes are related to micelles in that they self-assemble, however unlike micelles 
liposomes have a bilayer, which has hydrophilic heads both inside and out and a 
hydrophobic layer in between the two, shown in figure 11. Liposomes are often formed 
from polymers and phospholipids.82  Hydrophilic compounds can be retained in the 
centre of the liposomes or hydrophobic compounds can be contained within liposome 
wall, but these can escape encapsulation by diffusing through the phospholipid 
membrane.82 Liposomes are biocompatible vesicles therefore have good potential for 
medical applications. One area of great interest with liposomes is drug delivery due to 
the potential of liposomes to increase the circulation life of proteins and peptide. 
Inclusion of these molecules is made possible due to their amphiphilic nature and their 
ease of surface modification.65 Mirahmadi et al investigated using liposomes as 
potential carriers for cancer drugs to treat peritoneal carcinomatosis and were found to 
be 15.51 times more effective than the free drug.83 Some lysosomes have been 
modified with polymers84 and other substituents to help improve drug targeting and 
release,85 nutrient sensing, signalling and metabolism.86  
Another polymeric based nanomaterial with potential in nanomedicine is that of 
polymeric nanoparticles (PNs).  PNs are formed in two ways, either using preformed 
polymers, or creating the polymer from its basic units, monomers. In the latter case the 
polymer is formed at the same time as the nanoparticles, using a ‘bottom up’ approach 
building the nanomaterial from its building blocks.  Using this approach polymeric 
nanomaterials such as dendrimers and nanogels can be synthesised,87 each of which 
have shown promise in nanomedicine. Dendrimers for example are branched polymers 
that are grown outwards from a central core (or in reverse starting at the periphery and 
polymerising to the core) to form a ‘spherical’ polymer. Depending on how many 
fragments are attached to form the dendrimer, the dendrimer is grown to a certain 
generation, often to a 3rd or 4th generation (3G, 4G). These have shown promise in for 
Micelle: Hyrophillic outter layer
Hydophobic inner layer
Liposome: Hydrophillic outer 
layer and core. Central layer 
hydrophobic.
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use as contrast agents in MRI imaging,88 delivering agents to stem cells to aid their 
proliferation and differentiation,89 for use in microbiocides for HIV and STI prevention87, 
90 and also in drug delivery.91  
 
Figure 12 – structure of a dendrimer 
 
Using preformed polymers to create nanoparticle dispersions can also be achieved. In 
this method the polymers are dissolved in a solvent (such as water) and the drug is 
dissolved in a solvent, which is immiscible to the first solvent (such as chloroform), an 
emulsion is then formed either spontaneously (depending on the solvents used and 
method chosen) or with intense mixing for example with a sonicatior. In some cases 
nanoparticles remain in the emulsion, in others the organic solvent is removed to leave 
a dispersion in water (if that is one of the original solvents) and finally both solvents can 
be removed (for example by freeze drying or spray drying the emulsion),92 leaving a 
solid which when re-dispersed in water gives a nanoparticulate solution. These all 
produce particles where the active is suspended in a solution stabilised with polymers 
and surfactants to prevent the particles from aggregating.93  
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Figure 13 - How organic nanoparticles are stabilized when they are re-dispersed in water. 
Another method involves monomers, such as methyl cyanoacrylate, being dispersed in 
an acidic aqueous medium with a surfactant and no initiator. This dispersion is added 
to an aqueous solution of surface-active agent containing the active ingredient and 
stirred vigorously to induce polymerisation. This gives mixed particles of active and 
polymer. The mixture is centrifuged to remove the surfactant and any excess of 
monomer or active.93 These polymeric nanoparticles have been developed for use in 
biomedical imaging94 and drug delivery.95 Many of these nanomaterials have shown 
potential application in drug delivery due to their unique properties. 
1.5 Nanoparticles and their use in drug delivery 
Drugs have obvious benefits for improving and sustaining life and much research has 
been carried out to develop more and more drugs to combat an ever increasing 
number of illnesses. However, many drugs produced, although proven in vitro to have 
positive effects in fighting the disease, have difficulties when administered to the body. 
For example some drugs are not water soluble and therefore injecting them into the 
body becomes very difficult. Other drugs can be administered but once in the body 
have poor bioavailability.  In order to compensate for the lack of uptake of the drug the 
patient is in effect given an overdose of the drug to ensure enough of the medicine is 
present within the body to obtain the desired effect on the diseased tissue. It is 
therefore becoming increasingly important to find not just new drugs but also new 
delivery methods which can overcome these problems that hinder otherwise very 
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promising medicines. Due to this gap between possibly life saving treatments and the 
ability to deliver them effectively to the body huge efforts have been put into generating 
synthetic materials, such as micelles and polymer nanoparticles. 
Materials for drug delivery are normally considered to be suitable if their size is ≤200 
nm due to the width of microcapillaries in the body.96 This allows the drug to be carried 
in the blood stream to any location within the body.  Most research in this area has 
been focussed on naturally and synthetically derived polymeric nanoparticles due to 
their high stability and because surface modification can be carried out easily. Different 
polymer nanoparticle formats have been or are being developed to exhibit different 
required properties such as controlled release, sustained release, disease specific 
localisation, to accumulate at specific site (for example in tumours), improve 
bioavailability and/or solubilise drugs for systemic delivery.19, 96 Nanoparticles have 
advantages over microparticles in drug delivery due to their small size. Nanoparticles 
are not only taken up by cells more efficiently but are also taken up by a wider variety 
of cells and intracellular components more than microparticles. Nanoparticles also 
open up the possibility of carrying drugs to difficult locations in the body such as 
crossing the blood-brain barrier. 96 
Once the drug has been loaded onto the nanoparticle and been delivered to the 
required site it is important that the carrier is then degraded or excreted from the body. 
This is to avoid the nanoparticles from building up inside the body, where they may 
become toxic over time and cause problems in the long term, particularly in drugs that 
are administered over a prolonged period. Biodegradable polymers for drug delivery 
systems have been researched for several decades. These are often polymers that 
degrade or are catabolised down to carbon dioxide and water by naturally occurring 
microorganisms such as bacteria and fungi.  
Nanoparticles have great potential in nanomedicine for controlling drug release, 
targeting drugs to specific sites and also protecting labile molecules from degrading 
(such as proteins, peptides and DNA).96 Drug delivery systems consist of a nano-
matrix, which acts as a delivery system by dissolving, entrapping, adsorbing, attaching 
and/or encapsulating the drug. Each type of interaction has its advantages and each 
delivery system is constructed to give different properties and release mechanisms in 
order to achieve the best or most suitable delivery or encapsulation of the particular 
drug.  
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There are many nanomaterials that are in various stages of development and licenced 
for drug delivery purposes, some of the most important discoveries, as reported by the 
Institute of Nanotechnology in 2008, are shown in table 1. 
Nanomaterial Drug Applications Prooduct names 
Dendrimers Astodrimer sodium Microbicide Vivagel 
Liposomes Doxorubicin Breast cancer Doxil 
Daunorubicin Anthracyline antitumor 
antibiotic 
DaunoXome 
Amphotericin B Fungal infections, 
Cryptococcal Meningitis 
in HIV-infected patients 
AmBisome 
Amphotericin B invasive aspergillosis Amphotec 
Prostaglandin E1 Vasodilator and platelet 
inhibitor 
liprostin 
Vincristine Acute lymphoblastic 
leukemia,  
Marqibo 
Paclitaxel Anticancer drug  Taxol 
Canfosfamide Ovarian cancer and non 
small cell lung cancer  
Telcyta 
Paclitaxel Anticancer drug Taxosomes 
Docetaxel Anticancer drug ATI-1123 
Docetaxel Anticancer drug  Taxotere 
Micelles Paclitaxel non small cell lung cancer Genexol  
Paclitaxel Breast cancer Nanoxel 
Estradiol Menopausal hot flushes Estrasorb 
Cisplatin Pancreatic cancer Nanoplatin 
N/A Anti-viral Nanoviricide 
Insulin Diabetes Basulin 
Nanocrystal Sirolimus Immunosuppressant Rapamune 
Aprepitant Prevent nausea/vomiting 
side effects of 
chemotherapies 
Emend 
Fenofibrate Reduces cholesterol TriCor 
Megestrol acetate Helps gain weight Megace ES 
Amphotericin B Invasive fungal infections Abelcet 
Fenofibrate Reduces cholesterol Triglide 
Cyclosporine Immunosuppressant Bioral 
Nanoporous silicon 32-Phosphorus Brachytherapy BrachySil 
Nanopowder Gentamicin Inhalable antibiotic NanoGENT 
Polymer 
nanoparticles 
Camptothecin Anticancer drug IT-101 
Paclitaxel Breast cancer Abraxane 
Miconazole Antifungal Loramyc 
SiRNA Solid tumours CALAA-01 
Table 1 - Licenced nanotechology enabled drugs and applications that were in development in 
2008.19 
As can be seen the majority of currently licenced nanomaterials are polymeric based, 
this being due to their high biocompatibility and ease of modification. As mentioned 
above, creating a drug delivery system is useful for many different reasons including 
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increasing bioavailability, controlling drug release, targeting drugs to specific locations 
and overcoming solubility or patient compliance issues. However, before a delivery 
system can be used in a clinical setting, gathering knowledge on the safety and 
efficacy of the nanomaterial over free drug alternatives is legally required. In order to 
do this being able to monitor a drug delivery system in vitro and in vivo is of high 
importance.  
1.6 Monitoring NP distribution (imaging of NP’s) 
Multifunctional nanoparticles are of high interest in nanomedicine with the distinct 
advantage of being able to deliver a drug whilst monitoring the nanoparticle’s 
dissemination and localisation within the body. Thus drug delivery systems, which can 
improve pharmacokinetics of a drug, while controlling the drug’s release rate and 
location, all with the ability to track the delivery system anatomically are sought after.97 
For imaging, the agent used is required to provide a high signal to noise ratio, be active 
in biological media, and have good pharmacokinetic/pharmacodynamic behaviour to 
enable prolonged viewing where required without compromising the performance of the 
tracker.98 To track nanomaterials different methods are utilised, and the ability to track 
them is especially relevant when researching their ability to target specific locations in 
the body. Tracking nanoparticles has enabled imaging of specific diseased tissues 
such as tumours,99 liver fibrosis,100 and inflamed cardiovascular tissue.101 One method 
by Rolfe et al, which has enabled targeting nanomaterials to melanoma cells and 
imaging them via 19F MRI (magnetic resonance imaging). There is minimal fluorine 
occurring naturally in the body and therefore detection of the fluorine moieties gives 
excellent signal with almost zero background noise.98 Although targeting the 
nanoparticles to specific tissues can increase concentrations of the 19F at target 
locations, making detection easier, using 19F for imaging has shown to take several 
hours scanning time and therefore using this technique for some things such as 
imaging of blood pooling, would not be suitable.102  
Another agent used for tracking nanomaterials is that of quantum dots (QDs). Quantum 
dots are made of semiconductor materials (such as CdSe/ZnS)103 or materials whose 
fluorescence is related to their size and shape, with the intensity of fluorescence 
increasing as size decreases. Quantum dots consist of just a few hundred or thousand 
atoms and are just 2-10 nm in size, which is similar to the size of large proteins.104 This 
small size gives them several benefits such as the ability to swap with both inorganic 
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and organic nanoparticle cores to study the behaviour of the material in question. QDs 
can also be incorporated into much larger nanomaterials without having a substantial 
impact on the carrier, enabling monitoring of their intracellular movement and 
distribution. Not only this but QDs can also be used for mimicking release from a 
nanomaterial to show distribution and final clearance of a potential drug.104 However 
quantum dots, such as cadmium based QD’s, have shown to have high levels of 
toxicity, giving them limited direct use in drug delivery. 
Fluorescence itself is a highly utilised agent for tracking and imaging nanomaterials. 
Fluorophores are molecules that contain aromatic regions, which, when excited at 
specific wavelengths fluoresce. Fluorophores have many advantages including high 
sensitivity, robustness, ease of use, and they have undergone significant use in past 
and current research, continually enriching our knowledge of their potential and 
characteristics.105 Many different fluorophores and incorporating techniques have been 
used to load the fluorophore onto respective nanomaterials. One such approach is that 
of aggregation induced emission (AIE) where the fluorophore gives off strong emission 
when it is in high concentration encapsulated in the nanomaterial, however once it is 
released from the nanomaterial it is highly diluted and a signal can no longer been 
seen.106, 107  This is the inverse of many organic fluorescent molecules which can suffer 
from aggregation-caused quenching (ACQ) where they show high fluorescence at 
lower concentrations.108 In the case of AIE fluorophores highly fluorescent 
nanoparticles can be obtained by encapsulating the fluorophore in high quantities in the 
matrix of the material. Such nanoparticles have the advantage of high fluorescence 
emission, ease of production and low toxicity. Their disadvantage is that they can have 
quite high particle sizes of 400-600 nm106 which would be too big for use in drug 
delivery. Because of the latter characteristic, the impact of the fluorophore on the 
nanomaterial should be carefully considered.  
In a very different approach Wang et al conjugated a fluorophore to their co-block 
polymers with which they formed micelles. The fluorophore used significantly amplified 
its fluorescence in environments with lower pH (present in tumour cells) thus enabling 
visual detection of tumour sites by contrast with healthy tissues.109 By conjugating the 
fluorophore to the nanoparticle, it is possible to prevent bleeding of the fluorophore 
from the nanoparticle, which is of high importance when using the fluorophore to track 
the nanoparticle distribution.110 
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The quantum yield of a fluorophore is an important measure to consider when 
incorporating one into a nanomaterial as a fluorescent tracer.  Strong emission is 
required to be able to detect the fluorescent tag at low concentrations. The quantum 
yield of a fluorophore can be obtained by measuring the number of photons emitted 
and the number of photons that are absorbed and dividing the first by the latter111. 
Therefore if a fluorescent molecule was 100 % efficient every photon absorbed would 
result in a photon being emitted and fluorescence being seen. However even 
molecules with a quantum yield of 0.1 are considered to be relatively fluorescent.  
Photobleaching is also an important phenomenon that needs to be evaluated when 
choosing the molecule to be used for a specific application. Photobleaching occurs 
during the observation of almost all fluorescent molecules. It is where an irreversible 
photochemical change takes place in the molecule preventing it from fluorescing any 
more.112 How the photochemical change takes place is not established, although one 
theory involves interactions between excited fluorophores and other molecules in the 
local environment. Fluorescence occurs when a fluorescent molecule is illuminated at a 
certain wavelength, its excitation wavelength, which is peculiar to each fluorescent 
molecule. An electron is excited from the ground state energy level (S0) to the excited 
state energy level (S*). The excited electron can then either return to the ground state 
via the release of a photon – which is seen as fluorescence, or via an intersystem 
crossing where the electron moves to the excited triplet state (T*), this radiationless 
transition can give rise to phosphorescence which has a much longer life time, 
milliseconds, rather than nanoseconds, which is true of fluorescence. This is due to the 
transition from the T* state to the S0 state being “forbidden,” therefore kinetically 
unfavoured and in turn taking much longer to occur.112 
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Figure 14- This Jblonski diagram represents the movement of excited photons, which release 
of fluorescence or phosphorescence on their return to the ground state.  
If a molecule has a high quantum yield for intersystem crossing then more molecules 
are likely to cross from the S* excited state to the T* Triplet state. When in the T* triplet 
state the molecules interact with their environment for a much longer period of time, 
compared to those which remain in the S* before returning to S0. Therefore it is 
possible that due to the molecule being highly reactive when it is in the excited triplet 
state it may undergo irreversible reactions with molecules in its environment, 
preventing anymore photons from being emitted. It is therefore highly likely that both 
the fluorescent molecule and its environment have an effect on how many photons are 
emitted before the fluorophore is destroyed.112 It follows that fluorophores that suffer 
heavily from photobleaching should be avoided in order to prevent undesired loss of 
fluorescence. 
The properties of a fluorophore need to be carefully considered and their impact on the 
nanoparticle matrix should be taken into account. The size of a nanoparticle in 
nanomedicine is key and should be taken into consideration when incorporating the 
fluorescent tag into the nanogel matrix. For drug delivery the desirable particle size 
depends on the final target, however particles below 200 nm are more suitable95 to 
ensure passage through capillaries.96 Particles below 5.5 nm in diameter should be 
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avoided as work by Choi et al found particles of this size were rapidly cleared by the 
renal system.113 Having a narrow distribution of particles sizes is also important as 
large size variations can have a negative impact on pharmacokinetics. This is because 
different sized fractions will release their drug payloads at significantly different rates.95  
The impact of the morphology of the nanoparticle matrix is not the only characteristic to 
consider. Although the use of fluorophores is wide-spread in nanomedicine ensuring 
the fluorophore is chemically bonded to the nanoparticle is essential, as leaking of the 
fluorophore from the nanoparticle is common,110 at which point the fluorophore loses its 
purpose. Another advantage of using a polymeric-based nanoparticle is that there are 
many fluorescent monomers commercially available and/or synthetic procedures 
already established to modify other fluorescent molecules into polymerisable 
equivalents, thus enabling easy addition of a fluorophore to a polymer matrix with a 
strong covalent bond.110 
Using nanomaterials to aid the delivery of drugs clearly has many advantages and is a 
fast growing and popular area of pharmaceutical research. Polymeric-based 
nanoparticles have shown great promise with respects to their biocompatibility and 
ease of modification, this combined with the excellent features of fluorophores to 
enable a drug delivery system to be continually monitored whilst delivering a drug load 
make them an ideal combination for creating a multifunctional drug delivery system. It 
is in this specific context that this thesis has been developed. 
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1.7 Aim and objectives 
The aim of this project is to synthesise novel polymeric nanoparticles characterized by 
low toxicity and tagged with a fluorescent label that will allow in vivo monitoring of drug 
delivery. The work was organised in 3 main objectives: 
1. Synthesis and characterisation of the fluorescent nanoparticles. 
2. In vitro and in vivo toxicity studies, using zebrafish. 
3. Preliminary evolution of drug uploading and release both in vitro and in vivo. 
In order to simplify the discussion of the results, each objective is covered in a 
dedicated chapter, here below summarized. 
Chapter 2 focuses on the development of a novel drug delivery system based on 
organic polymeric nanoparticles using high dilution radical polymerisation. Different 
fluorescent labels, were evaluated and their polymerisable derivative prepared. The 
chemical structures of the labels were confirmed by 1H-NMR and 13C-NMR. The 
incorporation of the fluorescent labels into the nanogels was analysed and their impact 
on the morphology was evaluated. The nanogels were further developed, by altering 
the polymerisation parameters, to obtain the best possible properties for their end 
application of drug delivery. Coumarin labeled fluorescent nanogels were obtained with 
good yields, small particle size of <150nm and with sufficient solubility to be taken to 
the next step. The particle size of the nanogels is characterised by dynamic light 
scattering and transmission electron microscopy. Incorporation of the fluorescent tags 
was evaluated by UV-Vis spectroscopy and the fluorescence intensity was monitored 
via a spectrofluorimeter.  
Chapter 3 focuses on the evaluation of the toxicity of the coumarin labeled nanogels. 
Initially the nanogels were studied for their toxicity in vitro, using several different 
assays namely Alamer blue, MTT, LDH and cellular uptake. This work was carried out 
in collaboration with Dr. Diana Velluto at Queen Mary’s School of medicine and Dr. Zhu 
and Claudia Mioa at Cranfield University. Following this work the nanogels were 
analysed in vivo, in Danio rerio, better known as zebrafish as the model. The nanogels 
were administered via two different routes, initially their distribution was evaluated via 
oral delivery and secondly via intravenous delivery. During these studies the zebrafish 
were monitored via microscope and confocal microscope and injected using 
microinjection in collaboration with Dr. Caroline Brennan at Queen Mary’s School of 
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biological and chemical sciences. This work was carried out under my personal fish 
license (70/24303), Dr. Brennan’s project license (70/7452) at the Queen Mary Fish 
Facility. 
The final chapter of the results and discussion, chapter 4, covers the work carried out 
on the upload and release of tamoxifen both in vitro and in vivo. Tamoxifen, a therapy 
used for breast cancer, was loaded into the nanogels using the molecular imprinting 
approach. Acrylic acid was used to interact with tamoxifen via an ionic bond (analysed 
via H1NMR), allowing release at reduced pH, which was a characteristic of cancerous 
cells. The upload and release of tamoxifen was analysed via HPLC. Finally the 
nanogels were administered to transgenic ubi:switch zebrafish, which triggers a 
fluorescence change in the fish on exposure to tamoxifen. The fish were analysed for a 
change in fluorescence using a fluorescent microscope and again carried out in 
collaboration with Dr. Brennan.  
As this project was multi-interdisciplinary in order to facilitate the reading of this thesis a 
short introduction to specific topics has been included at the beginning of each of the 
results and discussion chapters. 
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2 Nanomaterial preparation and characterisation 
introduction 
This first chapter of the results and discussion will centre on the synthesis and 
characterisation of fluorescent-tagged nanogels, describing the different fluorophores 
that were evaluated as well as the synthesis of the nanoparticles, focusing in particular 
on the optimisation of the polymerisation conditions. 
 Nanogels as drug delivery carriers 2.1
Although polymeric materials were initially developed in the early 1900’s,114 their 
potential applications as drug delivery systems have only been studied in the last 20 
years, thanks to the significant advances in the area of nanotechnology, in particular 
nanomaterials, that have led to the preparation of a large number of nano systems.115    
Among the most interesting ones that have been evaluated in great depth there are, 
micelles, lysosomes and solid-lipid nanoparticles, all of which are described in detail in 
the introduction (section 1.4.3). These systems are all characterised by the fact that 
they are self-assembled systems.  All three types of materials offer substantial 
advantages, such as increasing bioavailability of drugs, increasing drug deposition in 
diseased tissues and reducing side effects associated with the drug and in many cases 
the materials have reached the clinical trial stage and commercialisation.116 Currently 
approximately 600 clinical trials are being carried out using lipid-particle drug delivery 
systems116. One particularly successful case is that of SP1049C, which is a polymeric 
micelle formulation loaded with the cancer drug, doxorubicin.117 SP1049C has been 
shown to overcome drug resistance in doxorubicin resistant cells and has passed 
phase II clinical trials and is currently in phase III118. However, despite the interesting 
potential of these self-assembled systems, a number of issues, including physical 
chemical instability in certain solvent systems and ability to deliver a drug mainly 
through diffusion remain unsolved, therefore limiting their applications as drug delivery 
vehicles.119 This has led to exploration of different materials for use as carriers of 
pharmacologically active molecules, such as polymeric nanoparticles.  
Polymeric nanomaterials are characterised by high stability, as a direct result of the 
presence of a strong network of covalent bonds. Among these are nanogels, which 
have particular potential, given their ability to support stable colloidal solutions.120 
Nanogels are commonly defined as polymeric cross-linked particles forming a 3 
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dimensional network121 where at least one dimension measures between 1 and 100 
nm.122 It is the ability to cross-link between polymer chains that gives nanogels a 
significant advantage over simple block co-polymers. No longer relying on self-
assembly (section 1.4.3), the stability of these materials is higher due to their cross-
links and they have an increased polymer density, as a direct result. The size of 
polymeric gel can be controlled, from micrometres (microgel) to nanometres (nanogel) 
by simple alteration of the experimental conditions under which the preparation is 
made123. Nanogels in particular are characterised by a high surface to volume ratio, 
which makes them very suitable as hosts for molecules. Their large surface area also 
makes multivalent bioconjugation feasible and biomolecules can be incorporated into 
their porous interior network.124, 125 Furthermore these polymeric gels can be prepared 
to respond to specific external stimuli, that induce physical changes in their structure, 
by using specific functional monomers. The polymers can respond to changes in pH 
and temperatures and trigger the relase of the incorporated molecules. This makes 
them particularly attractive as drug delivery systems.126 
The first example of polymeric gels used for drug delivery refers to water soluble cross-
linked polymers termed ‘hydrogels’. Hydrogels were first developed for medical 
applications by Witchterle and Lím in the 1950’s.127 They used 2-hydroxyethyl 
methacrylate and ethylene dimethacrylate to form a co-monomer hydrogel. It was these 
hydrogels that were used for the production of the first soft contact lenses, and due to 
their enormous commercial success, created great interest in developing the material 
for other medical applications.128  
The selection of components used for the nanogel preparation is responsible for its 
characteristics:  the use of monomers with a high degree of hydrophilicity (such as 
acrylic acid) produces a nanogel with a high affinity for water.129 This permits the water 
to seep in between the polymer chains inducing swelling of the polymer. Such 
nanogels provide an ideal vehicle for drug delivery because the high hydrophilicity of 
the carrier facilitates administration of otherwise insoluble drugs. Other advantages of 
hydrogels towards drug delivery include biocompatibility, their ability to be stimulus-
responsive and the ease with which they can be chemically modified during 
polymerisation129. 
A number of different approaches for the synthesis of nanogels have been developed 
over the past two decades. One method commonly used is precipitation 
polymerisation. This method involves dissolving the selected monomers in the required 
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solvent alongside a surfactant, adding them to a flask under nitrogen with an initiator 
and heating the solution for several hours to initiate polymerisation. The resulting 
nanogels are, by contrast, insoluble in the solvent used and therefore when 
polymerisation takes place they precipitate and can be isolated by filtering them off 
from the solution.130, 131 This method requires the use of surfactants, such as sodium 
dodecyl sulfate (SDS), which can be toxic and therefore ensuring their complete 
removal after polymerisation is a substantial concern before the nanogels can be 
considered for use in nanomedicine.132  
One of the most utilized is the inverse micro emulsion method, which has been used to 
form acrylate-based nanogels. In this example laureth-3 surfactant is used to form 
water swollen surfactant micelles in the continuous oil phase. All the monomers are 
dissolved in the aqueous phase and the crosslinking occurs inside the water micro 
droplets. Shaking the mixture until a single, transparent phase is obtained forms the 
emulsion. The initiator is injected into the emulsion during removal of dissolved 
oxygen.133 After polymerisation, extraction and dialysis are required to remove the 
surfactant and solvent (heptane). In another system tween 80 and span 80 were used 
as the surfactants for an inverse emulsion which again required washing with hexane 
and water as well as centrifuging to remove the surfactants, before the nanogels could 
be isolated.129  
The emulsion polymerisation method is reliable and has been used for a variety of 
applications such as food134 and drug delivery.135 However, the use of surfactants is 
required, an additional component to the polymerisation solution that is bound to have 
an impact. Surfactants are surface-active agents, which congregate at the surface and 
interfaces to alter the surface properties.136 Surfactants are composed of two parts, one 
which interacts with the aqueous phase, often referred to as the hydrophilic head and 
the other, which interacts with the solvent, known as the hydrophobic tail. Due to their 
dual characteristics, these surface active amphiphillic molecules adsorb at the 
interfaces and can also lead to the formation of micelles in order to reduce free energy 
of the system.137 This is because when the hydrophobic section of the molecule is in 
contact with the water it distorts the ‘normal’ structure of the liquid, increasing the 
overall energy in the system. By accumulating at surfaces, interfaces and in micelles it 
minimises the interaction of the hydrophobic section with the aqueous medium, and the 
liquid can return to the normal structure.137 This is due to the hydrophobic sections of 
the surfactant accumulating together either at surfaces or in the formation of micelles 
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minimising their interaction with the aqueous liquid. This can be seen more clearly in 
figure 15. 
 
Figure 15 – A diagram of the acumulation of surfactant at the surface and forming a micelle. 
Surfactants are well known to stabilise colloidal systems by surrounding the particles 
with one or two layers of the surfactant, which also prevents aggregation via steric 
hindrance. Although highly useful in stabilising systems, surfactants can be highly 
toxic132 and are an extra, undesired material added to the final product, which can be 
difficult to remove. In this project it was decided to consider an alternative approach for 
the synthesis of nanogels: the high dilution radical polymerisation method, which does 
not require the use of surfactants. The next section will provide more details about this 
system and how it was applied.  
2.1.1 High dilution radical polymerisation 
High dilution radical polymerisation or solution polymerisation was initially developed 
and explored by Graham and his group in 1998.123 It is based on the principle that a 
radical reaction at high dilution prevents particle-particle interaction, and therefore 
inhibits the formation of larger units. The use of high dilution relinquishes the need for 
surfactants, although the extent of the dilution is dependent on the chemical structure 
of the monomers used and the solvating power of the porogen in the polymerisation 
solution. Given a set of monomers and cross-linker, the chosen solvent must ensure 
that the polymer-solvent interactions are stronger than the intra-polymer attractive 
forces, in order to prevent the polymer chains contracting and interacting with one 
another. Linear polymers have a natural tendency to coil, in order to achieve the 
conformation of lowest energy, and although many different variations occur, the 
difference in energy between the conformations is so small that the polymer can easily 
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change from one conformation to another.138 According to Einstein’s viscosity law 
equation, if the viscosity of the solution is divided by the viscosity of the solvent, the 
viscosity of the solvent is directly proportional to the volume fraction that the sphere (or 
in this case polymer) occupies.139 If a long linear polymer is obtained, when it is 
solvated the chains interact with the solvent, occupying a larger volume fraction of the 
solvent, therefore increasing its viscosity. In the case of nanogels, as a result of the 
presence of intramolecular crosslinking, the nanopolymers cannot uncoil and therefore 
do not expand in the same way as a linear polymer, meaning they behave more as a 
sphere and occupy a much smaller fraction of the solvent and therefore have 
correspondingly little effect on the viscosity of the solvent.138  
𝜂𝑟 = !!! = 1 + 2.5Φ    Equation 1 
Einstein’s viscosity law, where ηr = relative viscosity, ηs = viscosity of the solvent, η = viscosity of 
the solution, and Φ = volume fraction that the sphere’s occupy 
Although nanogels when formed behave more like ‘Einstein’ sphere’s than a linear 
polymer, ‘dead chains’123 of polymer will occur in the nanogel, which will help to 
stabilise the nanogel in solution. This is referred to as the ‘auto-steric stabilisation’ 
effect in the literature.140 When a ‘good’ solvent for the ‘dead chains’ at the surface of 
the particle is selected, the chains will swell and lead to strong repulsive forces 
between individual particles. If however a poor solvent is chosen, these chains 
contract, weakening the repulsive forces and giving rise to intermolecular cross-linking 
and ultimately macrogelation.   
The high dilution radical polymerisation methodology has a number of advantages:  i) 
there is no need for the use of surfactants, therefore reducing the number of 
components in the solution and simplifying the purification step as a result; ii) the 
reduction in the time required to isolate the polymers; iii) reduced costs; iv) highly 
homogenous particles sizes with low polydispersity; v) the ability to control the particle 
size by altering the parameters, giving a highly flexible system that can be tailored to 
form a nanogel with the desired characteristics.  
2.2 Nanomaterial characterisation results and discussion 
2.2.1 Choice of monomers, cross-linker and solvent 
The polymers developed in this project were intended for use in aqueous solutions, and 
therefore there was a clear need for monomers that could form polymers that have 
good solubility in water. Amide bonds have a relatively good affinity to water, due to 
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hydrogen bonding, and are also abundant in the human body as a result of peptide 
bonds. Acrylamide (structure shown in figure 16) was therefore selected as the 
backbone monomer for this work as previous data suggested that acrylamide based 
nanogels show good solubility in aqueous solutions. The cross-linker is an essential 
requirement for the preparation of stable nanogels, in order to allow the formation of 
the three dimensional structure and the specific cavities. The chemical structure of the 
cross-linker and its proportion in relation to other monomers in the system are also key 
factors that impact the morphology and physicochemical characteristics of the 
materials, therefore careful studies were required in each system to identify the most 
suitable set of conditions. In addition, given that the radical polymerisation is a random 
process, it was important that the incorporation of the different monomers and the 
cross-linker in the final matrix reflected the ratios that were used in the 
prepolymerisation mixture.  
Different monomers have different reaction rates, as a result of their varied chemical 
structures and hence stability of the corresponding radicals, as in the case of a styrene 
units versus acrylic acid, where the former forms a radical that can be stabilised by 
resonance. A method to estimate reactivity for a variety of monomers was developed 
by Alfrey and Price in 1996141 and tables of reaction rates can be found in the literature. 
Therefore careful consideration of the structure of co-monomers and cross-linkers 
should be given when carrying out radical polymerisation reactions. The more similar 
the chemical structure of the polymerisable unit of the monomers and the cross-linker, 
the more likely it is that their incorporation in the polymeric matrix will reflect the ratios 
used in the prepolymerisation solution.  
Given the previous considerations, two cross-linkers containing acrylamide bonds were 
selected for consideration, ethylene bis acrylamide and methylene bis acrylamide, 
these structures are presented in figure 16.  
 
Figure 16– Structures of the cross-linkers MBA (1), EBA (2) and the monomer acrylamide (3). 
Past research on the synthesis of nanogels in the Resmini group had primarily focused 
on their use in catalysis,142, 143 Ania Servant successfully imprinted a vinyl pyridine-
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EDGMA based nanogel, with indole, for use as a catalyst for the Kemp elimination. In 
this system the rebinding and release of the target analyte was the primary focus in 
order to facilitate the reaction. In this project the nanogels’ application was completely 
different and therefore their solubility in water had a much higher priority. The 
substantial change from using methacrylate systems to acrylamide ones should 
increase their solubility and increase their potential as a drug delivery carrier. Several 
points, including the ability to solubilise these chosen acrylamide-based monomers 
need to be taken into consideration when choosing a solvent for HDRP.  
CHOICE OF SOLVENT 
The solvent should completely dissolve all the monomer components required to form 
the nanogel, so that a homogeneous solution can be obtained. Given the choice of 
acrylamide based monomers, a strongly polar solvent was required. Water is an 
obvious polar solvent, and as the final nanogel was required to be dissolved in water it 
might on first examination seem like an ideal candidate. However water could cause 
several problems. Firstly, if a hydrophobic drug is to be uploaded onto the nanogels, it 
will by its nature not solvate in water. This would prevent interaction between the 
nanogel and the drug, if the drug is loaded onto the nanogel during polymerisation. Not 
only this but water is also a protic solvent and could interfere with hydrogen bonding 
that may be used as the interaction between the drug and the nanogel. Other protic 
solvents, such as methanol and ethanol, were eliminated for the same reasons, leading 
to the conclusion that an aprotic polar solvent would be better suited for the purpose. 
After a number of evaluations DMSO was shown to be a good solvent for the 
polymerisation due to its highly polar aprotic nature.144 It was also shown to have the 
ability to solvate both polar and non-polar compounds, even highly aromatic 
compounds,145 enabling both polar monomers and a non-polar drug such as tamoxifen, 
to be solvated. This solvent had been extensively used in the Resmini group146 for the 
preparation of acrylamide based microgels and nanogels. DMSO was chosen as the 
solvent for this project and preliminary experiments confirmed it to be the most suitable 
solvent for this type of acrylamide based polymers, allowing the formation of microgels 
and nanogels in good yields.  
Given a set of monomers, the polarity of the solvent will determine the maximum 
monomer concentration that can be used to obtain micro / nanogels without observing 
any macrogelation. A plot of the type shown in figure 17, that shows the dependence of 
the initial monomer concentration on the solvating power of the solvent, measured by 
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the solubility parameter, can be obtained experimentally. Micro/ nanogels  are obtained 
when the Initial Monomer Concentration (IMC) is below the critical gelation 
concentration (CGC), while higher values of the IMC will lead to macrogelation. If 
concentrations of monomer closer to the CGC line are used microgels are obtained, 
however if concentrations closer to the base line are used nanogels can be obtained.  
Figure 17- An example of a microgel/ nanogel formation plot. 
At the end of the polymerisation reaction, if a micro/ nanogel is formed, the solution 
appears as a low viscosity transparent liquid, otherwise if high viscous liquid or lumps 
of gelatinous type materials can be observed, macrogelation has occurred. Even with a 
relatively high concentration of monomers (CM) such as 20 %, a free flowing micro/ 
nanogel ‘solution’ can be obtained. This so called solution is in fact a colloidal 
dispersion of polymer nanoparticles, which behave more like Einstein spheres than 
dissolved linear polymer coils.123 To analyse this theory three nanogels were set up 
each containing 80% Ethylene bis acrylamide and 20 % Acrylamide using DMSO as 
the solvent, the only variable was the CM, which was set at 2, 1.5 and 0.5%. The gels 
obtained can be seen in figure 18.  
Critical gelation concentration  
Macrogel 
formation 
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Figure 18 – Photograph of nanogels at different stages of macrogelation, a) macrogelation 
CM=2, b) nanogel beginning to macrogelise, lying on the CGC line, CM=1.5 c) microgel or 
nanogel, CM=1. 
This experiment showed the CM needed to be set at 1% or below to obtain 
micro/nanogels. Another advantage of this polymerisation method is that the size of the 
particles obtained can be easily controlled by altering the experimental parameters of 
the preparation. The lower the concentration of monomers (CM) is kept from the critical 
gelation limit, the smaller the size of the particles formed and the more homogeneous 
the preparation tends to be. Using this approach it is possible to form particles of size 
between 1 and 100 nm, normally referred to as nanogels. Having established the 
solvent and cross-linker to be used in this nanogel synthesis, focus then turned to the 
initiator of the polymerisation.  
INITIATOR OF CHOICE  
In order for polymerisation to take place an initiator must be used to begin the chain 
reaction. The initiator is required to firstly dissociate into two radicals and then react 
with a monomer from which the radical can then continue its polymerisation through 
propagation. The rate of dissociation relies both on the nature of the solvent and the 
temperature at which the reaction takes place. The dissociation can be triggered by 
either heat or irradiation such as UV light or γ rays. Initiators for free radical 
polymerisation require a labile group such as azo (-N=N-) disulphide (-S-S-) or 
peroxide (-O-O-) group for the dissociation to take place.147 One well known initiator 
which thermally decomposes to form cyanisopropyl radicals and release nitrogen gas is 
2,2’-azobis(isobutyronitrile), (AIBN, 4, structure presented in figure 19). This initiator 
had proven to be very effective in previous research within the group, and was 
therefore a reliable choice for initiating the polymerisation of the nanogels. The amount 
A B C 
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of AIBN added was set at 1% of all double bonds in the prepolymerisation mixture, 
based on previous work and literature data.148, 149  
 
Figure 19– Structure and decomposition of AIBN (4).  
The use of AIBN to initiate the polymerisation of acrylamide based monomers in DMSO 
forms a suitable base on which to develop nanogels as a drug delivery system. 
However in order to monitor the nanogels during analysis of the material’s toxicity, 
incorporating an agent with which monitoring the nanogels becomes viable is required. 
It was noted in section 1.6 of the introduction that the use of fluorophores for monitoring 
nanomaterials is highly utilised, giving vast data on potentially suitable tags with which 
to tag the nanogels. Therefore identifying a suitable fluorescent monomer was a 
substantial part of this section of this project.  
2.3 Selection of fluorescent monomer 
In this section the work carried out for the identification of a suitable fluorescent 
monomer to be incorporated into the nanogels is described. A fluorescent tracker is 
required in the nanogel to enable in vitro and in vivo monitoring of the particles. A 
number of fluorescent monomers were examined as potential tags for inclusion in the 
nanogels, via covalent bond during the polymerisation reaction, or uploading post-
polymerisation.  For the nanogel to be suitable for this purpose the incorporated 
fluorophore needs to have a reasonable quantum yield to limit the quantity required in 
the nanogel but still be detectable at concentrations required for administration. The 
structure of the fluorophore was also important to ensure good incorporation into the 
nanogel without having a negative impact on the nanogel size, solubility and stability.  
2.3.1 Introduction 
Section 1.6 of the introduction gave an overview of the important features the 
fluorescent tag in the nanogel should possess. The fluorescent tag should not 
significantly alter the morphology of the nanogels as this could impact their solubility 
and/or stability, seriously limiting their potential applications.  
Particle size and distribution of the nanogel also influences the colloidal stability and 
therefore the overall solubility of the nanogel. Brownian motion occurs in all colloidal 
N N
N
2
(4)
+N N NNN N NN
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systems and is defined as the movement of particles in a system, whereby the particles 
move randomly due to collisions between the particles and the molecules in the 
solvent.150 When a solution is not homogenously dispersed, smaller particles are 
attracted to the larger one, destabilising the system and causing aggregation and 
ultimately resulting in precipitation.137 One significant feature of a drug delivery system, 
over a free drug is its ability to deliver a hydrophobic drug in a water-soluble carrier,151 
therefore it is important that the fluorescent tag should not negatively impact on the 
solubility of the nanogel. 
In section 2.1.2 the effect of the chemical structure of the monomers on the 
polymerisation rate was mentioned. A similar concept also applies to the fluorescent 
tag. In order for the tag to be incorporated successfully and with the expected 
monomer-tag ratio, the fluorescent monomer was designed to contain an acrylamide-
based group, to ensure that a similar reaction rate to the cross-linker and acrylamide 
could be achieved. In addition it was important to ensure that the bond between the 
fluorophore and the polymer matrix was stable under the physiological conditions 
required for drug delivery to avoid the risk that the fluorophore could become detached 
from the nanogels during the experiments. 
Finally, given that these nanogels would have to be used in experiments in vivo using 
Zebrafish, it was essential to avoid having fluorescence emissions in the two 
wavelength bands 430-450 nm and 570-630 nm152 where the zebrafish have a strong 
autofluorescence.  
2.3.2 Dansyl as a fluorescent tag 
Initial screening of the literature identified Dansyl as an interesting fluorescent tag. It 
had previously been used as a fluorescent switch when conjugated to a thrombin 
binding aptamer (TBA). Thrombin is an enzyme responsible for many homeostasis 
mechanisms in the body. In particularly it plays a major role in coagulation. Titio et al 
used dansyl and cyclodextrin attached to a TBA to create a dual-purpose thrombin 
inhibitor which both blocks the binding site and the dansyl fluorephore switches on, 
creating a fluorescent signal. Dansyl does not inhibit the aptamer by altering its 
morphology, crucial for rebinding, and the dansyl tagged TBA remains soluble in 
water.153 On this basis dansyl was considered a good candidate as a fluorescent 
tracker for the nanogels.  
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A dansyl based fluorophore had been previously used in a nanosensor by Arduini et 
al154 (using dansyl as the sensor for Pb+ ions). In their system the fluorescence was 
quenched on contact with the lead ions. As dansyl had high enough fluorescence 
intensity to be used for detection it was thought that this molecule could also have high 
enough intensity for tracking, and could be applied to our system. Dansyl contains both 
a tertiary amine group and a sulfide group both of which increase the solubility of the 
compound. The structure of dansyl is also relatively small and therefore would have 
less impact on the final morphology of the nanogel. Added to these significant 
advantages dansyl can be acquired at a low cost and a synthetic procedure for creating 
a monomer had already been established in the literature. The protocol for synthesising 
dansyl amino ethylene acrylamide was published by Yin et al.155 The synthesis was 
obtained in two steps, the reaction scheme is given in figure 20. Initially adding 
ethylenediamine to dansylchloride, enabed an acrylamide group to be formed at the 
end of the molecule in the second step. The acrylamide group provides a strong amide 
bond to the nanogel that would not be cleaved by hydrolysis. The presence of the 
acrylamide functional group should also ensure a similar reaction rate to the rest of the 
monomers raising the  reasonable assumption that the percentage of tag added to the 
prepolymerisation system should be similar to the percentage incorporated in the final 
nanogel. To form the fluorescent tag dansyl chloride was added dropwise to a THF 
solution of ethylenediamine at 0 °C under nitrogen before being worked up to obtain 
89% yield of the yellow product dansylaminoethylamine. Dansylamioethylamide was 
further reacted with acryloyl chloride in presence of triethylamine in ice under nitrogen 
and after 24 hours at room temperature the product was isolated via flash 
chromatography to give a 65% yield of the pale yellow/green solid product, 
dansylaminoethylacrylamide.   
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Figure 20- A reaction scheme detailing the reactants required for the two step synthesis to form 
dansyl amino ethyl acrylamide.  
Having successfully synthesised the dansyl tag and characterised it via 1H-NMR and 
13C-NMR the tag was incorporated into the nanogel formulation. The amount of dansyl 
tag in the prepolymerisation mixture was varied from 20 % to 60 % to evaluate how it 
would impact the nanogel’s solubility.  
Nanogel Dansyl 
monomer 
(%) 
Cross-
linker 
(EBA) 
(%) 
Yield of 
nanogel 
(%) 
𝑛!"  /mg of 
nanogel 
(exp) 
(mol/mg) 
𝑛!"  /mg of 
nanogel 
(theo) 
(mol/mg) 
Incorporation 
(%) 
JRP09 20 80 88 7.20*10-7  9.04*10-7 80 
JRP13 40 60 43 1.17*10-6 1.59*10-6 74 
JRP14 60 40 68 1.59*10-6 2.12*10-6 75 
Table 2 – incorporation results of the dansyl monomer into the nanogel. EBA is ethylene bis 
acrylamide, CM: Concentration of monomers.  𝑛!"= number of moles. exp = experimental result. 
theo = theoretical result. The yield of nanogel is the percentage of nanogel collected compared 
to the mass of monomers put in the prepolymerisation mixture.  
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2.3.2.1 Stability and solubility of the dansyl tagged nanogels 
Three nanogels containing varying amounts of the dansyl tag, 5, were prepared, 
namely JRP09, JRP14 and JRP15 (table 2). The first set of experiments concentrated 
on studying the solubility of the polymers in water, an essential feature given the 
envisaged application as drug delivery systems. In addition it was important to achieve 
sufficient solubility to allow the in vivo experiments to be carried out using zebrafish as 
the model. The nanogels were not soluble in 100 % water, however they were soluble 
in 94% water with 6% DMSO (V/V) at the concentration of 0.01 mg/ml of polymer and 
in 85% water with 15% DMSO (V/V) at the concentration of 0.1 mg/ml. Although some 
DMSO was required to completely solubilise the nanogels, the solubility achieved was 
high enough for initial studies to be carried out. Therefore the quantification of the 
fluorescent tag into the nanogel was evaluated to ensure a reliable and reproducibly 
tagged nanogel was formed.  
2.3.2.2 Incorporation of the dansyl monomer into the nanogel 
The quantification of the fluorescent tag incorporated in the nanogel was important to 
ensure that it was consistent with the ratio of monomers used in the polymerisation. 
Quantification was achieved by UV-Vis spectroscopy by using a reference line and the 
Lambert-Beer law that directly correlates absorbance against concentration at a fixed 
wavelength.156 Dansylaminoethylamide was used to create a reference line for the 
dansyl monomer incorporation rather than the final monomer 
dansylaminoethylacrylamide, (5a) because once the monomer is incorporated into the 
nanogel the double bond of the monomer ceases to exist and the absorption peak of 
the molecule with and without the double bond present would be different. 
Nevertheless a minor error between the precursor molecule (5a) and the dansyl tag (5) 
incorporated into the nanogel would exist. Therefore a nanogel solution in DMSO was 
initially scanned for its absorption wavelength when the dansyl tag was incorporated 
into the nanogel matrix and then varying concentrations of dansylaminoethylamine 
were evaluated for their absorbance at this wavelength (339 nm).  Three different stock 
solutions of dansylaminoethyl amine were prepared at different concentrations in 
DMSO using volumetric flasks. Each solution was cross-diluted three times producing 9 
solutions with different concentrations ranging from 0.02 mM to 0.23 mM. By preparing 
3 different stock solutions by weight and cross-diluting, experimental errors can be 
easily identified and corroboration of actual concentrations is easily achieved. The 
absorbance maximum of each solution was obtained at 339 nm and plotted against the 
corresponding concentrations of dansylaminoethylamine, 5a. 
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Figure 21– Calibration curve of dansylaminoethylamine, 5a, in 100% DMSO. The absorbance 
value for each concentration was obtained by a UV-Vis spectrometer, using the crossdilution 
method.  
 
The molar absorption coefficient (also referred to as extinction coefficient) can be 
determined from the calibration curve using equation 2. Where 𝜀 is the molar 
absorption coefficient, A is the absorbance, c is the concentration and l is the path 
length of the cell. The molar absorption coefficient was calculated from the reference 
line to be 4173 M-1cm-1 (S.E.) with a R2 value of 0.9949.  
𝐴 = 𝜀𝑐𝑙   Equation 2 
The molar absorption coefficient obtained from the reference line was then used to 
calculate the incorporation of the monomer into the nanogels by measuring the 
absorption of known concentrations of nanogel and comparing them to theoretical 
values taking into account the chemical yield of nanogel obtained. As the concentration 
of a sample is directly related to its absorbance, the concentration of an unknown 
sample can easily be obtained. The incorporation data are presented in table 2 above. 
On analysis of the results it can be seen that a relatively high proportion of the 
dansylaminoethylacrylamide monomer was incorporated into the nanogels. JRP09 with 
20 % dansyl tag in the prepolymerisation mixture had an incorporation of 80 %. 
Nanogel JRP13 with 40 % dansyl tag had an incorporation of 74% and JRP14 with 
60% dansyl tag had an incorporation of 75% (table 2).  This indicated that the reaction 
rates were comparable and that the reasonable assumption that the final nanogel 
consisted of the desired fractions of the polymer (which were initially disposed) were 
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verified. To establish what percentage of fluorescence tag was required in the nanogel 
formulation for detection, the emission of the nanogels was evaluated.  
2.3.2.3 Fluorescent studies with the dansyl tagged nanogels 
Having demonstrated the successful incorporation of the dansyl based monomer into 
the nanogel matrix, the next step focused on determining the minimum concentration of 
tag required to ensure optimal tracking of the polymers. Previous in vivo studies using 
zebrafish have used concentrations of approximately 0.1 mg/ml.157 To be absolutely 
sure the nanogels could be detected at the levels anticipated as being required in vivo, 
it was decided to assess the nanoparticles for fluorescence at 0.01mg/ml. Solutions of 
three dansyl containing nanogels (JRP09, JRP13 and JRP14, table 2) were prepared 
at 0.01 mg/ml, in 100 % ethanol and measured for their fluorescence at an excitation of 
339 nm. All three nanogels showed fluorescence emission, figure 22, however only 
JRP13 and JRP14 could be considered sufficiently fluorescent for use in vivo. JRP9, 
which contained only 20 % of the fluorescent tag showed a much lower fluorescence 
emission, however there appeared to be no correlation in the emission between JRP13 
and JRP14 and the amounts of dansyl tag that was used in the preparation.  
	  
Figure 22– Fluorescence intensity of three dansyl containing nanogels measured at 0.01 mg/ml 
in ethanol. Measured at excitation 339 nm, emmission 470 nm. 
The dansyl moiety however contains hydrophobic features and there was concern that 
a very high incorporation of the tag would have significant impact on the solubility of the 
nanogels.  Nanoparticles reported in the literature contain as little as 2% (wt) of 
fluorescent tag compared to the total polymer,158 with a much lower fluorescence 
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intensity than that of JRP09 therefore suggesting that the values obtained with JRP09 
would be sufficient for in vivo monitoring. 
2.3.2.4 Particle size studies with the dansyl tagged nanogels 
Efficient drug delivery systems should ideally have a particle size smaller than 200 nm, 
to allow easy passage through capillaries and to avoid being removed by the spleen126. 
In addition small particle sizes are known to lead to stable colloidal solutions, 
preventing aggregation and sedimentation. Nanogels formed using the dansyl 
monomer, 5, were all made with a CM=1 (JRP09, JRP13 and JRP14), a concentration 
that is considered to be on the high side but one that ensures good yields of polymers. 
As the CM was closer to the solubility limit of the monomer in DMSO, the risk of 
obtaining larger microgels rather than desired nanogels was higher. The particle size 
was evaluated by dissolving the nanogels in 100% DMSO with sonication, with a 
concentration of 0.1 mg/ml nanogel. The sample was sonicated once more before 
analysis on the zetasier via dynamic light scattering (DLS). 
Table 3 – nanogel preparations with dansyl as the fluorescent tag. EBA is ethylene bis 
acrylamide, CM: Concentration of monomers. Ave diameter: the average particle size taken from 
a distribution of particles, measured on the DLS Zetasizer in 1% DMSO 99% water at a 
concentration of 0.1 mg/ml. 
JRP09 contained the largest amount of cross-linker and had the least polydispersed 
and smallest particle size of the three samples, shown in table 3. This is because the 
cross-linker tightens the structure into a small compact particle, preventing the 
nanogels from interacting with each other and aggregating. JRP13 had a significantly 
reduced yield compared to the others. This abnormality could be due to the particles 
with the small particle size being lost during dialysis. The nanogels were isolated using 
a 35000 daltons dialysis tube to remove the solvent and any small material remaining 
after polymerisation. As the particle size of JRP13 is mainly 8 nm a greater quantity of  
smaller, material is likely to have also been formed and been lost during the dialysis, 
having a negative effect on the yield. As can be seen in figure 23 the distribution of 
particle size was multimodal and much larger material than the average (35 nm) 
indicates, was also obtained. A multimodal system is much more likely to suffer from 
Polymer CM 
(%) 
Dansyl 
monomer, 
5 (%) 
 EBA (%) Ave. diameter (nm) Yield (%) 
JRP09 1 20 80 35±2.1 88 
JRP13 1 40 60 Mixture of 8±1.9 
250±209 (M) 
43 
JRP14 1 60 40 190±69 68 
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flocculation, than one with a monodispersed system. Due to the polydispersed system 
lowering the CM was investigated to see if a monodispersed system could be obtained. 
However, this had a negative effect on the yield. This could be due to a significant 
decrease in molecular weight of the material and therefore loss of the material through 
dialysis. Due to the polydispersity of the dansyl systems, and the likely influence of 
Brownian motion, the nanogels were highly likely to suffer from poor stability.  
Figure 23 - The average particle size trace of a nanogel containing the dansyl fluorescent tag 
A particle size trace of JRP09 at 0.1 mg/ml in 100 % DMSO. Fourty scans of the nanogel were 
carried out with each line (in different colours) representing the average particle size of the 
sample over 10 scans. 
Over the course of these studies further investigations did confirm that the colloidal 
solutions were not stable over a long period of time. The nanogel precipitated out of 
solution after just a few hours. Due to the poor stability of these nanogels, long-term 
suspension required for toxicity studies would be extremely difficult to achieve, even 
with parameter changes to the nanogel system. Therefore other fluorescent molecules 
were explored as possible candidates. As fluorescein is often used as a fluorescent 
tracker in biological159 and medical applications,160, 161 it was next to be evaluated as a 
potential tracker. 
2.3.3 Fluorescein as a fluorescent tag 
Fluorescein has been used for many applications including immunoassays,160 
biological imaging,159 measuring blood volume,162 and drug delivery163 to name a few. 
Its hydrophilicity and low detection limit160 are two of its greatest advantages and 
therefore supported its selection as the next candidate for tracking our nanogels. 
Fluorescein O-methacrylate (structure shown in figure 24) has a number of oxygens 
increasing its water solubility. Whereas dansyl has negligible water solubility, 
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fluorescein has a water solubility of 80 g/L.164  In addition fluorescein also has a much 
higher quantum yield (Φ = 0.95165) than that of dansyl (Φ =0.5166). This would also 
potentially reduce the amount of fluorescent tag required in the nanogel. The 
fluorescein tag has an emission wavelength of 537 nm, which again is outside the auto-
fluorescence ranges of the in vivo model. Although different from the other acrylamide-
based monomers, the methacrylate group should have a similar reaction rate to the 
acrylamide groups as the charge can still be delocalised across both oxygens. In 
addition this fluorescent monomer is readily available and inexpensive to use.  
 
Figure 24 – Fluorescein O-methacrylate, (6), the structure of the next potential fluorescent tag 
for our nanogels, and free fluorescein, (6a).  
Nanogels were synthesized using the fluorescein monomer; these nanogels are 
described in table 4 (page 66). The yields of these nanogels were significantly less 
than those obtained with the dansyl fluorescent tag. This could have been due to a 
number of causes, one of which could be the poor incorporation of the fluorescein 
monomer into the nanogel. This was further explored by evaluating the nanogels in a 
series of investigations. As previously, one of the first steps was the evaluation of the 
solubility of the fluorescein tagged nanogels. 
2.3.3.1 Solubility of the fluorescein tagged nanogels 
Solubility of the fluorescein tagged nanogels in water, as with the previous nanogels, is 
a key factor for the final application of drug delivery, as well as for use in the toxicity 
studies. Analysis showed that these fluorescent nanogels were soluble in ethanol, DMF 
and DMSO alongside ACN and acetone when they were combined with water at 
concentrations up to 0.1 mg/ml. However, for the in vivo studies it was necessary that 
the nanogels were soluble in water with as little solvent as possible, if not pure water. 
The fluorescein tagged nanogels were not soluble in 100 % distilled water but they 
were soluble with just 1% DMSO and 99% water (V/V) at concentrations up to 0.1 
mg/ml. Therefore the nanogels with fluorescein as their fluorescent tag had much 
better solubility characteristics than the dansyl tagged nanogels. This result was not 
unexpected due to the more polar structure of fluorescein compared to dansyl. As their 
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solubility was considered to be sufficient, evaluation of the fluorescein incorporation 
into the nanogels was subsequently investigated. 
2.3.3.2 Incorporation of fluorescein monomer into the nanogels 
Establishing and quantifying the incorporation of fluorescein O-methacrylate into the 
system was important, to ensure the final polymer had a reproducible and reliable 
composition of units that clearly reflected the prepolymerisation mixture. As previously 
with dansyl, investigations were made in order to obtain a reference line for the 
fluorescein monomer, however the resulting data were not satisfying. A satisfying 
calibration line could not be obtained (figure 25) and the plotted data appear to form a 
curve, initially giving a linear curve (until ~60 μM) however due to the large errors in the 
data establishing reliable incorporation rates of the Fluorescein O-methacrylate 
monomer in the nanogels could not be achieved when the Lambert Beer law was 
applied.  
 
Figure 25 – A graph showing the relationship between the concentration of fluorescein and its 
absorbance. Measured at 490nm absorbance. 
Table 4 – nanogel preparations with fluorescein as the fluorescent tag. CM: Concentration of 
monomers. EBA is ethylene bis acrylamide, CM: Concentration of monomers. Ave diameter: the 
Nanogel 
preparation 
CM 
(%) 
fluorescein O- 
methacrylate 
(%) 
Cross-linker 
(%) 
Average 
diameter DLS 
(nm) 
% yield 
JRP03 1 20 80 210±2.57 20 
JRP04 1 40 60 330±5.1 46 
JRP05 1 60 40 350±9.6 45 
JRP06 1 80 20 290±8.2 57 
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average particle size taken from a distribution of particles, measured on the DLS Zetasizer in 
1% DMSO 99% water at a concentration of 0.1 mg/ml.  
Table 4 shows the data relating to the fluorescein nanogels synthesis and 
characterisation. The chemical yields were overall lower than the ones obtained with 
the dansyl monomer and the particles sizes were overall larger. Interestingly it would 
appear that the yield increased with the percentage of fluorescein but not 
proportionally. This was concerning and potentially indicated that incorporation of the 
fluorescein monomer into the nanogels matrix was not consistent giving rise to 
unpredictable variation in behaviour during polymerisation, significantly reducing their 
reproducibility. The methacrylate nature of the fluorescein monomer could have led to a 
different reaction rate from the acrylamide cross-linker.  Although both contain a 
stabilising group, the difference could be enough to prevent interaction between the 
cross-linker and the monomer, thus creating much smaller and tighter nanogels 
consisting mainly of cross-linker, which would be lost during dialysis. To establish if 
enough fluorescein was incorporated into the nanogels for tracking, the fluorescence of 
the nanogels was evaluated.  
2.3.3.3 Fluorescent studies with fluorescein tagged nanogels 
Establishing the fluorescence intensity of the nanogels was a key step, as the 
incorporation of fluorescein into the nanogels by UV spectroscopy could not be 
determined. The fluorescein monomer had been introduced into the nanogel system for 
the sole reason of tracking the nanogel, therefore detecting reasonable fluorescence 
from these nanogels was central, if fluorescein was to be a successful tag. Nanogels 
JRP03 to JRP06 were polymerised with 20-80 % fluorescein O-methacrylate 
respectively (table 4). All nanogels had intense fluorescence, and even with just 20% 
fluorophore in the prepolymerisation, the mixture appeared to be fluorescent enough to 
be tracked, with the potential possibility of lowering the percentage of the fluorescent 
monomer even further. 
Figure 26 shows that all the fluorescein containing nanogels were emitting 
fluorescence at an excitation of 490 nm. There was no correlation between the amount 
of fluorophore in the nanogels and the emission. As JRP03 and JRP04 had 20-40% 
fluorescein in the polymerisation and had higher emission values than JRP05 and 
JRP06, which contained 60-80%flophore and had the lower two emission intensities. 
This could be due to the nanogels reaching a plateau due to the high quantum yield of 
fluorescein. However, coupled with the unexpected trend of increasing yield on 
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increasing % of fluorecein in the nanogel polymerisation, it is more likely that there was 
a problem during polymerisation of the nanogels.  To investigate what effect the 
fluorescein tag had on the nanogels, the particle size was measured via DLS. 
 
Figure 26 – Fluorescence intensity of 4 fluorescein containing nanogels measured at 0.01 
mg/ml in ethanol at an excitation of 490 nm.   
 
2.3.3.4 Particle size for fluorescein tagged nanogels 
The effect of the fluorescein tag on the particle size of the nanogels was investigated, 
as the nanogel needed to be ≤200 nm to be suitable for drug delivery120. All nanogels 
were measured at 0.1 mg/ml in 1% DMSO, 99% water (V/V). All of the particle size 
traces were much more uniform and giving much narrower distributions than those 
containing the dansyl tag. The dynamic light scattering particle size trace of JRP03 is 
given in figure 27. Although very stable, these particle sizes are too big to be eligible for 
drug delivery, as they would struggle to pass through capillaries. However this could be 
addressed by altering other parameters of the nanogel preparation at a later date.  
Fluorescein has a larger chemical structure than the dansyl group, and it is therefore 
expected to negatively impact the size of the nanogels. Data obtained with this 
fluorescent tag indeed showed that an increase in the percentage of fluorescein 
monomer used in the polymerization mixture resulted in a significant increase in 
particle size. JRP03 with just 20 % fluorescein had the smallest particle size of just 210 
nm, JRP04 with 40 % fluorescein tag was 330 nm and JRP05 with 60 % increased in 
size to 350 nm. However JRP06 with 80 % fluorescein in its polymerisation mixture had 
a particle size of 290 nm. These data clearly indicated that there were a number of 
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factors that were contributing to the inconsistency of the results, leading to a study to 
evaluate   the stability of the nanogels in a variety of solvents. 
Figure 27 – The particle size distribution of fluorescein containing nanogel JRP03 at 0.1 mg/ml 
in 1% DMSO 99% water. Fourty scans of the nanogel were carried out with each line (in 
different colours) representing the average particle size of the sample over 10 scans. 
2.3.3.5 Stability of the fluorescein tagged nanogels 
A major concern of using fluorescein O-methacrylate was the stability of the ester 
bond, i.e. whether the fluorescein molecule would hydrolyse when exposed to water. 
This would be a major issue as during isolation of the nanogels, via dialysis, and for the 
toxicity studies, as  the nanogels would have to be exposed to water for long periods of 
time.  
Figure 28 – Mechanism of the hydrolysis of Fluorescein O-Methacrylate 
The nanogels’ stability was analysed via thin layer chromatography (TLC) during 
polymerisation, dialysis and also after the nanogels were isolated via freeze-drying. 
Analysis showed that the fluorescent tag was slowly hydrolysed even during the 
polymerisation process, far too early for its practical use. It appeared that the DMSO 
was promoting hydrolysis of the ester bond as the spot of free fluorescein was present 
in the TLC plate when analysed during the polymerisation process. In addition the 
experiments confirmed that isolation via dialysis in water was not effective at removing 
the excess fluorescein molecules, which were not soluble in water and therefore 
precipitated in the dialysis tubing and remained there throughout dialysis. To 
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counteract this, dialysis was attempted using 50 % acetone, 50 % water (V/V) in which 
fluorescein was soluble. When the dialysis eluent was altered, hardly any fluorescein 
was detected in the nanogels, indicating therefore that incorporation of the fluorescein 
tag into the nanogel matrix had been very poor.  
Further studies were carried out to establish a better solvent system in which to 
prepare the polymers, however each attempt did not lead to any improvement. DCM 
gave the least amount of fluorescein release from the nanogel, however AIBN required 
an activation temperature of 60 °C and with a boiling point of 40 °C it was not a viable 
combination. Other solvents, (ACN and DMF) were tried with a much lower CM of 0.5% 
however these solutions led to macrogelation. Even if a viable polymerisation system 
could have been attained, it was highly likely that the fluorophore would have been 
released during the dialysis phase or the toxicity studies. Therefore it was decided to 
investigate  other potential fluorescent monomers with a more stable bond between the 
fluorophore and the nanogel. 
2.3.4 Coumarin as a fluorescent tag 
A new fluorescent tag that was evaluated was trifluoromethylcoumarin acrylamide 
(TCA), which has an amide bond that can be used to link the coumarin unit to the 
nanogel. TCA is also a smaller molecule than fluorescein and would therefore have 
less impact on the final size of the nanogel. Coumarin derivatives have been used 
previously to tag PEG based block polymers, which self assemble to form micelles. In 
this application the coumarin does not prevent solubility of the polymer in water to at 
least 1 mg/ml. In addition, only one unit of coumarin is used per block polymer which 
remains fluorescent enough to detect at concentrations as low as 8 μg/ml167. As 
coumarin has been incorporated into another polymeric nanomaterial (micelles) well, 
without having a negative impact on the material’s characteristics and also had the 
benefit of being readily available, coumarin was the next fluorophore set for analysis.  
7-[4-(Trifluoromethyl)coumarin] acrylamide (TCA) (structure is displayed in figure 29) is 
a very interesting fluorescent molecule, it has a nice compact chemical structure, with 
an aromatic system that can contribute to hydrophobic interactions, the acrylamide 
polymerisable unit which ensures high stability of the tag-nanogel link and the presence 
of the trifuoromethyl unit with high dipole characteristics, that should help with the 
overall solubility. In terms of fluorescence emission, with its maximum around 430 nm. 
although it is outside one of the zebrafish autofluorescence zones, it does fall in the 
middle of the second autofluorescence band, typical of when the cells die. This issue 
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was identified as having the potential to disrupt analysis of the nanogels in vivo, 
however advice was given that this problem could be circumvented, by maintaining the 
settings on the confocal microscope, the smart gain was maintained at 729 and the UV 
light intensity was set at 60 %. The presence of the acrylamide group, would also allow 
us to expect a good yield in tag incorporation in the acrylamide-based nanogels.  
  
Figure 29 – Structure of 7-[4-(Trifluoromethyl)coumarin] acrylamide, (7) and 7-amino-4-
(trifluoromethyl) coumarin, (7a). 
Three nanogels were initially prepared, with the aim to carry out some preliminary 
studies that would help evaluate whether this monomer was a viable option (table 5).  
Table 5– Nanogel preparations with coumarin as the fluorescent tag. CM: Concentration of 
monomers. Ave diameter: the average particle size taken from a distribution of particles, 
measured on the DLS Zetasizer in 1% DMSO 99% water at a concentration of 0.1 mg/ml. 
Where A is acrylamide, EBA is ethylenebisacrylamide and TCA is 7-[4-
(Trifluoromethyl)coumarin] acrylamide. 
The yields of the TCA tagged nanogels were all fairly low, less than 50%. In fact the 
yield appeared to decrease with increase of 7-[4-(Trifluoromethyl)coumarin] acrylamide 
in the formulation. JRP29 has 48% yield with just 10 % TCA content, JRP30, with 20 % 
TCA content, has a yield of 37%. The yield of JRP31, with the highest content of TCA 
at 30 %, is just 17%, which is a drop in yield of 54% compared with JRP30. as the drop 
in chemical yield is proportional to the concentration of TCA, and this phenomena had 
not been observed before, it was concluded that the TCA was likely to be quenching 
the radicals produced by the AIBN initiator and therefore reducing the overall yield. 
This hypothesis was actually supported by literature data. 
Quinones, which contain two conjugated oxygens, are known to quench radicals due to 
stabilisation of the radical over several resonance structures168. The radical is then 
stabilised, making it less reactive and stalling the active chain radical, which prevents 
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Nanogel 
preparation 
CM TCA (%) A (%) XL (EBA) 
(%) 
Ave. 
diameter 
(nm) 
Yield (%) 
JRP29 1 10 20 70 72±0.47 48 
JRP30 1 20 20 60 62±0.84 37 
JRP31 1 30 20 50 61±1.9 17 
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further addition of monomer. Trifluoromethyl coumarin has a semi-quinone structure 
and therefore has the potential to inhibit the radical polymerisation. Some coumarin 
derivatives have been exploited for this trait and used to actively scavenge free-
radicals in the body to prevent oxidative damage169, 170. Therefore although it may 
initially impact on the polymerisation process, the incorporation of the coumarin 
monomer into the nanogel could have a beneficial side effect whilst circulating within 
the body. This radical-inhibitory effect can be counteracted by an increase in AIBN, so 
this result was not of a huge concern. Of higher priority were investigations into the 
impact of the hydrophobicity of coumarin on the nanogel’s overall solubility.  
2.3.4.1 Solubility of coumarin tagged nanogels 
The application of these nanogels as a drug delivery system requires them to have 
sufficient solubility in water, both for administration purposes of the end product but 
also in the short term for enabling the in vitro and in vivo studies. All the monomers in 
the nanogel preparation were chosen with their suitability for solubility in mind. 
However, finding a fluorescent monomer with good fluorescent properties and high 
water solubility is challenging due to the opposing characteristics. Fluorescence occurs 
in molecules with conjugated systems, which tend to be highly hydrophobic. Coumarin 
itself is a hydrophobic molecule and could therefore limit the solubility of the nanogels 
tagged with TCA. Due to the presence of the coumarin unit the nanogels were not 
100% soluble in water at 0.1 mg/ml but the coumarin containing nanogels were soluble 
at 0.1 mg/ml in just 1% DMSO with the remaining 99% being made up with distilled 
water (V/V) which was an acceptable ratio for this stage of the process. This increase 
in water solubility over the dansyl tag, and the more stable amide bonds linking the 
coumarin to the nanogel were promising results. The next step focused on the 
evaluation of the coumarin incorporation in the nanogels.  
2.3.4.2 Incorporation of the coumarin monomer into the nanogel  
In order to estimate the incorporation of coumarin into the nanogels, the molar 
absorption coefficient of the coumarin monomer needs to be determined. Estimating 
the incorporation of TCA into the system is important, to ensure the final polymer has a 
reproducible and reliable composition of units that clearly reflect the prepolymerisation 
mixture. Therefore a precursor to the coumarin acrylamide monomer was sort after, in 
order to perform UV anlysis and gain a reference line for the fluorophore. One 
molecule, which was commercially available and therefore highly advantageous to use, 
was that of 7-amino-4-(trifluoromethyl) coumarin (TMAC). TMAC does not contain the 
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double bond present in TCA but also loses the carbonyl group, which will have an 
impact on the molar absorption coefficient. Therefore to analyse the difference between 
the two molecules the UV spectra of the two molecules were compared with the 
spectra of JRP29.  
 
Figure 30 - The UV-Vis spectra of TCA, TMAC and nanogel JRP29 in 100 % DMSO. Where 
TCA is 7-[4-(Trifluoromethyl)coumarin] acrylamide, (7) and TMAC is 7-amino-4-(trifluoromethyl) 
coumarin, (7a). 
TMAC clearly has a significant peak shift to the right compared to TCA and the 
absorption value of TMAC is significantly lower than TCA, despite the concentration of 
TMAC being higher than that used for TCA. The TCA peak for JRP29 can be seen to 
lie directly beneath the peak in the TCA Spectra and therefore gave a much better 
comparative for the nanogels. The use of TCA with the saturated bond being hydrated 
would have been a better choice, however as TCA was commercially available, it had 
excellent solubility in DMSO and the fluorophore was ultimately just to enable tracing of 
the nanogel for toxicity studies, it was considered to be within close enough range, 
despite the double bond, to allow an insight into the incorporation of the monomer into 
the nanogel. Therefore a reference line was obtained using TCA, to which the 
absorbance of known concentrations of the various nanogel preparations, were 
compared. The reference line, figure 31, was established by using the cross-dilution 
method, measuring the absorbance of the TCA solutions at 345 nm (which was 
previously established to be the absorption peak of TCA in JRP29) at varying 
concentrations.  
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Figure 31 - A calibration curve of TCA in 100 % DMSO. Absorbance measured at 345 nm. The 
extension co-efficient is 16821 and the R2 value is 0.9964. 
Once the calibration curve for TCA was established, several different concentrations of 
the coumarin tagged nanogels were analysed via UV-Vis spectrometry and the 
absorbance was determined for each concentration. Several coumarin containing 
nanogels were evaluated, with approximately 0.35 mg of each polymer added to 2 ml 
of DMSO. Various dilutions, between 0.015 and 0.06 mg/ml, were formed of each stock 
solution and each of the dilutions was measured for their absorbance at 345nm. The 
number of moles of TCA was calculated using the molar absorption coefficient and 
compared to the concentration of the nanogel. The results of the experimental number 
of moles of TCA in each nanogel were calculated for every dilution and the results were 
averaged. These were cross-referenced with the calibration curve and theoretical 
incorporation to obtain the incorporation of coumarin in each nanogel. 
Nanogel TCA 
(%) 
A (%) XL 
(EBA) 
(%) 
Yield 
(%) 
𝑛!"  /mg of 
nanogel 
(exp) 
(mol/mg) 
𝑛!"  /mg 
of nanogel 
(theo) 
(mol/mg) 
Incorporation 
(%) 
JRP29 10 20 70 48 5.09*10-7  6.24*10-7 86 
JRP30 20 20 60 37 1.30*10-6 1.95*10-6 >99 
JRP31 30 20 50 17 1.35*10-6 1.21*10-6 >99 
Table 6 – incorporation results of the coumarin monomer into the nanogel. A= acrylamide, EBA 
= ethylene bis acrylamide.  𝑛!"= number of moles. exp = experimental result. theo = theoretical 
result.  
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The data confirmed that the TCA monomer was incorporated with a good ratio. JRP29 
has the lowest incorporation of 86%, this nanogel has the lowest amount of coumarin 
monomer in the polymer and has the highest yield. The poor chemical yields in nanogel 
synthesis have already been discussed together with the radical quenching role of 
coumarin. This characteristic is also expected to impact the incorporation. With higher 
amounts of coumarin in the polymerisation, more of the radicals will be stabilised, 
suspending the polymerisation faster, without much incorporation of the cross-linker. 
Therefore the higher the amount of coumarin in the mixture, the lower the overall yield 
and the higher the incorporation value.  
On close analysis, the results appear to indicate a very good incorporation of the tag 
into the polymers, with over 99% of monomer estimated to be incorporated into JRP30 
and JRP31. However, if this fluorophore was chosen, investigations into increasing the 
amount of initiator would be necessary to ensure nanogels are composed of the 
desired monomer ratios. Before in depth nanogel studies were carried out, establishing 
the size of these nanogels was required to assess their suitability for a nanodelivery 
system. 
2.3.4.3 Particle size of coumarin tagged nanogel  
As mentioned previously, efficient drug delivery systems should ideally have a particle 
size smaller than 200 nm126. All coumarin tagged nanogels were measured at 0.1 
mg/ml in 1% DMSO, 99% water (V/V). All of the particle size traces were much more 
uniform and giving much narrower distributions than those containing the dansyl or 
fluorescein tags. The size of the nanogel reduces slightly on increase of the amount of 
coumarin present (table 6). JRP29 with just 10 % TCA has a particle size of 72 nm, 
JRP230 with 20 % TCA has a particle size of 62 nm and JRP231 has a particle size of 
61 nm and contains 30 % TCA. The hydrophobicity of the nanogel increased as the 
coumarin content increased, thus reducing the swelling of the nanogel and maintaining 
a more compact structure. An example of the particle size distribution of JRP29 
coumarin nanogel is shown in figure 32.  
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Figure 32 - The particle size distribution of coumarin containing nanogel JRP29 at 0.1 mg/ml in 
1% DMSO 99% water. Fourty scans of the nanogel were carried out with each line (in different 
colours) representing the average particle size of the sample over 10 scans. 
At this stage the nanogels were obtained, with with particle sizes in the desired range, 
and they also displayed a good water solubility and incorporation of the fluorophore, 
therefore the only outstanding issue to be evaluated related to the fluorescence 
emission and whether this could be considered high enough to study the incorporation 
and toxicity of the nanogels both in vitro and in vivo.  
2.3.4.4 Fluorescent studies with coumarin tagged nanogels 
The primary function of the fluorophore is to enable tracking of the nanogel during in 
vitro and in vivo experiments. One of the nanogels (JRP29) was evaluated for its 
fluorescence at the required concentrations for the toxicity studies of 0.1 and 0.01 
mg/ml.  Figure 33 shows that the nanogel containing coumarin was emitting 
fluorescence at an excitation of 377 nm; therefore TCA had successfully been 
incorporated into the nanogel. The fluorescence was evaluated at two different 
concentrations for JRP29, 0.1mg/ml and 0.01mg/ml. Both solutions clearly show strong 
fluorescence emission, with a good dependence on concentration. 
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Figure 33 – Fluorescence intensity of the coumarin tagged nanogel JRP29 at 0.1 mg/ml and 
0.01mg/ml in ethanol. Excitation is 377 nm and emmission is 445 nm. 
The TCA tagged nanogels had a small, narrow particle size, reasonable fluorescence 
emission, a stable amide bond and therefore good chemical stability, reasonable 
solubility and good incorporation thus warranted further investigation. Two slight 
concerns with the nanogels needed to be addressed, the first was the likely quenching 
of the free radicals by the coumarin monomer which has a negative impact on the yield 
and the second is the need for complete water solubility, for which the overall drive 
during the following studies is to increase the water solubility.  
2.4 Synthesis of soluble fluorescent nanogels 
In the next stage of the project the focus was the optimisation of the nanogel 
formulation with the aim of obtaining nanoparticles with ideal characteristics for the 
application in drug delivery.  In order to achieve this, the work concentrated on 
improving the chemical yield, and obtaining particles with smaller size and also 
considerably increasing the water solubility.  
2.4.1 Addition of acrylic acid 
The coumarin tagged nanogel described in the previous section showed good 
solubility, although this was not deemed sufficient to carry out preliminary studies of 
toxicity, therefore the addition of a comonomer was required, that would increase the 
hydrophillic nature of the nanogel. One monomer that has been widely used to 
increase solubility of many materials is acrylic acid. Acrylic acid has been used to make 
even highly hydrophobic material, such as carbon nanofibres, hydrophilic by attaching 
acrylic acid to their surface171. Acrylic acid has also been used as a co-monomer in 
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many different polymer preparations due to its hydrophilic nature, including block co-
polymers172, hydrogels173 and nanogels174. Acrylic acid contains two oxygen atoms in 
its small structure, which significantly increases the water interaction of the nanogel 
when it is incorporated. 
Acrylic acid has a pKa of 4.25175 which at neutral pH carries a negative charge as the 
acid is largely dissociated. Therefore the negatively charged oxygen will form ionic 
interactions with H+ ions present in water, alongside those which are undissociated 
interacting with water through hydrogen bonds, both  of these features aiding the 
solubility of the nanogels. Not only does acrylic acid substantially increase the 
hydrophilic nature of the nanogels, it also introduces a negative charge. This therefore 
gives a secondary use for the co-monomer by potentially using the carboxylic acid 
group to interact with a drug. Acrylic acid (AA) was introduced into the nanogel at 10% 
of the prepolymerisation mixture to evaluate its effect on these acrylamide-based 
nanogels. There was a significant increase in solubility, where before 1% of DMSO was 
required to solubilise the nanogel, on addition of AA the nanogel was 100% water 
soluble at 0.1mg/ml.  Not only this, with the addition of AA the yield of the nanogel also 
increased by over 18%. Due to this positive result, acrylic acid was included on all 
further nanogel preparations to aid their solubility in water. 
Nanogel 
preparation 
TCA 
(%) 
XL 
(%) 
AA 
(%) 
A 
(%) 
CM 
(%) 
AIBN 
(%) 
Yield 
(%) 
Solubility 
in 100% 
water 
(mg/ml) 
Soluble in 
1%DMSO 
99%water 
(mg/ml) 
JRP29 10 70  20 1 1 48 No 1 
JRP2105 10 70 10 10 1 1 61 0.1 >1 
Table 7 – Nanogel preparations showing the effect of addition of acrylic acid. JRP29 and 
JRP2105 were polymerised for 4 days at 70°C using Ethylene bis acrylamide as the cross-linker 
(XL) and JRP254 and JRP2106 were polymerised for 4 days at 70°C, using Methylene bis 
acrylamide as the cross-linker (XL). 
[This project was interrupted after 1 year of study to undertake a placement as part of a 
Marie Curie IAPP project in a company, Polyintell, in France. During the suspension of 
studies optimisation of polymerisation parameters by other members of the group led to 
significant findings.] Firstly, methylene-bis-acrylamide was identified as a better cross-
linker for the nanogels, reducing hydrophobicity due to the reduction in carbon atoms 
between the acrylamide groups and therefore also leading to a tighter more compact 
structure. Secondly it was shown that reduction of the total monomer concentration (CM 
) from 1% to 0.5% led to nanogels with smaller particle size and lower polydispersity. 
Furthermore data suggested that reduction of the polymerisation time from 4 days to 2 
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days did not significantly impact on the chemical yields, while improving the overall 
time required to obtain each preparation. 
As a result of the data obtained in the group, it was agreed that the changes could also 
be implemented in this project, as better results were expected. Therefore a series of 
experiments were carried out following my return to QMUL using MBA as the cross-
linker, Cm = 0.5% and a polymerisation time of 2 days. The next section describes the 
results obtained.  
2.4.2 Cross-linker choice and content 
As the research in the group showed methylene bis acrylamide as a better cross-linker 
for nanogel formulations, its use in this acrylamide-based system was considered a 
high priority. In addition, research by Ken Shea had proven that nanogels could be 
obtained using concentrations of cross-linker as low as 5%176. Therefore investigations 
were carried out not only to evaluate which of the two cross-linkers would afford better 
nanogels, but also to establish the lower limit for the cross-linker concentration that 
would still lead to nanogels. The work was entirely driven by the objective of 
significantly increasing the water solubility of the nanogels, by partially offsetting the 
presence of the highly hydrophobic fluorescent tag.  
The first step was to lower the total concentration of the monomers, to a value of CM 
equal to 0.5%, shown to be optimal. The acrylic acid concentration was maintained to 
10 %, as before, to retain the solubility, while the concentration of 
trifluoromethylcoumarin acrylamide (TCA), was dropped to 5%, to further aid 
hydrophilicity of the nanogels. In previous studies TCA was shown to have a high 
intensity of fluorescence, so it was expected not to impact significantly on the tracking 
of the nanogels.  
Nanogel 
preparation 
TCA 
(%) 
EBA 
(%) 
MBA 
(%) 
AA 
(%) 
A 
(%) 
CM 
(%) 
Yield 
(%) 
Average 
diameter By DLS  
(nm) 
JRP255 5 20  10 65 0.5 25 295±18 
JRP257 5 50  10 35 0.5 27 352±22 (M) 
JRP259 5 70  10 15 0.5 51 509±34 (M) 
JRP241 5  20 10 65 0.5 30 107±4 
JRP251 5  50 10 35 0.5 58 130±16 
JRP253 5  70 10 15 0.5 51 255±45 (M) 
Table 8 – Nanogel preparations for cross-linker comparisons. Polymerisation was carried out at 
70 °C for 2 days in DMSO. JRP251 and JRP253 were measured in 1%DMSO at 0.1mg/ml for 
DLS, all others measured in 100% water 0.1mg/ml. M=multimodal. 
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Analysis of the data, gathered in table 8, indicates that the choice of MBA or EBA does 
not have any significant impact on the chemical yields of the nanogels. However the 
concentration of cross-linker in the polymer solution appears to positively impact the 
yield, with higher percentages leading to better yields. For example JRP255 with 20 % 
EBA has a yield of just 25% however when the EBA is increased to 70 % the yield is 
increased to over 50 %. The loss of material is likely due to loss of smaller material 
during the dialysis step used for the isolation of the nanogel. This is also confirmed by 
the fact that the higher the percentage of cross-linker and the larger the particles tend 
to be. This is true for both cross-linkers, however the MBA nanogels have a much 
smaller particle size than those containing EBA. For example JRP255 with 20% EBA, 
has an average particle size of almost 300nm whereas the equivalent MBA nanogel, 
JRP241 has a particle size of just 107nm. MBA has just one CH2 group between the 
acrylamide groups, instead of the two in EBA, thus reducing the size of the cross-liner 
and creating a tighter more compact nanogel. This therefore gives an overall smaller 
and less polydispersed particle size. Taking into consideration both the yields and 
average particle sizes, the MBA is incorporated into the nanogel more effectively, 
losing similar amounts of material with half the particle size of equivalents containing 
EBA. 
Due to the significant improvement in the nanogels, MBA was chosen as the final 
cross-linker and its percentage maintained below 50 molar percent of the 
prepolymerisation mixture. The CM fixed at 0.5% was giving particle sizes in the ideal 
range therefore further preparations were all formed using a total monomer 
concentration of 0.5%. 
2.4.3 Amount of initiator required 
Traditionally the percentage of initiator used for the nanogels synthesis in the group 
has always been kept at 1% of all the double bonds in the mixture. However, as the 
yields were still less than 50%, it was decided to investigate whether an increase in 
initiator content would help increase the overall yield. Termination of the radical 
polymerisation reaction can happen via three mechanisms: firstly, termination by 
combination, whereby two radicals react to form a bond, combining the two polymer 
chains; secondly termination by disproportiation, where two radicals react but the two 
polymers chains remain separated, leaving a saturated bond on the end of one and an 
unsaturated bond on the other; lastly chain transfer can occur, in which case a 
hydrogen is scavenged from another molecule (which could also be the solvent) and 
Judith Ray 2014  Chapter 2  
  79 
 
termination of that polymer occurs although another radical is yielded147. These three 
processes are affected by the monomers in the system and their reactivities. Therefore 
the amount of initiator tailored for a particular system needs to be identified, in order to 
achieve optimal yields of polymer without promoting particle-particle reactions. In this 
particular case the presence of the semiquinone structre in the fluorescent tag and its 
ability to promote quenching required additional experiments, where the concentration 
of initiator was varied to maximise the nanogel yields.  
A small set of experiments was carried out where the concentration of AIBN was varied 
between 1% and 3% while maintaining all the other parameters unaltered. 
 
 
 
 
Table 9 – Nanogel preparations; carried out at 70 °C for 2 days with a CM of 0.5% in DMSO. 
Particle sizes all carried out in 100% water at 0.1 mg/ml. 
The results, presented in table 9, confirmed as expected, that the yield did increase as 
a result of the initiator increase. JRP216 with just 1% AIBN had a yield of 48%, when 
AIBN was increased to 2% in nanogel JRP217 the yield increased by 43% to give 69% 
and also reduced the particle size of the nanogel. By introducing more initiator into the 
system, more radicals will be formed initially, forming many more, but smaller 
nanogels, which would reduce their average particle size overall. However on further 
increase of AIBN to 3% (JRP218) the yield increases by 20 % but there is a significant 
undesired increase in particle size, and in fact formed a microgel. This increase in 
initiator was a step too far, creating an excessive number of radicals promoting inter-
particle polymerisation, forming much larger polymer gels. From the positive results 
obtained when the initiator was increased to 2% of the bonds, 2% AIBN was chosen as 
the default concentration for the initiator. 
2.4.4 Polymerisation time 
Nanogels obtained during the studies to identify the most suitable fluorescent tag were 
all polymerised for four days, as this was considered to be the optimal length of time in 
the group. In order to establish whether this timeframe could be improved to shorten 
the overall length of time required for the polymerisation, a number of experiments 
Nanogel 
preparation 
TCA 
(%) 
XL 
(%) 
AA 
(%) 
A 
(%) 
AIBN 
(%) 
Yield 
(%) 
Average 
diameter By DLS  
(nm) 
JRP216 5 35 10 50 1  48 191±6 
JRP217 5 35 10 50 2  69 110±4 
JRP218 5 35 10 50 3  83 >1000 
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were carried out. Table 10 shows the data relative to three nanogel preparations, all 
done under the same set of experimental conditions, only differing in polymerisation 
time. Due to the improvement seen with MBA over EBA when analysing cross-linkers 
in section 2.3.1, MBA was used in these nanogels. 20 % MBA cross-linker was chosen 
due to the reduced particle size obtained in comparison to the nanogels containing 35, 
50 or 70 % MBA cross-linker. MBA was used as cross-linker in a concentration of 20 
%. Although this is low and the yield was expected to be less than 40 % based on 
previous work, it was chosen nevertheless because the particle sizes, determined by 
DLS were all in the range considered to be valuable for drug delivery (particle size less 
than 150 nm) 
Nanogel 
preparation 
TCA 
(%) 
MBA 
(%) 
AA 
(%) 
A 
(%) 
Polymerisation 
time 
Yield 
(%) 
Average 
diameter 
By DLS  
(nm) 
Solubility 
in water 
(mg/ml) 
JRP232 5 20 10 65 1 day 32 141±26 >1 
JRP241 5 20 10 65 2 days 30 107±4 >1 
JRP238 5 20 10 65 3 days 33 188±2 
(M*) 
>1 
Table 10 – Nanogel preparations carried out at 70 °C, at a CM of 0.5% in DMSO. M* = 
multimodel distribution. Particle sizes all carried out in 100% water at 0.1 mg/ml. 
Analysis of the data indicate that effectively there is no significant change in the 
percentage yield of nanogel obtained as a result of changing the polymerisation time. 
There seems to be a more substantial variation in particle size, as a result of variations 
in polymerisation times, however as these were not really significant and did not 
appear to have a trend, it was decided to use a 2 day polymerisation time to reduce 
preparation time. 
2.4.5 Concentration of fluorescent tag 
Trifluoromethylcoumarin acrylamide (TCA) was set at 5% of the nanogel monomers in 
the initial studies to investigate other parameters and their effect on the nanogel. 
Having decided on the limits for the other variables, the final parameter to investigate 
was the effect of TCA on the nanogel. Previous studies (section 2.2.4.2) showed that 
TCA incorporation was very good, and 10-30 % of the nanogel composition had been 
TCA content. However, the solubility of these nanogels was still not sufficient as they 
required 1% DMSO in order to be solubilised. Since the initial investigations into using 
TCA as a fluorophore, the protocols for the preparation of the nanogels had changed 
significantly, with the addition of acrylic acid, the use of MBA instead of EBA and 
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changes to its concentration, shorter polymerisation times and high amount of initator. 
Therefore new nanogels were prepared with TCA concentrations ranging between 2.5 
and 10 % in the polymerisation mixture.  
Nanogel 
preparation 
TCA 
(%) 
MBA 
(%) 
AA 
(%) 
A 
(%) 
CM 
(%) 
Yield 
(%) 
Average 
diameter 
By DLS  
(nm) 
Solubility 
in water 
JRP234 2.5 20 10 67.5 0.5 40 171±41 >10mg/ml 
JRP235 5 20 10 65 0.5 31 123±2  10mg/ml 
JRP236 10 20 10 60 0.5 30 153±3  0.1mg/ml 
Table 11 – Nanogel preparations with varying amounts of fluorescent tag. Particle sizes all 
carried out in 100% water at 0.1 mg/ml. 
Three nanogel preparations were obtained, all again using 20% MBA as cross-linker. 
The percentage yields were essentially unaffected by the variations in concentrations 
of the fluorescent tag and the particle size (carried out in water at 0.1 mg/ml) was also 
not significantly altered and it was comprised between 100 and 200 nm. However the 
most significant change that was observed related to the solubility of the isolated 
nanogels. The variation in hydrophilicity is very substantial when going from 10% TCA 
to 2.5%, with a 100-fold increase in solubility, results shown in table 11.  
In order to analyse the nanogels using fluorescence spectroscopy with as much 
accuracy as possible, samples of the polymers were prepared with similar 
concentration of coumarin tag, with each of the nanogels prepared to form a 1x10-5 mM 
TCA solution. Therefore twice the mass of JRP234 (2.24 mg in 2 ml) was used to that 
of JRP235 (1.12 mg in 2 ml) and half as much mass was used for JRP236 (0.56 mg in 
2 ml). These solutions were measured for their fluorescence at an excitation of 345nm. 
The emissions (measured at 445 nm) of the nanogel solutions are presented in table 
12. JRP234 (2.5% TCA) contains half the amount of TCA than JRP235 (5%) and 
should therefore produce twice the fluorescence intensity over JRP234. A significant 
increase in fluorescence was seen between that of JRP234 and JRP235, at the same 
concentration of nanogel. JRP235 however does not improve its emission over JRP234 
even though the coumarin content has once again increased, from 5% in JRP235 to 10 
% in JRP236 as its emission would be their emission would be roughly the same at the 
same concentration of nanogel. Therefore both a significant decrease in solubility of 
the nanogels is seen, when 10 % coumarin tag is used, and no benefit seen from the 
increased amount of fluorophore. This could be due to self-quenching, if the molecules 
are in too close contact (which by an increase in content in the nanogel preparation 
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could be made possible) and collide with each other it is possible the excited 
molecules, on collision, lose their energy177. 
Nanogel % TCA 
in 
nanoge
l  
Conc of 
nanogel 
(μg/ml) 
Emission 
intensity  of 
sample (cps) 
Theoretical 
Emission at  
57 μg/ml (cps) 
TCA 
incorporation 
(%) 
JRP234 2.5 57 2084681 2084681 >99  
JRP235 5 23.5 1694161 3388322 >99 
JRP236 10 11.8 845320 3381280 >99 
Table 12 – Fluorescence emission at 445 nm (excitation 345 nm) of coumarin incorporated 
nanogels and the percentage of incorporation.  
Nanogels containing just 2.5-5% coumarin in their formulation produce yields 
comaparative or higher to those containing higher quantities of coumarin tag. The 
solubility is significantly increased (100 fold) when the coumarin content was dropped 
from 10 % to 5 or 2.5%, which was the major focus in these latter investigations. 
Having just 5% TCA or less in the nanogel polymerisation yielded the best results, 
therefore JRP234 and JRP235 were utilised moving forward. 
2.4.6 Final Nanogel preparation and characterisation  
To ensure reproducibility subsequent sets of nanogels were prepared following an 
identical protocol to JRP234 and JRP235. JRP240 and JRP241 gave very similar 
results to their predecessor equivalents, reinforcing their potential as drug delivery 
system. Therefore the general procedure was identified as 10 % acrylic acid 2.5-5% 
TCA with just 20 % MBA cross-linking, the remainder of the nanogel being composed 
of acrylamide. The monomers were polymerised at 70 °C for 2 days with 2% AIBN 
using a CM of 0.5% in DMSO. The nanogels used for the toxicity studies are listed in 
table 13. 
Nanogel  TCA 
(%) 
MBA 
(%) 
AA 
(%) 
A 
(%) 
CM 
(%) 
Yield 
(%) 
Average 
diameter 
By DLS  
(nm) 
Solubility 
in water 
(mg/ml) 
Nanogel 
formulation 
and batch no. 
JRP234 2.5 20 10 67.5 0.5 40 171±41 >10 NG1 (batch1) 
JRP235 5 20 10 65 0.5 31 123±2  10 NG2 (batch1) 
JRP240 2.5 20 10 67.5 0.5 25 123±56  >10 NG1 (batch2) 
JRP241 5 20 10 65 0.5 31 107±4 10 NG2 (batch2) 
Table 13 – final nanogel preparations for toxicity testing, all nanogels were polymerised for 2 
days at 70 °C with 2% AIBN. 
The solubility and size of the nanogels are consistent between the equivalent nanogels 
and very similar particle size distributions were obtained. There was a slight drop in 
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percentage yield for JRP240, which was due to material being lost during dialysis. As 
these nanogels proved to be reliable and reproducible, the nanogels were fully 
characterised by dynamic light scattering and TEM before moving on to investigate 
their toxicity. To facilitate the reading of this thesis from now on the nanogels will be 
referred to as NG1 and NG2 according to their formulation with the batch number 
associated with that formulation (see table 13). The two formulations can be viewed in 
table 14. As JRP29 was also required for further analysis in chapter 3, this has also 
been given the preparation name NG3, no batch number is associated with this as only 
one batch was produced.  
Nanogel preparation NG1 NG2 NG3 
TCA 2.5 5 10 
Acrylic acid 10 10 0 
Acrylamide 67.5 65 20 
Methylene bis acrylamide 20 20 0 
Ethylene bis acrylamide 0 0 70 
AIBN 2% 2% 1% 
CM 0.5 0.5 1 
Polymerisation time 2 days 2 days 4 days 
Table 14 – The three different nanogel preparations used for further studies showing the ratio of 
the monomers in the system, CM is the concentration of monomers. 
2.4.6.1 Particle size via dynamic light scattering using a Malvern Zetasizer 
Throughout this chapter dynamic light scattering (DLS) has been touched upon as a 
method of obtaining an average particle size or average diameter of a nanoparticle. 
DLS, also referred to as Photon Correlation Spectroscopy (PCS) provides the 
hydrodynamic radius of particles. The technique exploits the Brownian motion theory 
and relates the size of particles to their motion in suspension. Samples are analysed by 
illuminating them with light, in this case a laser, and measuring the scattered light. 
Particles that are ≤ 250 nm in size scatter light in every direction; however, when a 
group of particles is present constructive and destructive interferences will occur and 
consequently the scattered light intensity will vary. As these particles are in solution 
they are constantly moving, therefore the light intensity is constantly rising and 
depleting over time forming intensity fluctuations178. A detector is placed at 90 to the 
beam to avoid detection of reflected light and the intensity is recorded as a function of 
time. The random movement of the particles results in broadening of the signal. The 
rate of these light intensity fluctuations is measured on the Zetasizer and the similarity 
of two signals in a particular time frame τ (1 μs) are correlated. An auto-correlation 
function G(τ) (the function with a time shift) can be defined as: 
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𝐺 𝜏 =   𝐺!𝑒!!"#   Equation 3  
Where D is the translational diffusion coefficient 
The movement rate of particles is dependant on their size, larger particles will move 
slower and smaller ones faster. Therefore measuring the light fluctuations and 
correlating them to their rate of fluctuation can indicate the size of particles. The 
hydrodynamic radius d(H) can be calculated using the Stoke-Einstein equation 
(equation 4) once the speed of fluctuation has been quantified using the translational 
diffusion coefficient (D).  
𝑑 𝐻 = !"!!"#   Equation 4  
 Where k is the Boltzman constant, T is the temperature in Kelvin and η is the viscosity. 
Although the hydrodynamic radius d(H) gives a good indication of the size of particles, 
it is dependent on the nature of the solvent, how the particles swell in that solvent and 
the viscosity of the sample and therefore not an accurate representation of the real 
core particle size179. Therefore there are often discrepancies between the particle size 
obtained via DLS and particle sizes obtained via other methods such as Transmission 
electron microscopy.  
The standard size distribution of a sample given by the zetasizer is in light intensity, a 
volume distribution of particle size can be extrapolated from the light intensity using the 
refraction index of the solvent and polymer investigated. From the volume distribution a 
number distribution can also be calculated. However, small errors in collected or 
correlated data can give large errors in the final hydrodynamic radius. For example, if a 
solution contains two different sized populations of particles equal in number, some of 
5 nm and some with 50 nm, three very different graphs would be given (figure 34).  
Figure 34 – Number, Volume and light intensity distributions of a sample containing two 
populations of particles, one with 5 nm and one with 50 nm diameters178.  
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As the number of particles in each of the two populations was equal, peaks of equal 
size can be seen in the number distribution. However, when observing the volume 
distribution of the particles the peak for those at 50 nm is 1000 times larger than that of 
those at 5 nm as would be expected according to the volume of a sphere (4/3 πr3). The 
light intensity for the 50 nm particles is larger still, with an increase of 106. This can be 
explained by Rayleigh light scattering as larger particles scatter more light than smaller 
ones. The Rayleigh scattering equation shows there is a direct relationship between 
the diameter of a particle and the amount of light scattered to the power of 6, equation 
5. 
𝐼 = 𝐼!   !!!"# !!!! !!! ! !!!!!!!! ! !! !    Equation 5  
Where λ is the wavelength,  I0 is intensity of the beam of light, θ is the scattering angle, n is the 
refractive index of the particle and d is the diameter of the particle. 
Taking this into account and looking in depth at the particle size distribution of JRP240 
using all three distributions, it can bee seen that the particle size given by light intensity 
is in this case confirmed by those by volume and number. The distribution of both 
volume and number are slightly skewed to the left, indicating that more of the particle 
population is slightly below 100nm than above. These particle size distributions can be 
seen in figure 35. 
Judith Ray 2014  Chapter 2  
  86 
 
 
Figure 35 – Particle size distributions of JRP240 at 0.1 mg/ml in water using light intensity, 
volume of the particles and number of particles. Twenty scans of the nanogel were carried out 
with each line (in different colours) representing the average particle size of the sample over 10 
scans. 
2.4.6.2 Particle size conformation via TEM imaging 
JRP240 was further analysed by TEM to visually support the DLS average particle size 
obtained. Transmission electron microscopy (TEM) is a very powerful technique, highly 
exploited in the field of nanomaterials, which allows imaging diffraction and chemical 
analysis of solid materials180. Material can be magnified to more than 10000 times by 
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use of the electron microscope. The electron beam gives high resolution images which 
give the TEM a significant advantage over a simple light microscopy.  Electromagnetic 
lenses can magnify the image portrayed by the electron beam, which can be 
converged and focused on a detection surface (such as a fluorescent screen, 
photographic film or a CCD camera) by adjusting these lenses. TEM images are 
obtained with light and dark areas, which differentiate between materials of different 
densities by accounting for the amount of transmitted electrons passing through the 
material. Therefore the contrast of the image is dependant on the density of the sample 
analysed; for less dense samples a staining agent may be required to gain an image 
with good contrast and resolution.  
a)  b)  
Figure 36 – TEM images of JRP240. 
The TEM image of JRP240 shows the nanogels at around 40-50nm in size. This is not 
unexpected as nanogels swell in water, therefore their diameter in aqueous solution is 
likely to be larger than when dry. The DLS particle size trace does have an average of 
123 nm. This can be accounted for the irregular shape of the nanogels seen in figure 
36b where some of the nanogels are longer in one direction than in another. These 
images confirm that the particle size of the nanogels are less than 200 nm and 
therefore suitable for drug delivery.  
2.5 Nanogel preparation conclusions 
Nanogels were identified as a suitable polymeric nanomaterial for drug delivery with 
their significant advantage of intermolecular cross-linking, mainting a small structure 
with high surface to volume ratio and their flexibility to adapt the nanogel for the desired 
purpose. High dilution radical polymerisation was found to be a promising method for 
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the nanogel synthesis, eliminating the need for surfactants and giving good control of 
the size of the nanogel given by the ability to change various parameters. An 
acrylamide-based nanogel was decided upon due to the hydrophilic nature of 
acrylamide.  
Having established the material and method of choice for this drug delivery system, 
three fluorescent tags were evaluated for their use as a tag to track the nanogels. A 
dansyl based tag was eliminated due to stability issues once incorporated into the 
nanogels and Fluorescein was eliminated due to the tag being released from the 
nanogels via hydrolysis. Trifluoromethylcouamrin acrylamide was identified as the 
fluorophore with the best properties for tagging the nanogels. It’s high fluorescencent 
emission and good incorporation coupled with the amide bond between itself and the 
nanogel proved to be a reliable combination.  
The initial nanogels had limited solubility therefore further investigations found acrylic 
acid significantly increased their solubility. Use of Methylene bis acrylamide as the 
cross-linker was determined to give the most suitable nanogels when used at 20% of 
the polymerisation mixture. The concentration of monomers was lowered to 0.5% to 
maintain a small and narrow particle size and the polymerisation was discovered to go 
to completion within 48 hours at 70 °C. An increase of the initiator, AIBN from 1 to 2% 
of all double bonds in the polymerisation was found to counteract the slight inhibition of 
the free radicals by the coumarin monomer.  Finally investigations into the amount of 
TCA required in the nanogel formulation identified that TCA accounting for ≤5% of the 
total monomers gave best results with respect to particle size, solubility and 
fluorescence.   
Nanogels containing TCA, together with acrylamide, acrylic acid and methylene 
bisacrylamide cross-linker, were successfully obtained and had a diameter of less than 
200 nm. These nanogels also contained enough fluorophore to be tracked in vitro and 
in vivo, whilst maintaining high solubility (10 mg/ml) in water. These nanogels therefore 
have the ideal characteristics for testing the nanogels safety, and therefore shall be 
used to assess the safety of acrylamide-based nanogels via toxicity testing in the 
following results and discussion chapter.  
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3. Safety Studies 
Achievements in the area of nanomaterials have significantly advanced research in the 
development of novel drug delivery systems. Previously the focus was primarily on the 
synthesis and development of new drugs and their delivery was very much a 
secondary and expensive area of research. However, in the past few decades 
nanotechnology has enabled advances in medicine that previously could not have 
been imagined. There is still very little research that goes from bench to in vivo studies 
and on to clinical studies due to the high costs entailed181. Research in pharmaceutical 
applications was forecast to grow to 18 billion US Dollars this year with less than 4% of 
the FDA budget being allocated to nanoparticle safety. The effects of long term and 
chronic exposure to nanoparticles are still unclear and this is a cause for concern. In 
particular correlative and predictive in vitro and in vivo data on nanotoxicity is still 
lacking.  As a result, finding methods and in vivo models for the evaluation of toxicity 
with substantially reduced time and costs is of high interest, particularly for the 
pharmaceutical industry182, 183. 
The previous chapter described the successful synthesis of a water-soluble nanocarrier 
tagged with a fluorophore. The next section reports on the investigation of the safety of 
the nanogels, an essential feature if these nanomaterials are to be further developed 
for medical applications. In general terms there are three major concerns over the 
toxicity of nanomaterials: (i) short term effect in the body; (ii) accretion inside the body 
over the medium-long term; (iii) effect on the environment when excreted. There are 
many novel nanomaterials that are developed everyday and for each of these 
systematic studies of toxicity are required. There is a clear need for information that 
can provide a more general picture on the impact of these nanoparticles184. Not only 
this, the acrylamide monomer used to create these nanogels has previously been 
identified as a neurotoxicant which inactivates proteins leading to disruption of terminal 
processes and impaired neurotransmissions. Acylamide has also shown signs of 
reducing fertility and causing tumours in animals.185 Therefore any remaining monomer 
that remained in the nanogel after isolation could be of concern. In this results and 
discussion chapter, the nanogels safety studies are described and interpreted. Initial 
experiments were carried out in vitro using several assays for validation, however the 
main results were on the safety of the nanogels in vivo using Danio rerio as the animal 
model. 
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3.1 Establishing a suitable method for preliminary experiments 
in determining the toxicity of acrylamide based nanogels 
3.1.1 The legalities of drug control and animal testing 
The toxicity of drugs has been known for many centuries, it was Paracelsus (1493-
1541) who said “The right dose differentiates a poison and a remedy.”  
However control of drugs and proving their safety is of relatively recent concern. It was 
less than 100 years ago, in 1937, when sulphanilamide was successfully used to treat 
streptococcal infections in tablet form. However, on demand for a liquid form of the 
drug, pharmacists found sulphanilamide to be soluble in diethylene glycol and sold the 
dissolved drug as sulphanilamide elixir, which caused severe kidney damage and 70 
deaths186. On reaction to this the US FDA (Food and Drug Administration) introduced 
the first regulatory act to prove the safety of drugs prior to marketing in 1938. This 
required drugs to be tested on two animal species with histopathological examination. 
The thalidomide debacle of 1957 in Germany, which led to 15,000 foetuses to be born 
deformed, and causing the death of a significant number of those, led to regulatory acts 
in Europe and the need to prove efficacy of drugs, not just their safety186, 187. Since then 
drug legislation and regulation has developed and refined, not only to protect humans 
from the dangers of unproven exposure to new therapeutics, but also to protect 
animals from unnecessary dosages and pain in the testing laboratories.  
One of the more recent acts with regards to animal welfare in science in the UK is the 
1986 Animals (scientific procedures) Act, which came into force on 1st January 1987. 
This law requires trained personnel to obtain licences for carrying out procedures on 
animals, a licence for the project in which the animals will be used and also a licence 
for designated establishments where the animals are housed and experimented on188. 
All countries in the European Union were required to transpose their existing laws on 
the use of animals for scientific purposes over to a new European directive, 
2010/63/EU by 1st January 2013. This law brought all countries in line to maintain a 
high standard of animal welfare in science across Europe189. It requires the 
implementation of the 3R’s initially laid out by Russell and Birch in 1959, Replacement, 
Reduction and Refinement190. Replacement, where possible, expects that studies 
should be carried out by non-animal means, such as in vitro testing, computer 
modelling, chemical methods and statistical assessment,. Reduction seeks to keep 
the number of number of animals used to an absolute minimum, through: the use of the 
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most appropriate species and strain; attention to experimental design with appropriate 
statistical methods; limited sample variation by use of inbreeding and finally the use of 
animals with a scientifically controlled state of health. Refinement provides a reduction 
in the amount of stress an animal is exposed to by: maintaining enriched environments; 
good handling; the use of less invasive techniques wherever possible and effective 
pain control with efficient nursing care. It was therefore essential that all of the above 
requirements were adhered to during the research carried out for this project and that 
careful consideration and planning of the experiments took place.  
In view of the above regulatory requirements and safety standards it was necessary to 
review the methods that are currently used to assess toxicity of nanoparticles and their 
reliability, and to understand the levels of toxicity that are currently considered 
acceptable by general scientific consensus.  
3.1.2 Review of in vitro techniques, cell types used and 
concentration of the nanoparticle to use for the in vitro studies  
In alignment with the Replacement principle discussed above of keeping the use of 
animal testing to an absolute minimum, in vitro testing is the first logical step in 
establishing the efficacy of any new therapy. In order to establish a thorough 
assessment of the nanogels’ toxicity in vitro, previous studies were analysed to 
determine assays that would be consistent with other relevant research. One of the 
most common assays, to evaluate the toxicity of polymer-based nanoparticles in vitro, 
is the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazoliumbromide) assay191, a 
colorimetric test for the assessment of cell viability. NAD(P)H-dependent cellular 
oxidoreductase enzymes may, under defined conditions, reflect the number of viable 
cells present. These enzymes are capable of reducing the tetrazolium dye MTT 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide to its insoluble and blue coloured 
formazan. Other cell viability assays include the XTT192, sulforhodamine B193, neutral 
red194 and the alamar blue assay195, which are all fundementally different, measuring 
different defects in the cell to determine cell viability. One assay often used for cell 
viability and that works in reverse to the MTT assay mentioned above, is the LDH 
assay196. This measures the lactase dehydrogenase released when the cell membrane 
is disrupted and cell death occurs. Although it is reported less frequently than the MTT 
assay, it is still regarded as a reliable method194. It is clear that different assays give 
different cytotoxicity results as they rely on different functions in the cell. As a result, it 
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is prudent to carry out more than one cytotoxicity analysis in order to get a more 
comprehensive view of the material’s toxicity194. 
Cell viability assays are often combined with a cellular uptake assay, normally, but not 
only, performed by using flow cytometry197. Cytometry is a laser-based, biophysical 
technology employed in cell counting, cell sorting, biomarker detection and protein 
engineering, by suspending cells in a stream of fluid and passing them by an electronic 
detection apparatus where fluorescent cells are detected and counted. Cellular uptake 
can also be analysed via visual analysis using optical fluorescent microscopy196. In the 
latter method it is also possible to locate where in the cell the fluorescently tagged 
material has gone.  
It is consistent with good practice to carry out both a cell viability assay, to establish the 
toxicity level of the therapy to healthy cells, and also a cellular uptake assay, to 
establish that it is actually entering the cells in order for the therapy to have its effect. 
However many polymeric nanoparticles, produced for a drug delivery application, are 
not tested for their cell viability or cellular uptake and even fewer go on to in vivo 
studies. This gives rise to a lack of consistent advance/promotion from bench to in vivo 
studies and on to clinical studies181. 
Of those materials that are analysed for their toxicity at the in vitro level, it is important 
to establish the cell type and concentration of polymeric nanoparticles applied in order 
to evaluate the final nanogel results. The type of cells used in these assays often varies 
according to the end application of the drug delivery system193, 197, 198. Many therapies 
developed for cancer treatments are tested on malignant cells such as MCF-7 cells, 
(breast cancer cells)199-201. In this way the researchers can assess both the toxicity of 
the nanocarrier and the therapeutic effect of the loaded drug202. Burts et al used this 
kind of cell to assess how effective their nanoparticles were at releasing the drug, 
doxorubicin, on application of UV light (the trigger). They used concentrations of up to 
100 μM of drug, at a loading of 10% drug onto the nanoparticle. This assay gave Burts 
very positive results, seeing the cell viability drop to less than 10 % when the drug 
release was triggered, but without this significant change when the drug wasn’t loaded 
(as part of the control)203.  
Keratinocytes, (skin cells) are commonly used for in vitro assays. These are frequently 
used, because they are quite resilient, due to their protective nature; they differentiate 
and proliferate well in vitro, reducing variation between lines. One study by Payyappilly 
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into the development of self-assembling block co-polymer micelles used keratinocyte 
HaCat cells to evaluate their cytotoxicity204. The nanomaterial was applied to the cells 
at 1-5 mg/ml. Other research by Teixeira et al however looked at the cytotoxicity of 
their nanomaterials at concentrations up to 1 mg/ml, focussing on lower 
concentrations205. The concentrations (1-5 mg/ml) used in the above two assays are 
comparatively high compared to the concentrations that were decided upon for the 
nanogels used in this project. Although the nanomaterials created in the studies above 
were both created with drug delivery in mind, they had different end applications to the 
nanogels produced in this project.  
Having established that more than one cell viability test and a cellular uptake test would 
be necessary to determine the preliminary in vitro toxicity of the nanogels, focus turned 
to the selection of the best in vivo model with which to to proceed, keeping in mind 
replacement, reduction and refinement. Analysis of extant literature suggests that mice 
are the most commonly selected species for initial in vivo experimentation 206. 
3.1.3 Discussion of in vivo models 
In vivo testing allows the evaluation of effect of the materials across a much wider 
range of cells and enables analysis of its distribution. Initial in vivo studies are normally 
carried out on small rodents such as rats207, 208, hamsters209, gerbils210 and guinea 
pigs211, sometimes with comparisons being made of observed differences of effect 
between species211. By far the most utilised in vivo model is mice206. These are 
commonly used as an initial in vivo model as they are cost effective and have 
physiological similarities to humans. Not only this, more than a thousand mutant loci 
have been discovered which occur either spontaneously or are formed via radiation or 
chemical modifications. The discovery of these mutant loci has given rise to many 
potential models of different human diseases206. The ability to create new mouse 
models has been significantly increased through the better knowledge of the mouse 
genome and transgenic technologies, which allow modifications to virtually any gene. 
There are many mouse models with a homologous gene, which mutates in both mice 
and humans, where the mouse phenotype is highly similar to that of the human one. 
This enables relevant in vivo study of the disease development in question and 
provides a suitable model for testing treatments and preventative medicines212.  
Mice have been used to analyse the effect of many nanomaterials including 
nanotubes213, PEG based nanoparticles214, solid lipid nanoparticles215, micelles216, 
lysosomes217, and many more217-220. In fact for a new therapeutic to pass through to 
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clinical trials, the first step of pre-clinical trials is that the material must be evaluated in 
a rodent species. For the development of a new drug, preclinical trials require dose-
escalation, animal scale up with both rodents and non-rodent species as well as 
repeated administration studies with the final formulation. Dogs, often beagles, are 
used to study the drug’s toxicity when repeatedly administered as well as observing the 
pharmacokinetics and pharmacological effects221. Once these steps have been 
completed, and the toxic levels and efficacy of the materials have been evaluated in 
animals, the material can then progress to clinical trials in humans. The use of a good 
in vivo model for use as an initial high throughput model with easy stage identification 
of good candidates is highly advantageous. Because of this, finding ways to eliminate 
poorer performing drugs and drug delivery systems with reduced cost is highly 
desirable, and would potentially increase the success rate once entering rodent 
studies. 
3.1.3.1 Zebrafish as an in vivo model 
A relatively new and highly interesting in vivo model emerging as an initial high 
throughput system for toxicity testing is that of Danio rerio, better known as 
zebrafish222. In vitro assays using cell cultures are useful for giving an initial indication 
of toxicity however they frequently have significant differences from in vivo results. This 
is due to the drug encountering many different processes including absorption, 
distribution, metabolism and excretion in the in vivo model which cannot all be 
accounted for in cell culture experiments. Advancing the drug development process 
using in vivo tests on zebrafish is an increasingly popular choice, as it allows the 
quantification of materials’ toxicity before embarking on a costly mammalian study223. 
There are often large discrepancies between results found in in vitro and in vivo models 
when mammalian models are used224. By analysing toxicity in another animal species 
before embarking on a rodent trial, provides a clear advantage:  if lack of toxicity is 
observed in both fish and rodents then further analysis in preclinical and clinical trials 
can go ahead with a predictably better success rate. 
Zebrafish have many advantages for assessing the preliminary toxicity of a drug 
delivery carrier. They are very small, with adult fish being around 3cm long and their 
larvae being between 1 and 4 mm long, making them cheap and easy to maintain. 
Zebrafish reproduce in large numbers with a single clutch of eggs normally containing 
100-200 eggs with a single larva being able to survive in one well of a 96 well plate for 
up to 7 days, thus enabling testing of large numbers of materials at once223. Drugs 
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and/or their carriers can easily be administered to the zebrafish embryos as at an early 
stage they can absorb material in their surrounding environment through their skin and 
gills. From 72 hpf (hours post fertilisation) they begin to swallow and at 5 dpf (days post 
fertilisation) they begin to actively feed and therefore the material in question can be 
administered orally. It is also possible to inject the material into the yolk of the zebrafish 
sinus venous or blood circulation of the zebrafish, giving an intravenous route of 
administration223, although this method can be time consuming. 
Zebrafish embryos are relatively large and for the first 24 hours of development the 
zebrafish embryos are completely transparent, allowing easy analysis of the embryo 
and any defects seen. Recent advances in targeting genetic modifications in the 
embryos allow breaks in their genome that are locus-specific and double stranded. This 
permits the generation of many mutant alleles that replicate human disease loci222. 
Zebrafish have been genetically modified to produce many different strains including an 
albino line (also known as Casper’s), which remain transparent throughout their 
adolescence and in fact never develop the pigmentation seen in wild type. The 
transparency and speedy development of these fish make them a particularly suitable 
species for in vivo imaging222. 
The following diagram225 (figure 37) shows a time course of zebrafish embryo 
development when incubated at 28.5ºC. Embryo development times vary according to 
the incubation temperature226. 
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Figure 37 – Development stages of a zebrafish embryo from fertilisation to 5 days post 
fertilisation.  
As zebrafish are a relatively new species for in vivo analysis of drug delivery systems, 
there are only a few published studies. Fako and Furgeson reviewed zebrafish as a 
correlative and predictive model for the assessment of biomaterial focussing on the 
toxicity of PAMAM dendrimers, fullerenes, carbon nanotubes, metal oxide and copper 
nanoparticles 183 . They concluded that zebrafish provide a useful system for bridging 
the gap between in vitro cell culture assays and rodent in vivo studies. Of the few 
published studies one or two groups have looked at fullerenes 227 and nanotubes 228. 
Most other nanotoxicology studies have been on metals and metal oxides for example 
both Lubick 229 and Griffitt et al 230 looked at copper and metallic nanoparticles230, 231  
and Zhu et al studied metal oxides 232. 
One group which used zebrafish for in depth analysis of a polymeric nanomaterial was 
Heiden et al 233, who investigated the toxicity of PANAM dendrimers. In this experiment 
zebrafish embryos were exposed to 0.2-20 μM dendrimer solutions at 6 hpf both 
continually for 114hrs (to 120 hpf) for prolonged exposure and some for a short burst of 
1.5 hrs. 24 hpf embryos were also analysed to evaluate the effects of the dendrimers 
once many of the main features of the zebrafish had been established. The larvae were 
analysed for both signs of toxicity such as altered body axis, malformations of the eye, 
jaw, heart, fins, yolk sack, slowed growth, failure to inflate the swim bladder and 
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oedema as well as general developmental progression such as gastrulation completion 
(early embryo development, 5-10 hpf), somite formation (10-24 hpf developmental 
stages), heart beat and spontaneous movement. They graded the larvae every 24 
hours on a scale of 0-4 of toxicity, 0 apparent health, 1 minor (1 morphological 
malformation), 2-moderate (2 morphological malformations), 3-severe (3 morphological 
malformations) and 4 death. This graduation enabled a more precise discussion of the 
toxic effects of the dendrimers. The toxicity was found to be dependent on the 
generation of dendrimer formed. 4th generation dendrimers were found to cause death 
to between 50% and 94% of embryos within the first 24 hours regardless of the various 
exposure times used. However when applied at 24 hpf the embryos had a better 
survival rate, which may have been due to the embryo being further developed or due 
to the fact that the membrane233 (normally referred to as their chorion) surrounding the 
embryo becomes less permeable at 12 hpf (as the embryos were only immersed in the 
dendrimer solutions for 18 hrs, to 42 hpf, and hence remained inside their chorion). For 
the purposes of studying the effects of a material administered at a later stage of 
development, exposing the embryos to the solution beyond dechorionation (when the 
embryo breaks through it’s chorion) would provide valuable and relevant data.  
In another study Kumar et al197 evaluated the acute toxicity of their poly 2-(hydroxyl 
ethyl methacrylate) nanoparticles in zebrafish. They administered the nanoparticles at 
concentrations of between 5 and 100 μM via immersion of the embryos, for 96 hours. 
The age of the zebrafish embryos was not specified. In this study the authors analysed 
the embryos for dechorionation retardation, oedema and bent trunk and tail 
malformations, of which they found no evidence, even at the highest concentration197. 
Using a different method He et al218 evaluated the toxicity of their coordination polymer 
nanoparticles in zebrafish embryos of less than 1 hpf. Between 50 and 100 pg of 
nanoparticles were injected into the yolk at the 4-cell stage and evaluated the embryos 
development at 6, 28, 52, 76 and 100 hpf. These nanoparticles slowed epiboly 
development, caused the embryos to have smaller heads, shorter bodies and caused 
pericardial oedemas. Even if it is time consuming, this method does ensure that the 
nanoparticles penetrate the embryo, as an alternative to the immersion technique, 
should the latter fail to demonstrate uptake of the nanogels.  
Evidence from the literature clearly suggests that once in vitro studies have provided 
promising results, analysis of the nanogels in vivo in zebrafish is a cheap and relatively 
fast option that generates a large quantity of data. It was concluded that the best 
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scientific procedure to adopt was an initial immersion of the zebrafish in the nanogel 
solutions, as this method is much less time consuming, with a lower threshold for error, 
and is a more commonly used technique, offering greater cross comparison.  
3.2 In Vitro toxicity results 
In this section each of the cell viability and cellular uptake assays are described and 
discussed. In order to establish the maximum concentration of nanogel required for a 
drug delivery application, it was necessary to evaluate current dosages of the drug 
prescribed in order to predict the higher end concentrations that may be required. The 
model drug chosen for this project was tamoxifen. Current medical forms of Tamoxifen 
such as Nolvadex are prescribed as either a one-tablet dose of 20 mg or a twice-daily 
dose of 10 mg. This has a blood circulation peak concentration of 20 ng/ml 5 hours 
after administration, with a requirement of ≥70 ng/ml steady state concentration to see 
a clinical response234. 65% of tamoxifen entering the body is excreted in the faeces235. 
To circulate tamoxifen at 100 ng/ml in the blood, with a target loading of 10% tamoxifen 
on the nanogels, these would need to circulate at a concentration of 1 μg/ml of blood. It 
follows that, to remain safe, the nanogel should not prove toxic at 1 μg/ml, If 
intravenously (as opposed to orally) administered, this stock solution could be much 
more concentrated therefore concentrations of up to at least 200 μg/ml nanogel was 
explored in our assays.  
Both cancerous cells and keratinocytes offer sound bases for analysing the cytotoxicity 
of these nanogels. Keratinocytes were chosen for assessing the nanogel’s cytotoxicity 
for several reasons: the ease of line maintenance and therefore reduction in variability; 
keratinocyte cell lines were readily available at Queen Mary’s medical school and 
Cranfield University; whilst cell lines in general vary widely as to their cytotoxicity 
results, Nogueira et al found that, when comparing cancerous cell lines to 
keratinocytes, the latter were found to have greater sensitivity to cytotoxicity. They also 
suggested using more than one cell line when analysing cytotoxicity, to gain more 
reliable results236. Alamar blue and MTT assays were selected as both had proven to 
be effective in evaluating cell proliferation in keratinocytes237, along side the LDH 
assay.  
3.2.1 Alamar Blue Assay 
Initially the alamar blue assay was carried out at Queen Mary’s Medical school to give 
an indication of the level of cytotoxicity of the nanogels before embarking on full in vitro 
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analysis. The alamar blue assay is a cell proliferation assay which works by the 
reduction of resazurin (a non-fluorescent dye195), to resorufin (abs 570 nm, ex 560 nm, 
em 590nm) a compound that emits in the red channel. The reduction of resazurin only 
happens in living, metabolically active cells. At the end of the test, only cells that are 
still viable produce the fluorescent dye, thus giving a quantifiable result. In this way the 
target cells are treated with the combination of the non-toxic, cell-permeable resazurin 
(acting as an indicator of continued metabolic activity) and the material of which the 
toxicity is unknown (which may or may not kill the cells, affecting the indication), and 
control cells are treated with just resazurin.  This allows clear and quantifiable analysis 
of the metabolic activity in the two groups of cells through observation of fluorescence 
after varying the timescales of treatment. These results then serve to indicate the 
cytotoxicity of the material under observation.  
In this study just one nanogel, NG1 (batch 2), with 2.5% coumarin fluorescent tag was 
analysed to get an initial assessment of the nanogel’s cytotoxicity. NG1 (batch 2) was 
chosen as it contained the least amount of fluorescent tag, which was likely to be the 
most toxic component of the nanogels. Initial investigations used comparatively low 
concentrations (up to 50 µg/ml) as Hamid et al had found alamar blue to be slightly 
more sensitive than MTT at lower concentrations237. This assay was carried out over 
over 5 days to obtain toxicity data for sustained exposure of nanogel, NG1 (batch 2). 
NG1 (batch 2) was applied to N-tert keratinocyte cells at concentrations of 1 µg/ml, 5 
µg/ml and 10 µg/ml for 48hrs, results displayed in figure 38a. As As these experiments 
did not show any apparent cytotoxicity to N-tert cells, the concentration of nanogels 
was increased to 50 µg/ml and the experiment was repeated over 5 days, figure 38b. 
The alamar blue assay confirmed that the nanogel had no significant impact on the cell 
viability with a >95% cell survival rate. 
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a) b)  
Figure 38 – Cytotoxicity results of nanogel NG1 (batch 2) in N-tert karetinocytes at 
concentrations of 1-50 µg/ml after a) 48hrs incubation, b) 5 days incubation. Three replicates 
were carried and the error given is the standard deviation between the replicates. 
 
3.2.2 MTT Assay 
To assess the toxicity of these nanogels, the MTT assay was performed, as this assay 
is used extensively for cell viability194. It was originally published by Mosimann but 
further developed by Denizot and Lang in 1986238 as well as many others since. It 
works on the basic principle of the reduction of MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazoliumbromide), which is yellow in colour, by mitochondrial succinic 
dehydrogenase in living cells, to a blue coloured formazan product238. The living cells 
can then be quantified by measuring the amount of absorbance per mm2 of sample and 
comparing treated cells to negative controls (untreated cells). 
As the alamar blue assay had shown promising results with concentrations up to 50 
μg/ml, the MTT assay was carried out at this concentration but also at higher 
concentrations, up to to 200 μg/ml to ensure the nanogels would not be cytotoxic at 
these higher levels. In this assay HaCat Keratinocyte cells were used as the 
experiment was carried out in collaboration with Cranfield University and these were 
the cells available.  
The MTT assay was carried out on HaCaT cells, with two nanogels, NG1 (batch 1) and 
NG2 (batch 1), neither of which showed significant toxicity after 3 days up to 200 µg/ml. 
97±4.2% of the cells treated with NG1 and 92±6.6% of those treated with NG2 were 
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viable after 3 days incubation at 200 µg/ml compared to the negative control. In the 
case of the positive control, hydrogen peroxide, there was a very significant impact on 
the number of viable cells even at the lower concentration. In fact in the first 24 hours 
the cell lines treated with either nanogel showed so much improved cell viability to that 
of the control cells that it indicated a positive effect on their proliferation by appearing to 
act as a nutrient resource. The study was carried out for 72 hours in total to ensure that 
the cells had stabilised and the cell proliferation was maintained and not reducing in 
comparison to the controls, which would have indicated a damaging, toxic effect. In fact 
the cells did stabilize by 72 hours and no significant apoptosis was seen in comparison 
to the negative control. The destructive effect of the hydrogen peroxide load in the 
positive control could be seen with 66±2.2% of cells surviving at the lower 
concentration (25 µg/ml) and less than 37±1.5% cell survival at the higher 
concentration of 50 µg/ml.  
a)
b)  
Figure 39 – MTT assay results for the nanogels at varying concentrations of nanogel after 24, 
48 and 72 hrs incubation with a) NG1 (batch 1) b) NG2 (batch 1). Three replicates were carried 
and the error given is the standard deviation between the replicates. 
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3.2.3 LDH Assay 
To confirm the results found with the MTT test, the LDH assay was carried out which 
works on an inverse method to MTT: it measures the amount of lactate dehydrogenase 
present in the media surrounding the cells. Lactate dehydrogenase is released into the 
extracellular medium when a cell dies as a result of irreversible damage to the cell 
membrane 194. If LDH has been released it aids the formation of pyruvate from lactate 
which at the same time reduces NAD+ (nicotinamide adenine dinucleotides) to NADH. 
It is the NADH produced by the first reaction that is used to convert a colourless 
tetrazolium salt (INT, 2-p-iodophenyl-3-p-nitrophenyl-5-phenyl tetrazolium chloride) to a 
red formazan product. It follows that the amount of LDH present (therefore the quantity 
of dead cells) is directly proportional to the amount of formazan product detected. 
When analysing the short term data at 4 and 8 hours no significant cytotoxicity was 
seen either with the nanogels or the positive control. However the LDH assay is well 
proven to need longer timeframes to be able to establish cytotoxicity194. After 24 hours 
the positive controls showed significant signs of toxicity and studying the cells at 48 
and 72 hrs the toxicity substantially increased, confirming this trend, see figure 40. The 
LDH assay was carried out on NG1 (batch 1) and NG2 (batch 1), neither of which 
showed any significant increase in the amount of LDH present over a 72 hour period, 
most significantly in comparison to the hydrogen peroxide positive control. At 48 hours 
the level of toxicity of the nanogels peaked with the highest seen in 200 μg/ml, which 
had a 31±0.34% increase of LDH for NG1 and 30±0.76% increase for NG2. However, 
this was significantly lower than the positive control which increased by 120±0.45% at 
the lower concentration. Furthermore the data was inconsistent with concentration, for 
example in the experiment using NG1 at 48hrs, 10 μg/ml had a higher amount of LDH, 
11±0.16% than the nanogel at 50 μg/ml which was 3±0.19%. However by 72 hours no 
significant toxicity could be seen in any of the nanogel concentrations with maximum 
increase in LDH at 200 μg/ml of 6±0.77% for NG1 and 19±0.94% for NG2. The data 
clearly indicate that the LDH levels return to normal values within 72 hours of 
incubation, suggesting that the slight increase in LDH over the shorter period was not 
of concern.  
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a)
b)  
Figure 40 – Cell viability via the LDH assay at 4, 8, 24, 48 and 72 hours of incubation with 
varying amounts of a) NG1 (batch 1) (2.5% coumarin tag) and b) NG2 (batch 1) (5% coumarin 
tag). Three replicates were carried and the error given is the standard deviation between the 
replicates. 
Potential differences in cell cytotoxicity between cell lines has been well 
documented236, however all three assays gave no evidence of toxicity of the nanogels 
despite differences in cell lines used. Having carried out 3 different cell viability assays 
and found no preliminary evidence of cytotoxicity in keratinocyte cells, in the next stage 
it was important to establish that the cells were internalising the nanogels. At this stage, 
it was deemed appropriate to proceed to carry out in vitro investigations, specifically 
with a cellular uptake assay where the cells were analysed by confocal microscopy for 
visual analysis of the nanogels in the cell structures.  
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3.2.4 Cellular uptake of nanogels 
As no cell toxicity was observed using any of the in vitro tests so far, it was important to 
establish that the cells were taking up the nanogels. To ensure a potential application 
of these nanoparticles, where the therapeutic drug could be delivered into cells using 
them as a carrier system. This was analysed via two methods. The first was by flow 
cytometry using emission at 450 nm. Two different nanogels were used for 
examination: NG1 (batch 2) (2.5% coumarin tag) and NG2 (batch 2) (5% coumarin 
tag), together with a negative control control sample. For reliable indication of cellular 
uptake, the nanogels loaded with the coumarin tags should emit fluorescence and 
therefore a peak in fluorescence intensity should be detected at 450 nm wavelength.  
In this method the N-tert-1 keratinocyte cells were incubated with the fluorescent 
nanogels NG1 (batch 2) (2.5% coumarin tag) and NG2 (batch 2) (5% coumarin tag) at 
50 μg/ml for two hours before being washed with PBS. The remaining cell suspension 
was added to a stream of liquid, thus diluting the solution so there was as close to one 
cell per droplet of liquid as possible. Just before the droplet formed, the fluorescence of 
the liquid stream was measured for every cell passing through. A control sample was 
also measured for fluorescence and the sample was then compared to the control. The 
results for nanogels NG1 (batch 2) and NG2 (batch 2) against a control can be seen in 
figure 41. Cells exposed to both nanogels exhibited fluorescence at 450 nm showing 
uptake of the nanogels into the N-tert-1 cells. The cells exposed to NG2 (batch 2) 
contained far more fluorescence than those exposed to NG1 (batch 2). This is 
explained by the fact that NG1 (batch 2) contained half as much fluorophore (2.5% 
coumarin monomer) compared to nanogel NG2 (batch 2) (5% coumarin monomer), 
therefore the fluorescence intensity seen in NG1 (batch 2) was far lower than that 
exhibited by NG2 (batch 2). This gave a clear indication that the nanogels were being 
taken up by the skin cells. However, to visualise the cellular uptake, and provide further 
positive confirmation of it, the cells were analysed via confocal microscopy.  
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Figure 41 – FACS results of the cellular uptake of NG1 (batch 2) and NG2 (batch 2) into N-Tert-
1 keratinocytes analysed by flow cytometry.  
The cells prepared for the visualisation experiment were incubated at 37 °C in the 
relevant nanogel solution for 2 hours at 50 μg/ml before being washed with PBS, and 
fixed with 4% paraformaldehyde. The cells were then analysed for fluorescence using a 
Zeiss 510 confocal microscope. In the images from using the confocal microscope 
presented in figure 42 the nanogel can be clearly seen in the cytoplasm of the cells, 
showing that the nanogels successfully entered the keratinocyte cells. Preliminary 
experiments had already shown that the cells had taken up the nanogels and moreover 
that the latter did not appear to be cytotoxic in keratinocyte cells at concentrations up to 
and including 200 μg/ml in three complementary cell viability assays. Consequently, it 
was considered safe and prudent to continue and expand on the toxicity studies in vivo 
using zebrafish.  
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Figure 42 – Confocal images of the nanogels’ cellular uptake in the cells. A-C are controls, D-F 
are treated withNG1 (batch 2), G-I are treated with NG2 (batch 2). A, D and G show the 
fluorescence, B, E and H are the bright field and C, F and I are the two overlaid. 
 
3.3 In Vivo toxicity results 
The purpose of the work described here was to evaluate any impact that the 
nanomaterial would have in vivo and allow study of their effect on a range of different 
cell types to which the nanogels would potentially be exposed.  
There are three areas of concern with nanoparticles and their potential toxicity. These 
are the safety of the NPs to the patient, the user (producer) and environmental safety. 
Through analysis of the toxicity of these nanogels in zebrafish preliminary data on their 
direct effect can be established: when applied in the short term; on excretion (if, indeed 
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they are excreted by the zebrafish); long term build up (if excretion is low) and 
consequent toxicity levels. Furthermore, given that zebrafish are a species of fish, 
these results would provide an additional indicator of potential hazards to aquatic 
species as a result of nanoparticles arriving in the sea through sewage routes (via 
watercourses and land run-off) when excreted from humans and/or animals after 
administration. 
3.3.1 Nanogel immersion evaluation 
One of the most common approaches used to assess the toxicity of nanomaterials in 
zebrafish, involves the suspension of the material under investigation in the zebrafish’s 
environment239-241. The OECD (organisation for Economic Co-operation and 
Development) recommends that zebrafish embryos should be used for acute toxic 
analysis screening before the blastula period begins (at 2.5 hours post fertilisation, 
hpf)242. Active feeding, however, does not begin until the larvae are 5 days old225 
therefore two sets of data need to be collected: that from immersion at the time point 
recommended by the OECD and that found at the later stage of development when the 
larvae begin to feed. Therefore both the 2 hpf stage and 48 hpf stage of development 
were evaluated in this study, with the fish being maintained in the nanogel environment 
beyond 5 dpf (days post fertilisation) to enable toxicity evaluation via active feeding. 
When analysing the zebrafish embryos at 2 hpf the emphasis was on whether the 
nanogels were toxic when passing through the chorion, the acelluar membrane 
surrounding the embryo, to the embryo itself. Initial experiments were carried out on 
embryos at 2 hpf, with both nanogels at 0.1 and 1 mg/ml each. Analysis of the fish for 
change in morphology and oedemas was noted along side the death of embryos.  
As the in vitro results had not shown any evidence of toxicity in concentrations up to 
200 μg/ml, it was decided to use two concentrations of the nanogel, one below the limit 
of that tested in vitro and one substantially higher, to see the impact of a such a high 
dose on the zebrafish embryos. In these experiments a genetically modified strain of 
zebrafish was used, often referred to as Caspers, due to their transparent nature 
throughout their development with the mature fish having transparent skin allowing 
visual analysis of organs and cellular activity222. This mutated strain has the advantage 
of not requiring the addition of PTU (1-phenyl-2-thiourea) in order for optimal analysis. 
PTU is used to prevent pigmentation in the fish, which can interfere with visual analysis 
of the zebrafish embryos, however, it is itself toxic at high doses. Injection of the 
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nanogels into the zebrafish could be considered at a second stage of the nanogels’ 
toxicity evaluation. 
To carry out these preliminary investigations the nanogels were ‘dissolved’ in fish water 
(0.03% salts) at 1 and 0.1 mg/ml and 10 embryos at 2 hpf (hours post fertilisation) and 
48 hpf were added to the different solutions. The embryos were added to the nanogel 
solutions at 2 hpf when they were at the 8-16 cell stage.  Using this stage of embryo 
allowed investigation of effects on very early stages of development. These embryos 
were removed from the nanogel solutions after 24 hours exposure and returned to 
fresh fish water. After just 6 hours a significant death rate in the higher concentration of 
both nanogels was seen. 40±5.8% of embryos had died in 1 mg/ml NG1 (batch 2) that 
contained 2.5% coumarin monomer and 50±11.5% of those in the same concentration 
of NG2 (batch 2) with 5% coumarin monomer. However at the lower concentrations the 
survival rate was more promising with a 70±5.8 and 80±5.8% survival respectively. 
After 24 hrs, all embryos exposed to the nanogels at the higher concentrations had 
died, as had those in 0.1 mg/ml NG2 (batch 2). However no further embryos had died 
in 0.1 mg/ml NG1 (batch 2), which also contained less coumarin monomer. See figure 
43. 
  
Figure 43 – Initial in vivo experiment carried out on 2hpf (hours post fertilisation) zebrafish 
embryos. Nanogel NG1 (batch 2) contained 2.5% coumarin monomer and NG2 (batch 2) 
contained 5% coumarin monomer. 10 zebrafish were exposed to the relevant solution for 24hrs 
before being returned to fresh fish water. For each replicate 10 embryos were placed in each 
solution and the experiment was carried out 3 times, the error bars give the standard deviation 
between the three experiemtents. 
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These experiments were highly preliminary and the first set carried out within the 
research group, therefore little knowledge was known on the number of embryos 
required per solution analysed and lethal concentration levels required to be 
established. Since obtaining these results it has been noted that when repeating these 
studies establishing a 10%, 50% and a no effect level of the nanogels on zebrafish 
ebryos would be required in order to establish a the margin of safety of the nanogels 
with using a minimum of 20 embryos per solution used.  
The experiemental results displayed in figure 43 show that after 48 hours 70±11.5% of 
the zebrafish survived in the lowest concentration, 0.1 mg/ml, of nanogel NG1 (batch 
2). All embryos (±5.8%) died within 24 hours exposure to NG2 (batch 2) at the same 
concentration, 0.1 mg/ml. NG1 (batch 2) contains half the amount of coumarin 
monomer (2.5%) compared to NG2 (batch 2) (5% coumarin). As the only significant 
difference between the two nanogels is the coumarin tag content, it could be that the 
coumarin tag itself is toxic to the zebrafish at very early developmental stages. 
Therefore to investigate whether the coumarin monomer may be impacting on the 
nanogel’s toxcicity at this stage of development, 2 hpf embryos were exposed to 
trifluoromethyl acetyl coumarin (TMAC, 7a chapter 2). TMAC is highly similar in 
structure to the monomer (TCA, 7, chapter 2) used, but without the terminating double 
bond which has already shown to be acutely toxicity243 and the double bond no longer 
exists once polymerisation has taken place. 2 hpf embryos were placed in solutions of 
TMAC 0.01 mg/ml (in 1% DMSO, 99% fish water v/v), nanogel NG3 at 0.075 and 0.025 
mg/ml (containing 10% coumarin monomer, in 1% DMSO, 99% fish water v/v) and 
controls in fresh fish water. The use of DMSO was required as a result of the low 
solubility of TMAC in water. NG3 was used as it contained a higher amount of 
coumarin monomer allowing lower concentrations of nanogel to be analysed yet 
producing high enough fluorescence to be tracked. A 24 well plate was used with 2 ml 
of the relevant solution being placed in each well, including fresh fish water for the 
controls. A single embryo was placed in each well and the well plate was studied at 24 
hour intervals under a microscope for signs of toxicity such as curvature of the 
notochord, oedema or death. All the embryos were maintained in their relevant solution 
for 3 days before being returned to fresh fish water.  
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Figure 44 – Results of a zebrafish experiment evaluating the toxicity of TMAC. Where TMAC is 
trifluoromethyl acetyl coumarin, NG3 is a nanogel containing 10% TCA. All solutions were 
formed with 1% DMSO in fish water (v/v) except the control with is 100 % fish water. Between 5 
and 8 Embryos were maintained in the relevant solution from 2 hpf for 3 days before returning 
to fresh fish water. For each replicate 8 embryos were placed in each solution and the 
experiment was carried out 3 times, the error bars give the standard deviation between the 
three experiemtents. 
This experiment showed that the TMAC alone was highly toxic to 2 hpf embryos all of 
which died within 24 hours of exposure. However the young embryos tolerated the 
nanogels at lower concentrations. Effectively NG3 at 0.025 mg/ml contained 0.0025 
mg/ml coumain monomer and NG3 (10% coumarin monomer) at 0.075 mg/ml 
contained 0.0075 mg/ml coumarin monomer. These concentrations of coumarin are 
lower than those used in the first experiement where NG1 containing 2.5 % couamrin 
was used at concentrations of 1 mg/ml and 0.1 mg/ml, effectively having  
concentrations of 0.025 and 0.0025 mg/ml couamrin tag and NG2 containing 5% 
coumain used at the same concetrations of nanogel, effectively dosing the embryos at 
0.05 and 0.005 mg/ml coumarin tag. Evidently these concentrations were too high 
therefore much lower concentrations of nanogel were used to compare with free 
coumarin. In this experiement 0.01 mg/ml of free couamrin (TMAC) was chosen as it 
was a lower dose of couamrin tag than that administered in the initial set of 
experiement but higher than that in the nanogels solutions of this experiement. 
However in hindsight dosing the nanogel at 1 mg/ml (0.01 mg/ml coumarin tag) would 
have been a sensible addition for a more direct comparison. In reality TMAC is a small 
molecule which will behave differently to the nanogels and likely be absorbed efficiently 
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across the gills of the zebrafish and therefore unless both nanogel and TMAC were 
directly injected into the zebrafish it is difficult to make a direct comparison.  It does 
however show that if the fluorescent tag is at any point released from the nanogel it 
would cause toxicity, giving indication that the nanogel remains attached to the 
nanogel. In this second (TMAC) experiment, figure 44, No zebrafish in the nanogel 
solutions appeared to have severe deformities such as curvature of the notochord or 
oedema (images of these deformities can be seen in figure 47). By contrast both 
Heiden et al and He et al found these deformities occurred when zebrafish embryos 
were immersed in some of their nanomaterials233, 244, leading to the conclusion that 
these acrylamide gels were showing a much lower degree of toxicity at concentrations 
of 0.025 to 0.075 mg/ml, and could be safely used in that range218. 
To analyse the effect of the nanogels on zebrafish at the later stage of development, 
the same protocol used for the 2 hpf zebrafish embryos was repeated with 48 hpf 
zebrafish. After 48 hours post fertilisation the zebrafish have developed the majority of 
their organs, having completed morphogenesis, and their development is known to 
slow down rapidly225. The effect of the nanogels on more stable juvenile larvae could 
thus be contrasted with that on those undergoing rapid early development process. 
The nanogels were developed to carry tamoxifen to treat breast cancer, not to treat 
growing foetus’ therefore analysing the effect of the nanogels on a more fully formed 
organism is a more representative model. Not only this, at 2 hpf zebrafish do not 
actively feed therefore any nanogel that had entered the 2 hpf embryos had done so 
through diffusion rather than through potential oral administration. Therefore to 
establish if toxicity was present at a later stage of development and the effect of the 
nanogels on more fully formed zebrafish fry, nanogels NG1 (batch 2) and NG2 (batch 
2) were dissolved at concentrations of 0.1 and 1 mg/ml, and 48 hpf embryos were 
placed in the solutions along side embryos in fresh fish water as controls. The embryos 
were studied under fluorescent microscope every 24 hours to evaluate nanogel intake 
and distribution and their toxic effects. 
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Figure 45 – Effect of nanogels on 48hpf (hours post fertilisation) zebrafish embryos. Nanogel 
NG1 (batch 2) contained 2.5% coumarin monomer and NG2 (batch 2) contained 5% coumarin 
monomer. The zebrafish were exposed to the relevant solution for 7 days before being returned 
to fresh fish water. The experiment was carried out in triplicate, but no variation in results was 
seen. 
This experiment gave strong evidence of better tolerance of the nanogels by the fry. 
This time they were exposed to the nanogel solutions for 7 days, as no impact on 
survival was seen, figure 45. 4 days after being immersed in their solutions, nanogel 
could be seen in the intestine of the zebrafish immersed in the solutions at the highest 
concentrations of nanogel (1 mg/ml) although it was very weak. As a consequence, the 
zebrafish were maintained in their nanogel solutions for a further 2 days when the 
fluorescence was more intense. At this point the zebrafish were analysed on the 
confocal microscope and images were obtained showing the nanogel present in the 
intestine, shown in figure 46b. On day 7 the zebrafish were removed from their relevant 
solutions and returned to fresh fish water. 5 days after being removed from their 
nanogel solutions the fluorescence could no longer be seen. During this period, the 
coumarin could be seen being excreted from the zebrafish in their faeces. No visible 
signs of toxicity were seen in the zebrafish such as oedema, bent tail or death during 
the two week period, therefore making it likely that the coumarin was still attached to 
the nanogels and the nanogels were still intact as if coumarin had been released, high 
levels of toxicity would have been expected and if the coumarin had be metabolised it 
would no longer be fluorescing. At this point the experiment was terminated. It cannot 
be fully established whether the nanogels entered the zebrafish via the gills or across 
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the body surface and gathered in the intestine or whether the nanogels entered the 
zebrafish through their drinking source. The latter is a possibility as zebrafish drink ~2μl 
g-1 fish per hour therefore in 6 days the fish would have drank ~80nl of nanogel 
solution. This volume of solution would allow for enough of the coumarin tagged 
nanogels (~80ng) to gather in the GI tract and therefore making it possible that the 
zebrafish have imbibed the nanogels.   
One concern when viewing the zebrafish, which was mensioned in the second chapter 
(section 2.2.4), was the fact that the emission of the coumarin monomer is close to the 
wavelength at which the zebrafish naturally show autofluoresence when the cells die. 
To overcome this problem control zebrafish (subjected to no nanogel solution) were 
analysed under the microscope in order to set the intensity of the fluorescent lamp at a 
point where no autofluorescence could be detected. Keeping these settings, a 
zebrafish that had been subject to the nanogel was then examined. This would ensure 
that any fluorescence detected would be the result of the nanogels present. 
The nanogels could be seen in the intestine of the zebrafish within 4 days exposure to 
the nanogels, but they could not be observed in the surrounding tissues of the fish. The 
lack of seeing them in surrounding tissues could be due to reduced concentration and 
therefore not being able to detect the coumarin. Therefore it was possible that the 
nanogels were not passing through the lining of the intestine. This experiment showed 
that the nanogels successfully entered the zebrafish, causing no visible signs of 
damage or distress to the fish and was also excreted by the fish, leaving no damage or 
risk of further toxicity if it had remained and accrued inside the body. The fish were 
immersed in the nanogels for 7 days, indicating that prolonged treatment, even at 
relatively high concentrations (~40 pg ng-1day-1 zebrafish which is equivalent to ~40 mg 
g-1day-1 for a mouse or ~30g kg-1day-1 for a human) did not adversely affect the 48 hpf 
fry. In spite of high tolerance of the presence of nanogels passing through the 
alimentary canal, the nanogels had not likely been exposed to the bloodstream or to 
the main tissues inside the zebrafish, if indeed the nanogels have been imbibed. 
Because of this, and because many drugs are delivered directly into the bloodstream 
for transport round the body, further investigation would be required to establish their 
safety there.  
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Figure 46 – Confocal images of Casper zebrafish A is a control and B is 6 days after exposure 
to NG1 (batch 2) (8 dpf). 
 
 
 
 
Figure 47 – Images of deformities which were considered when analysing toxic effects of the 
nanogels on juvenile zebrafish (NG2 1 mg/ml). A – oedeoma, B – curvature of the nortichord, C 
– healthy control 12 hpf, D – curvature of the nortichord at 5dpf, E – healthy control at 48-72 
hpf.  
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To investigate whether the free coumarin, TMAC, was also toxic at this later stage of 
development a new experiment was carried out with 48 hpf larvae. A 12 well plate was 
prepared with each well containing either 4 ml of 0.01 mg/ml TMAC solution or fresh 
fish water and one 48 hpf embryo was placed in each well. The embryos were 
analysed every 24 hours via microscope to check for any deformities (figure 47) or 
mortality. 
 
Figure 48 - Effect of the free coumarin, TMAC (7-amino-4-(trifluoromethyl) coumarin), on 48 hpf 
(hours post fertilisation) zebrafish embryos. 6 zebrafish were exposed to each solution. The 
experiment was carried out in triplicate, but no variation in results was seen. 
As with the younger embryos these 48 hpf larvae showed sensitivity to TMAC within 
the first 24 hour period, with all embryos exposed to it unable to survive, shown in 
figure 48. This experiment confirmed that the free monomer was highly toxic to 48 hpf 
zebrafish embryos when administered at a lower concentration, 0.01 mg/ml, than was 
incorporated into the nanogels, which at the higher concentrations, 1 mg/ml, 
(containing 0.025 and 0.05 mg/ml coumarin monomer for NG1 and NG2 respectively) 
showed no acute toxicity. Although it should still be noted that the TMAC, being a small 
molecule, may have entered the zebrafish through a different route potentially exposing 
the zebrafish to a different concentration of TMAC to the nanogels internally. This 
experiment, along side the experiment carried out with TMAC on the embryos at 2 hpf, 
also gave indication that the fluorophore was still likely to be linked to the nanogel with 
the acrylamide bond successfully resisting hydrolysis. Had hydrolysis occurred, the fish 
would have died from the toxicity of the coumarin monomer, following its release.  
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Initial studies of the coumarin tagged nanogels (JPR240 and JPRP241) showed no 
acute toxicity when administered through immersion. Free coumarin, TMAC, was also 
found to be acutely toxic to the zebrafish, indicating that the fluorophore was not being 
released via motabolisation of the nanogels in vivo as this would have rapidly killed the 
fish. However, it was highly likely that the nanogels were not passing through the lining 
of the intestine and therefore not reaching internal cells. A study of the effect of 
intravenous administration of the nanogels was required, in order to determine the 
toxicity of the nanogels when circulating in the blood. 
3.3.2 Intravenous administration 
The intravenous administration of substances to zebrafish is an alternative technique 
used when systemic circulation is required. Intravenous administration has been used 
previously for studies involving mutagenesis225 and toxicity evaluation228. The majority 
of microinjection into zebrafish occurs at very early embryo development stages during 
the cell division stage228, 245, 246. However, some groups have injected into zebrafish 
embryos at a later development stage. Of those that inject into embryos beyond the 
epiboly stage, where the embryos are not longer a blastodisc cell mound, the majority 
inject into the yolk of the embryo247-249. Injection into the yolk would not lead to the 
circulation of the nanogels in the bloodstream, as it would just be adding to the 
zebrafish’s nutrient source (although likely not benificially), effectively taking a 
secondary route into the bloodstream. Therefore the direct microinjection into the 
bloodstream was selected for this work, to ensure direct and provable circulation of the 
nanogels. Injection into the caudal vein at 28 hpf has been achieved before by 
Veneman et al who studied the bacterial proliferation of staphylococcus epidermidis in 
zebrafish through multiple exposure techniques249. Another study by McLeish et al also 
evaluated the toxicity of nanoparticles, this time on microinjection into the venial blood 
pool below the yolk at 48 hpf240.  
In order to select the optimal opportunity for intravenous injection of the nanogel 
sample, it was necessary to take account of the following features of early 
development in zebrafish. During the pharyngula development stage (24-48 hpf) the 
cardiovascular system evolves. All the chambers of the heart develop early on in this 
period of development and blood can be seen circulating in the closed system of 
arteries and veins. At around 36 hpf (hours post fertilisation) the caudal vein can be 
clearly identified across the yolk sack feeding into the heart, at which time the vein is 
still in the process of forming, is wide and less rigid, creating an optimal point of entry 
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for microinjection penetration into the blood stream. Therefore 36 hpf was the point in 
time chosen to inject the embryos. To ensure visual monitoring of the nanogel in 
circulation, a concentrated solution of 10mg/ml NG1 (batch 2) (2.5% coumarin tag) was 
formed and injected into the fish using a microinjector.  Approximately 54 ng of nanogel 
was injected into 6 Casper zebrafish at 36 hpf. When injected successfully the nanogel 
could be seen under a DAPI filter being pumped into the heart and around the 
cardiovascular system immediately after injection, image displayed in figure 49b.  
The fish were further observed on a confocal microscope showing that the nanogel 
was clearly circulating in the bloodstream after one 1hr, shown in figure 50. After 5hrs 
the nanogel could be seen concentrating in the hindbrain (displayed in figure 51), a 
result that would indicate interesting applications of nanogels for neural drug delivery. 
However as the blood brain barrier is not fully formed in the zebrafish at 36hpf, further 
experiment would be required with older fish to validate these results. After 12 hours 
post injection the nanogel could no longer be seen in the zebrafish. To demonstrate 
that this was not the result of any fluorescence quenching of the tag, a specific 
experiments was carried out. 100 μl of NG1 (batch 2) and NG2 (batch 2) (1mg/ml) 
were each incubated with proteins from 36 hpf homogenised embryos in a multiwell 
plate and mixed thoroughly at 28 °C. After 24hrs analysis of the plate indicated that 
fluorescence emission was unchanged, therefore providing evidence that the 
fluorescent nanogels were stable and that the tag was not altered in any way. The 
likely explanation the loss of fluorescence in the experiment above is that the 
fluorescent nanogels are motabolised by the zebrafish.  
One week after injection the same batch of fry used for the experiments previously 
described were still alive and well with no signs of curvature of the spine or oedema, at 
which point the experiment was terminated. In summary, the nanogels were 
successfully injected into the zebrafish at 36 hpf, could be seen circulating their blood 
stream and had no observable acute toxic effect on the fry. A short experiment was 
attempted aiming to evaluate the ability of the nanogels to cross the blood brain barrier, 
by injecting the larva at 8 dpf (days post fertilisation). Despite a number of attempts the 
difficulty of the injections, as a result of the more mature vessel system, resulted in 
significantly less nanogel being able to enter the system. Although the nanogel could 
be visualised at the time of injection, 20 minutes later it could be no longer detected, 
and no difference could be seen between the injected fry and the control, most likely as 
a result of higher dilution. Nanogels with increased fluorescence intensity will be 
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required to explore this line of research. As a result of limited time and facilities this 
was not pursued any further in this project.  
The work presented here has achieved far more than what many zebrafish in vivo 
studies do, in the evaluation of the toxicity of nanomaterials, by complementing the 
data obtained via immersion administration with results obtained via injection197, 233.  
 
Figure 49 A) Control, B) immediately after injection, nanogel seen in the blood vessels (some 
blood vessels indicated by the arrows), C) Nanogel dispersed into the cells of the zebrafish, 
medial view, D) Nanogel dispersed into the cells of the zebrafish, lateral view.  
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Figure 50 – Images taken 1 hour after injection on confocal microscope. A) Control 
fluorescence only, B) control fluorescence overlaid with bright field, C) Injected fluorescence 
only D) injected fluorescence overlaid with bright field. 
Figure 51 
– images taken 5 hours after injection. Nanogel can be seen circulating the cardiovascular 
system (B) and gathering in the hindbrain (D). A and C are controls.
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3.4 Conclusions 
Preliminary analysis of the nanogels synthesised in chapter 2 have shown no toxicity 
up to 200 g/ml in MTT and LDH assays. The nanogels have also been shown to be 
taken up by the cells using both FACS and microscopic imaging. Having obtained 
successful initial analysis with limited toxicity and good uptake, the nanogels were 
administered through immersion to 2 hpf zebrafish embryos at concentrations up to 1 
mg/ml. Though at higher concentrations the nanogels proved to be fatal at this age, at 
0.1 mg/ml the nanogels were less cytotoxic to the early stage development embryos. 
After analysis of the effect of the coumarin monomer itself, it was clear the fluorescent 
tag was toxic and could be hindering the evaluation of the nanogel’s toxicity. When the 
nanogels were orally fed to 48 hpf zebrafish for 5 days no acute toxicity (curvature of 
the notochord, oedema, death) was seen. Nanogel was clearly seen in the intestine of 
the zebrafish and yet it could not be seen to have passed through the lining of the 
intestine and entered internal cells of the zebrafish. Nanogel NG1 (batch 2) was 
injected into the caudal vein of the 36 hpf zebrafish where it could be seen immediately 
being pumped around the cardiovascular system and shortly afterwards diffusing 
throughout the zebrafish. 5 hours after injection the nanogel could be seen gathering in 
the hindbrain. No trace of the nanogel could be seen in the zebrafish 12 hours after 
injection. No adverse side effects could be seen 7 days after injection. This 
combination of preliminary toxicity analyses of the nanogel carrier itself, characterised 
by positive, non-toxic effects, gave strong evidence in favour of its use as a safe carrier 
for a therapeutic drug. Not only this, the study indicates that although the acrylamide 
monomer, which has proven toxicity, shows no preliminary toxicity in zebrafish once 
incorporated in the nanogel polymer, showing that any remaining monomer after 
polymerisation was highly likely to have been removed during the isolation process. 
Therefore the next step focused on the uploading of the drug. Tamoxifen was 
incorporated into these nanogels for further analysis of their efficacy as part of a drug 
delivery system.  
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4. Applying nanogels to drug delivery 
In this final chapter of the results and discussion, the results relating to the 
incorporation of tamoxifen into the coumarin-tagged nanogels are presented and 
discussed. European legislation requires that novel therapeutic agents are shown to be 
highly efficient and safe, before they can be used in clinical trials. The previous chapter 
focussed on measuring the toxicity and hence the safety of the nanogels as part of a 
drug delivery system. In this chapter the efficacy of the nanogel as a carrier is 
evaluated both in vitro, through chemical analysis, and in vivo, using a genetically 
modified strain of zebrafish that changes colour on detection of tamoxifen.  
4.1 Uploading the drug on to the nanogels 
The uploading of a drug on nanocarriers has been achieved via different approaches, 
including surface interactions, covalent links and encapsulation techniques.250 When 
deciding which uploading method to use, it is important to consider the ultimate 
application and purpose of the drug delivery system. If increasing bioavailability or 
masking foul tastes of therapies is the focus, simple encapsulation techniques are can 
be used250. However, when targeting specific tissues or attempting delivery to precise 
locations in the body, more complex methods are required.251-253 
4.1.1 Different approaches to uploading drugs onto drug delivery 
systems 
Encapsulation is often achieved by absorption of the drug into the delivery system,254 or 
by coating or surrounding drug particles in polymers and/or surfactants and subsequent 
evaporation of the solvents used in the process.255 The latter method has significant 
advantages, including the achievement of very high loadings of the selected drug and 
the creation of highly stable dispersions, both of which significantly increase 
bioavailability, and patient compliance.250 However, simple encapsulation of the drug 
often doesn’t target a drug to a specific location, which means there is no control over 
where the drug is released. Therefore drug leakage from the delivery system in random 
locations occurs as a direct consequence of this, leading to undesired side effects. 
Another approach to loading drugs on to a carrier is to use non-specific interactions 
between the drug delivery system and the drug itself. Moorthy et al loaded two drugs 
onto their Mesoporous Organosilica Hybrid Microcarrier, using hydrogen bonding and 
electrostatic interactions. In this system the two drugs loaded were ibuprofen, an anti-
inflammatory drug and 5-fluorouracil, a cancer therapeutic. They reported substantially 
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increased release of ibuprofen at higher pH (7.4), which was much slower at reduced 
pH (5.5) and the reverse for 5-fluorouracil. The reason for this was the difference in 
solubility of each of the drugs at different pH values: the cancer therapeutic, more 
soluble at the lower pH, being delivered to tumour cells which inherently have a lower 
pH, and ibuprofen, more soluble at the higher pH, being released in healthy cells, 
where the pH typically has a higher value. Their model effectively demonstrated 
delivery of two different drugs only to locations where they were required256. 
In some cases the drug is covalently linked to the drug delivery system through 
chemical bonds that can be broken through certain physiological conditions or during 
specified physiological processes. One example of this is a copolymer, N-(2-
hydroxypropyl) methacrylamide (HPMA), formed by Li et al  who loaded a cancer 
therapeutic (doxorubicin) onto it using a hydrazone link. The link was broken and the 
drug released only in conditions where the pH was significantly lower, typically those 
found in the endo/lysosomal compartment of tumour cells257.  
Although the formation of generic interactions allows the drug to be loaded onto the 
carrier, there are significant advantages in being able to use specific interactions to link 
the drug to the delivery systems, especially the ability to be selective and to trigger 
specific release. Among the different approaches that have been investigated, 
molecular imprinting has provided some interesting results. 
 
4.1.2 The molecular imprinting approach 
The first suggestion of imprinting was introduced by Polyakov in the early 1930s258 
when he discovered silica gels had a preference for re-binding a solvent additive when 
the additive was present during the gels’ formation259. This tendency to favourably 
rebind the additive present during formation, under specific conditions, is the essence 
of ‘imprinting’. This work was followed in 1949, by further research by Dickey, who 
imprinted analogues of methyl orange, noticing that the silica gels had an enormous 
preference for the dye, which was made available and present during their formation. 
He also highlighted that an increase in rebinding was seen, the closer the structure of 
the gel was to that of the analogue made present during formation260. However it was 
Wulff et al who first proposed formation of an imprinted organic bulk polymer which was 
able to separate a racemic mixture261. 
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The molecular imprinting approach is based on the self-assembly of functional 
monomers around a template or target molecule. Polymerisation of the functional 
monomers in the presence of a cross-linker, is followed by removal of the template via 
specific washing. This results in the formation of a 3-D cavity whose structure is 
complementary to the template used. The cross-linked matrix holds the functional 
groups in position allowing selective recognition and rebinding of the template molecule 
or a target analyte, which is highly similar in structure. A template analogue is often 
used for creating the MIP, which differs slightly in structure to that of the target analyte 
desired to be rebound. This can be for several reasons, one such reason is to prevent 
bleeding of the target analyte from the MIP once the template has been removed, for 
example in extraction techniques262. The molecular imprinting approach is 
schematically depicted in figure 52.  
Figure 52 – A systematic illustration of the molecular imprinting process.  
The key feature of this approach is the interaction between the template and the 
functional monomer. The stronger and more defined the interaction the higher is the 
selectivity and the imprinting efficiency of the resulting polymer. A number of different 
approaches based on different type of interactions have been investigated, which 
include covalent, semi-covalent and non-covalent. Despite the covalent approach being 
the one giving the best outcomes, non-covalent interaction examples dominate the 
literature. This is mainly due to the considerably higher availability of suitable functional 
monomers and the wider applicability of the approach to a variety of templates263. The 
next sections will provide more details about the different potential system. 
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4.1.2.1 Monomer – template interaction 
The monomer – template interaction for molecular imprinting is of high importance. 
There are several different methods of forming monomer – template complexes to 
imprint into the polymer matrix. The first is the ‘covalent approach’ introduced by Wulff 
et al259. In this method a covalent bond (bond energy of ~85 kcal/mol) is formed 
between the template and the monomer that can be broken and reformed in a specific 
environment264. This has the positive advantage of lending high stability to the complex. 
The functional groups normally used for this form of imprinting are alcohols, aldehydes, 
amines or carboxylic acids, directly limiting the possible number of template molecules 
available. Furthermore, it should be noted that the release of these molecules is mainly 
through hydrolysis, meaning such release could happen anywhere within the human 
body, thus losing the ability to target specific cells such as cancer cells.  
Another approach that has had significant success is the ‘semi-covalent approach’. 
Here, the template molecule is initially bound via a covalent bond, sometimes with the 
use of a spacer molecule. However, once the template is released, the target molecule 
re-binds to the polymer matrix via non-covalent interactions265. This approach could be 
feasible but it would require an extra step of polymerisation with the template, releasing 
the template and allowing rebinding of the target molecule/ model drug. If the drug can 
be directly used for the final monomer – template interaction without such need for 
template release and drug rebinding, it would reduce the preparation time as well as 
cost of preparation. 
The most widely used method in molecular imprinting is certainly the ‘non-covalent 
approach’ where strong interactions such as ionic bonds (bond energy of ~5 kcal/mol) 
or hydrogen bonds (bond energy of ~3 kcal/mol266), complemented by dipole – dipole 
interactions (bond energy of ~1.4 kcal/mol266), and Van der Waals (bond energy of 1-
0.5 kcal/mol266), take place between the functional monomers and the template 
molecules. In this instance re-binding of the template (or drug) occurs using the same 
non-covalent interactions used to form the complex initially as opposed to the semi-
covalent method, which creates the imprint using covalent interactions, and rebinds the 
template/target analyte using non-covalent interactions. By using this approach, 
targeting a drug to a specific location becomes feasible. If an ionic interaction between 
a drug and the drug delivery system is used, which is disrupted at a suitable pH, then 
the drug can only be released under these specific conditions. Thus preventing leakage 
in healthy cells and in turn reducing side effects and increasing drug deposition at the 
required site of action. The weakness of this method is that there is limited control over 
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the complex self-assembly, giving rise to heterogeneous rebinding sites. However for 
present purposes this could be an advantage. This is because the intention is to imprint 
the drug directly (effectively using the drug as the template), during polymerisation and 
to focus on the release mechanism allowing delivery of the therapeutic drug to a 
specific location in the body. As different arrangements of the ‘self-assembled complex 
will collapse at different rates, there is the potential for some variation in release times. 
The same feature could help prevent undesirable rebinding of the drug after the entire 
load has been released. However it is important to study the template (drug) – 
monomer interaction to ensure that experimental conditions are identified that 
maximise and favour the complex formation. 
4.1.3 Molecular imprinting and its application for drug delivery  
The molecular imprinting approach has been exploited in many areas of science267 
including sensors268, biosensors269, solid phase extraction270, chiral separation271 and 
catalysis272. However, their application in drug delivery is of particular interest. There 
are many natural processes in living organisms that rely on molecular recognition, from 
information transfer and reaction catalysis to fighting disease. These processes rely on 
a macromolecular ‘hosts’ to identify and interact with specific molecules of low 
molecular weight to function. Therefore it is of no surprise that being able to mimic 
these processes using synthetic materials could reap huge benefits when applied to 
drug delivery259. 
One application of molecular imprinting in drug delivery has been in ocular therapy. 
Ophthalmic drugs in general are known to have poor patient compliance and ≤ 5% of 
the drug reaches the tissue required when administered correctly. Molecularly 
imprinted hydrogel/silicone composites have been successfully produced which release 
antibiotic, ciproflaxin, over several days273. These contact lenses, due to their ability to 
allow enough oxygen exchange to prevent hypoxia when warn through the night, allow 
sustained delivery of the drug over 14 days. These imprinted lenses released a 
consistently higher amount of drug, over a non-imprinted control when low loadings 
were used. Therefore these ciproflaxin imprinted contact lenses could significantly 
improve patient compliance over repeat administration of eye drops.  
There are several molecularly imprinted polymers that have been developed for 
controlled release of a drug274-276. Salian and Byrne inprinted poly(HEMA-co-DEAEM- 
co-PEG200DMA) with the anti-inflammatory diclofenac sodium, via two different 
polymerisation techniques. They found that when living radical polymerisation (in which 
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a reversible termination step is introduced, creating a dormant species that can be re-
activated to continue the polymerisation as desired277) was used to form the polymer, a 
slower release rate of the drug was obtained which was more independent of 
concentration of the drug inside the polymer than when free radical polymerisation 
(where the polymerisation termination is fixed) was used278. Thus the drug transport 
succumbed less to Fick’s law of diffusion, which states the flux will flow from high 
concentration to low concentration. Javanbakht et al have also developed a molecularly 
imprinted polymer for the sustained steady release of dipyridamole, which prevents 
clotting of the blood and induces vasodilation. Their MIP (molecularly imprinted 
polymer) showed a slower release profile over their NIP (non-imprinted polymer), with 
the NIP releasing the full drug load within 20 hrs in acidic conditions and the MIP taking 
65 hrs for complete drug release279.  
Research into cancer therapies attracts considerable attention in general, due to it 
being the leading cause of death in adults in the US. Moreover problems associated 
with diagnosis’ and treatments, often given too late, along side the fact that the delivery 
of the majority of current oncology treatments are non-specific, create systemic toxicity 
and cause adverse effects280. Although focus has been given to researching cancer 
therapies using nanoscale technologies, in the case of molecular imprinting, very little 
is reported. However one MIP of tocopherol succinate, an analogue of vitamin E, which 
has shown to be selectively effective against malignant tumour cells, whilst harmless to 
healthy cells, has been formed and investigated281. This MIP proved to selectively 
rebind the target analyte over a non-imprinted polymer. However, no release profile of 
the drug was shown. The successful upload of a drug on to a drug delivery system 
solves only half of the problem: the precision of control over release of the drug and 
consequent targeting to a specific location is vital both to provide efficient load delivery 
and to prevent accidental leakage of the drug in undesired areas of the body. 
4.2 Drug template and functional monomer 
Loading the drug onto a drug delivery system is not the only consideration required 
when attempting to deliver a drug to specific locations in the body, the method of 
release is also of high priority. Molecular imprinting introduces an interaction between a 
functional monomer and drug template, which is critical in holding the drug in place. 
However disruption of this interaction is required to release the drug and careful 
consideration into the interaction used and therefore the environment required to 
disrupt it should be considered if a controlled and/or targeted release is to be achieved. 
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Before a functional monomer offering optimised interaction with the model drug could 
be chosen, investigation of the release mechanisms of drugs in current drug delivery 
devices was required.  
4.2.1 Mechanisms for release of a drug from a drug delivery system 
One of the benefits of using molecular imprinting for uploading and releasing a drug 
from a drug delivery system is the ability to target the drug toward specific (diseased) 
tissues. For example, as discussed before, by introducing an ionic interaction between 
the drug and carrier which is disrupted with reduced pH, prevalent in cancerous cells. 
In general, there are two well-documented ways of targeting a drug, the first is passive 
targeting. In this approach the anatomical differences between diseased and healthy 
tissues282 are exploited (such as a difference in temperature) allowing direction of the 
drugs to the tissues requiring them. By contrast, active targeting exploits the selectivity 
between a receptor and a ligand, giving rise to site-specific targeting. Active targeting 
can be achieved using receptor-ligand or antigen-antibody recognition, or by using 
aptamers (chemical equivalents of antibodies, they can specifically bind proteins or 
other cellular targets283)284. In either approach the release of the drug can be triggered 
directly by the recognition event, or the targeting moiety can be independent to that of 
the drug release. In the case of the latter leakage of the drug is common and can 
reduce the overall therapeutic effect and side effects may still be observed285. 
Therefore ensuring the release mechanism is triggered by the environment where the 
drug is required is highly desired. To gain insight into the potential of molecular 
imprinting as an approach for the release of a drug at a diseased site, reviewing other 
methods currently used for releasing drugs from drug delivery systems was of interest 
for comparison. 
One release mechanism that is highly utilised is that of simple diffusion. For example 
the majority of drugs encapsulated in micelles are released via diffusion and often rely 
on passive targeting such as the enhanced permeation and retention (EPR) effect, 
when used for delivery of drugs to tumours286. The EPR effect occurs due to the leaky 
vascular tissue formed surrounding tumours, allowing a higher amount of drug to be 
delivered to tumour cells over healthy cells. This is due to the higher permeability of the 
leaky vascular tissue surrounding tumours, over healthy tissues, allowing a higher does 
of nanomaterials to penetrate the tumour cells287. Reduced lymphatic drainage also 
allows retention of the drug in the tumour tissues252. Another method that has been 
reported is drug release via osmosis. In this case the encapsulated drug is solubilised 
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by the flow of water into the carrier, creating a water gradient. As water continues to 
flow into the carrier to dilute the drug and restore osmotic balance, it causes 
‘microcracks’ in the carrier, allowing slow release of the drug, and ultimately bursting 
the carrier releasing the final payload288. Another favourable system for delivering 
drugs are degradable drug delivery systems.  This is because of their ability to break 
down in to biodegradable and biocompatible materials, relinquishing the concern of an 
accretion of the material in question in the body during sustained delivery. The use of a 
biodegradable drug delivery system was investigated by Young et al, who aimed to 
slow the release of drugs for bone repair. By altering the proportion of the A block in 
their lactic acid (A block) propylene glycol (B block) block co-polymer they were able to 
control the degradation of the transport polymer and ultimately the release of the 
drug289. However, loss of drug through diffusion (thus poor control over accurate 
targeting and consequent inappropriate leakage) was still apparent which is a common 
occurrence in degradable drug delivery systems284. 
All of these methods exhibit controlled release, releasing the drug over a sustained 
period. However, both these release methods also lead to leakage of the drug from the 
carrier in undesired locations. This is due to the drug being released from the carrier 
continually, regardless of location and relies on localisation of the drug delivery system 
at the desired location, thus localisation of the drug delivery system at the diseased site 
is independent to that off the release of the drug resulting in leakage in undesired 
healthy tissues. Leakage of the drug not only affects the efficacy of the therapy but can 
also lead to side effects due to the effects of the drug on normal healthy cells285. 
By actively targeting diseased tissues and coupling that to the release of drugs at 
desired locations reduces the risk of drug release outside of desired tissues. One 
example of an actively targeted drug delivery system is Ligand-based vascular 
targeting agents (VTAs) which selectively bind to tumour blood vessels rather than 
normal ones, allowing coagulating drugs to be dispensed in the vascular structure of a 
tumour, blocking the blood vessels and cutting off the blood (and therefore oxygen) 
supply to the tumour290. One example of this is an antibody to VCAM-1 (vascular cell 
adhesion molecule -1, present in tumour vascular cells) which is covalently linked to 
human tissue factor, which is a gene which encodes for a coagulation factor. The gene 
is not triggered unless the anti-body binds the VCAM-1 and therefore formation of the 
coagulation factor to coagulate the blood is not triggered unless bound to tumor 
vascular cells291. This resulted in necrosis of 95% of the tumour cells. The remaining 
tumour cells were at the periphery of the tumour and often respond well to 
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antiproliferative antitumour therapies. For this drug active targeting was essential as 
cutting of blood supply to healthy tissues would result in very serious side effects if not 
death of the patient. However, the process of establishing suitable antibodies or 
peptide markers to target and encompassing that into a trigger on a drug delivery 
device is time consuming and expensive.  
Another interesting approach for releasing drugs is the one where a stimuli leads to a 
physical change in the conformation/structure of the delivery system, which results in 
the release. Examples of these include response to temperature and pHs. The use of 
pH as a trigger in drug delivery systems has been a widely investigated174, 256, 292, 293 
approach due to the pH of tumour tissues being acidic when compared with normal 
tissues294. The pH of healthy cells is normally 7.4295 whereas tumour tissues can have 
a pH as low  as 5.7294. Using this pH change as a trigger retains the drug in the drug 
delivery system until the target location is reached. This protects healthy cells from 
potentially toxic drugs (avoiding drug leakage) and targets tumour tissues (providing 
efficient drug release only where it is required). Min et al found that by targeting their 
micelles to tumour cells, by using the collapse of their micelles with a change in pH, the 
drug accumulated in much higher doses in the tumour tissue than in normal healthy 
tissues when administered in vivo in mice295. 
In order to prevent leakage of a drug, connecting the triggering event to the release of 
the drug is fundamental. Cancer therapies are notorious for their undesirable side 
effects such as hair loss and vomiting. Targeting a drug to tumour cells would have 
huge benefits by increasing drug deposits at the required site, providing a reduction in 
unwanted side effects, an increase in precisely controlled bioavailability and therefore 
eventual reduction in the total drug dose required284, 285. Molecular imprinting has been 
shown to have the ability to prevent unwanted drug release until an activation source is 
detected. The pH of tumour cells is proven to be much lower than that of normal 
healthy cells294 and this change in pH can be exploited by molecularly imprinted 
nanogels, which on detection of reduced pH trigger the release of the drug. A 
candidate anti-cancer drug, often used for the treatment of breast cancer, is Tamoxifen.  
4.2.2 Tamoxifen 
Tamoxifen, structure displayed in figure 53, is used medically to treat breast cancer as 
it competitively binds to the oestrogen receptor and prevents further production of 
breast tissue, effectively stopping the growth of tumours. More specifically, tamoxifen is 
a selective oestrogen receptor modulator (SERM), which acts as an agonist, binding to 
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the receptor, triggering a response in bones and the uterus. However, tamoxifen acts 
as an antagonist in breast tissue, binding to the oestrogen receptor in the breast tissue 
cells preventing it from binding oestrogen and triggering excessive reproduction of 
breast tissue296. A study in the Cancer Research journal in 1987 found that when MCF-
7 breast cancer cells were denied the oestrogen hormone, they adapted and continued 
to grow. However, when an anti-oestrogen was present growth of the cells was 
suppressed297. Cole et al were the first to prove clinical efficacy in 1971234 and since 
then tamoxifen has become a widely used drug to both treat and prevent breast 
cancer, at all stages of development.298, 299 However, tamoxifen has limited 
bioavailability and takes 4-8 weeks to reach steady state concentration, together with 
one of its metabolites N-desmethyltamoxifen.234 Moreover, tamoxifen also exhibits 
serious side effects such as endometrial cancers and drug resistance can occur when 
administered long-term.298 Creation of a drug delivery system that delivers tamoxifen 
only to the target tissues would increase the amount absorbed by the desired tissue, 
dramatically reduce its exposure to other undesired tissues and help prevent these side 
effects.298 
 
Figure 53 - Structure of tamoxifen. 
4.2.3 Tamoxifen – acetic acid interaction  
Tatavarati et al found that by incorporating an acidic monomer into a polymeric matrix 
can aid release of a weakly basic drug when the monomer forms a complex with the 
drug. Enhanced drug release only occurs providing the pKa of the drug’s conjugated 
acid is above that of the pH of the environment in which drug release is desired300. The 
pKa of tamoxifen’s conjugated acid in aqueous solution is approximately 11 according 
to Loftsson et al who investigated drug-cyclodextrin complexes301. This is well above 
the pH of tumour cells and therefore had good potential for release when complexed 
with an acidic monomer.  
One acidic monomer that has already been incorporated into the nanogels, originally to 
aid its solubility, is that of acrylic acid. Acrylic acid monomer has a pKa of 4.25175 and 
when incorporated into a polymer has a pKa of 4.75302 in aqueous environments. This 
N
O
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increase in pKa can be accredited to the increased stabilisation in the monomer due to 
the double bond, which disappears once polymerised and therefore the acid is slightly 
more easily dissociated in the monomer form than the polymer.  
Tamoxifen has an exposed tertiary amine group, which can interact with the acrylic 
acid. The carboxylic acid group on the acrylic acid is partially dissociated at normal pH, 
and the amine on the tamoxifen is reduced, allowing an ionic bond to form between the 
two. However, as the pH of the solution containing acrylic acid is reduced, as would 
occur when the complex reaches the malignant tissue, the interaction with tamoxifen 
will be disrupted and the tamoxifen will be released. The ionic interaction can be 
viewed in figure 54. 
 
Figure 54 – Tamoxifen – acrylic acid complex, forming an ionic interaction. 
4.2.4 1H NMR study of complex interaction 
Analysis of the ionic complex interaction can be carried out using nuclear magnetic 
resonance spectroscopy (NMR). This technique has been carried out many times 
previously for determination of binding constants and investigations of complex 
formation. Proton NMR in particular is of use for this study as it is highly sensitive to the 
proton environments, even when non-covalent interactions are of interest.  
In these studies acetic acid was used to study the interaction between the functional 
monomer and the drug in place of acrylic acid. This is due to acetic acid having a pKa 
of 4.76303, which is much closer to the pKa of the acrylic acid (4.75302) after 
polymerisation and therefore can be a better mimic of the interaction between 
tamoxifen and the functional monomer in complex once polymerised in the nanogel, 
than the acrylic acid monomer (pKa 4.25175).  
In the complex formed here between tamoxifen, which is the ‘guest’, and acetic acid, 
the ‘host’ is presumed to be through a non-covalent ionic interaction. This interaction is 
NH
O
O
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between the protonated tertiary amine nitrogen on the tamoxifen and the dissociated 
alcohol oxygen on the acetic acid. This interaction will decrease the positivity of the 
nitrogen on tamoxifen, theoretically shifting the hydrogens on the adjoining carbons 
downfield. Knowledge of the non-covalent interaction between a host (H) and a guest 
(G) in a complex ultimately comes down to binding constants. Analysis of binding 
constants, allow quantification of the association between two molecules. In the system 
reported here it was expected that the interaction would be 1:1, therefore only one 
binding site would have been given by each molecule of acetic acid to bind the 
tamoxifen. If true, stoichiometry would not come into play and the reaction of complex 
formation can be written as in Equation 6304. 
𝐻 + 𝐺 ⇌ 𝐻𝐺 Equation 6 
Where, H is the Host, G is the guest and HG is the complex formed. From this the 
association constant (KA) can be written as: 
𝐾! = !"! [!] Equation 7 
By substituting [H] = [H]0 – [HG] into equation 7, XHG=
[!!]! ![!"]  (where XHG is the amount 
of host in complex with the guest) can be re-arranged to give: 
[!"][!]! = !![!]!!!![!] = 𝑋!"  Equation 8 
It can be assumed that the chemical shift (δ) of interest is the weighted average of the 
free host (H) and the complexed host (HG) for a 1:1 system. As the total amount of 
host in the system (XHtot, free host + complexed host) cannot exceed 1 
(XHtot=XH+XHG=1) the observed chemical shift can be written as seen in equation 9.  𝛿!"# = 𝑋!𝛿! + 𝑋!"𝛿!"  Equation 9 
Where 𝛿!"#  is the observed chemical shift, XH is the amount of free host, XHG is the 
amount of complexed host, 𝛿! is the chemical shift of the free host and, 𝛿!" is the 
chemical shift of the complexed host. As XH = 1 - XHG  equation 10 can be obtained. Δ𝛿 ≡ 𝛿!"# − 𝛿! = 𝑋!"(𝛿!" − 𝛿!)  Equation 10 
Equation 8 can then be substituted into equation 10, to give equation 11. 
Δ𝛿 = !!!"!!![!]!!!![!]   Equation 11 
Where Δδ is the change in chemical shift, Δδtot is the maximum change in chemical 
shift, KA is the association constant and [G] is the concentration of guest in the system. 
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This method can then be applied to determine the binding constant between tamoxifen 
and acetic acid by using NMR spectrometry. 
4.2.4.1 The tamoxifen – acetic acid complex 
In the first set of experiments tamoxifen was reacted with increasing amounts of acetic 
acid and each time a 1H-NMR spectrum was recorded. The aim was to identify which 
protons would have their chemicals shifts affected by the interaction with the acid and 
to attempt to quantify the shift. Initially the proton environments affected by the ionic 
bond were required to be identified. The protons on adjacent carbons to the amine in 
complex (Hta and Htb) with the acetic acid would both be affected by the effect of the 
ionic interaction, these hydrogens are indicated in figure 55. 
 
Figure 55 – Interaction of Tamoxifen and acetic acid with labels marking those protons affected 
by the interaction. 
Tamoxifen and acetic acid were dissolved in d6-DMSO and 1H-NMR carried out. The 
complex was formed and analysed in d6-DMSO. DMSO was required for solubility of 
the drug and monomers for polymerisation and therefore analysis of the interaction was 
required under the same conditions.  However DMSO is not the ideal solvent in which 
to study the interaction due to its high dielectric constant (49), which inhibits the ionic 
interaction as it forms a stronger screening effect between charge carriers and counter 
ions reducing Coulomb interaction305.  The singlet peak for the CH3 groups on the 
tertiary amine (Hta) and the triplet peak for the CH2 group (Htb) attached to the amine 
could be seen to shift in ppm downfield, this is displayed in figure 56.  
H3taC NH
CH3taCH2tb
O
O
O
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Figure 56 – Stacked NMR spectrums of Tamoxifen a) alone, red b) with 0.5eq AA, yellow, c) 
with 1eq AA, green, d) with 2eq AA, turquoise, e) with 4eq, blue, f) with 8eq AA, purple and g) 
with 12eq AA, pink. Where AA=acetic acid. 
Analysis continued with the Hta peak to try to obtain the association constant, as it was 
a clear singlet that could more accurately be evaluated for its ppm shift. The values of 
change in chemical shift in function of acetic acid concentration can be seen in table 
15. 
[Acetic acid] 
(M) 
δHta in d6-
DMSO (ppm) 
ΔδHta in d6-
DMSO (ppm) 
0.0000 2.172 0.0000 
0.0355 2.177 0.0080 
0.0710 2.183 0.0170 
0.1420 2.191 0.0290 
0.2840 2.209 0.0550 
0.5680 2.230 0.0880 
0.8520 2.279 0.1720 
1.1360 2.321 0.2190 
2.2700 2.426 0.3690 
3.4100 2.604 0.4320 
3.9800 2.615 0.4430 
4.5400 2.637 0.4650 
Table 15 – Values of chemical shift (δHta) and of their variation (ΔδHta) in function of acetic acid 
concentration in d6-DMSO using H1NMR (400MHz). The chemical shifts are in ppm and relative 
to TMS (tetramethylsilane).  
When analysing the change in chemical shifts of the two peaks Hta and Htb, the 
variation in chemical shift of Hta can be seen to increase from 0.008 ppm (0.5 eq) to 
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0.465 ppm (128 eq) as concentration increases. When the chemical shift of Hta protons 
on Tamoxifen, compared to Hta in uncomplexed tamoxifen, in function of the 
concentration of Acetic acid added was plotted a clear curvature could be seen which 
plateaued at 32 equivalents.   
 
Figure 57 – Plot of the variation of chemical shifts ΔδHta of the protons Hta in complexed 
tamoxifen corrected from the value of the chemical shift of Hta in uncomplexed tamoxifen verses 
the concentration of acetic acid in d6-DMSO.  
The association constant was calculated using equation 11, which establishes the 
relationship between the change in shift of the Hta peak of Tamoxifen and the 
concentration of acetic acid. The data presented in figure 57 is fitted to a hyperbola 
using a ligand-binding model in sigma 8.0 data analysis software.  
𝑦 = !∗  !!!!∗!  Equation 12 
Where y= the change in chemical shift of the Hta proton, a is the total chemical shift 
multiplied by the association constant, x is the concentration of acetic acid and b = KA 
which is the association constant of the complex.  
As a plateau was reached, the equilibrium was quantified and the association constant 
was determined to be 0.31M-1. This association constant is quite low, which was 
predicted due to the high dielectric constant of DMSO inhibiting the interaction. In 
DMSO acetic acid has a pKa value of acetic acid is approximately 12.6 and the tertiary 
amine of tamoxifen would have a pKa value of 41-42. This therefore means acetic acid 
effectively becomes a much weaker acid in DMSO, meaning a much higher proportion 
of the acetic acid was present as the undissociated acid and therefore inhibiting its 
Amine methyl groups peak shift against increase in acetic acid 
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interaction with the tertiary amine on tamoxifen. This in turn means a much higher 
proportion of acetic acid needed to be present to obtain a good degree of complexation 
of the tamoxifen (128 equivalents was required for 65% of tamoxifen to be complexed). 
However this would be true if only the ionic interaction was considered. The tamoxifen 
molecule and the coumarin molecule (in the nanogel) both contain aromatic rings, 
therefore the ionic interaction between the tamoxifen and the acrylic acid is not the only 
interaction taking place. In fact π-π stacking of the aromatic rings (which have bond 
energies of 2-3 Kcal/mol) in the two molecules will also be occurring: this is well 
documented for polymers containing coumarin molecules167, 306. DMSO was used to 
help solubilise the drug, however it has high dielectric constant, which works against 
the formation of the ion pair. Therefore to try to maintain as much specific interaction 
between the tamoxifen and acetic acid as possible, and to reduce the non-specific 
interactions (which would cause bleeding of the drug in undesired areas) as far as 
possible, a 1:1 ratio of tamoxifen to acrylic acid was selected.  
4.3 Uploading drug into the nanogels and in vitro release 
studies 
The ionic interaction, along side the π-π stacking, between tamoxifen and acetic acid 
confirmed via 1H-NMR studies was discussed in section 4.2.4.1. This interaction was 
exploited in the nanogels, to create a drug delivery system that would prevent leakage 
of the drug while the carrier is moving towards its target location. Furthermore the ionic 
bond would be expected to be disrupted when the nanogels are internalised in 
tumorous cells, which are characterised by a reduced pH, leading to a pH triggered 
release.  
4.3.1 Formation of MIP/ NIP nanogels 
Having established that a good interaction between tamoxifen and acetic acid can be 
achieved, the drug was loaded into the nanogels at a ratio of 1:1, 0.5:1 and 0.25:1 
tamoxifen to functional monomer. The amount of tamoxifen was varied to analyse its 
effect on the system, without going above the crucial 1:1 ratio to avoid unspecific 
binding.  The nanogels were prepared using the same method as the non-imprinted 
nanogels obtained in chapter 2, except that, in this case, the drug was present in the 
polymerisation solution. For every MIP formed a corresponding NIP (non-imprinted 
polymer) was also synthesised, as a control. The nanogels were then characterised for 
their size and solubility and the data is presented in table 16. 
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Nanogel MIP/
NIP 
Ratio 
Fm:Tam 
% 
TCA 
(%) 
% A  
(%) 
% 
yield 
(%) 
Ave. 
diameter 
(nm) 
Solubility 
in water 
(mg/ml) 
NG1 
(BATCH 3) 
NIP N/A 2.5 67.5 40 230 ±15 10 
NG1A MIP 1:1 2.5 67.5 54 154 ±2 0.1 
NG1B MIP 1:0.5 2.5 67.5 38 167 ±3 0.1 
NG1C MIP 1:0.25 2.5 67.5 44 168 ±3 0.5 
NG2 
(BATCH 3) 
NIP N/A 5 65 50 217 ±18 10 
NG2A MIP 1:1 5 65 54 104 ±7 0.1 
NG2B MIP 1:0.5 5 65 52 130 ±2 0.1 
NG2C MIP 1:0.25 5 65 45 112 ±1 0.1 
Table 16 – Molecularly imprinted nanogels prepared. MIP/NIP nanogels contained 20 % MBA 
and 10 % AA and polymerised at 70 °C in DMSO with a CM of 0.5%, using AIBN at 2% of all 
double bonds by mol. All particle sizes were carried out at 0.1 mg/ml in 1% DMSO in water. 
Where TCA is trifluoromethyl coumarin acrylamide acrylamide, MBA is methylbisacrylamide, AA 
is acrylic acid and A is acrylamide. 
The addition of tamoxifen considerably reduced the solubility of the nanogel, however 
when both the amount of TCA in the formulation was decreased and the amount of 
tamoxifen was decreased a transparent solution could be obtained at 0.5 mg/ml. 
Tamoxifen is highly hydrophobic due to its three phenyl rings and coumarin is also 
hydrophobic due to its hydrophobic rings. It naturally followed that the solubility 
decreased with an increase of either of these molecules.  
The presence of tamoxifen appeared to have a significant impact on the particle size 
reducing it by approximately 70-80nm in all cases. The drug loaded nanogels also 
appeared to be more monodispersed, giving more narrow particle size distributions. 
The drug loaded nanogels containing 2.5% coumarin were all roughly 50 nm bigger 
than the 5% coumarin equivalent. This could be the result of strong hydrophobic 
interactions such as the π-π stacking, which would be holding the nanogels in a more 
tightly compact and rigid structure, also justifying the reduced solubility. The higher the 
content of coumarin tag in the formulation, the more π-π interactions taking place and 
the more tightly held is the polymer structure, which in turn increases the 
hydrophobicity of the nanogel. The more narrow particle size distribution of tamoxifen 
loaded NG1A compared to the unloaded NG1 (batch2) nanogel and are displayed in 
figure 58.  
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a)  
b)  
Figure 58- DLS traces of a) NG1(batch 2) with no tamoxifen loaded and b)NG1A with 0.42eq 
tamoxifen loaded. Both samples meaured at 0.1 mg/ml in water. 
Surprisingly, no significant difference was observed in the particle size with increasing 
amount of tamoxifen incorporated in the nanogels. A possible explanation for this is the 
overall low concentration of the drug in the nanogel solution; this could change if much 
higher amounts of tamoxifen were used. Following the successful incorporation of 
tamoxifen in the nanogels the next step focussed on characterising the loaded 
nanoparticle and evaluating the drug release. 
4.3.2 Tamoxifen uploading on to the nanogels  
Drug loading on carriers can vary a lot, with some carriers managing to load up to 
almost 2 equivalents of drug per carrier307. However, this is not the norm, when 
reviewing polymer-based nanocarriers, loadings up to 0.2 equivalents are more 
frequently encountered308-310. The percentage of drug successfully loaded on to a drug 
delivery system is dependent on variables such as the upload method, structure of the 
carrier and release mechanism. Work by Yan et al produced polymer-based 
nanospheres, which were passively tumour-targeted using sulfadiazine and loaded with 
between 0.1 and 0.25 equivalents of drug to carrier depending on the uploading 
method used and their nanosphere composition308, 311. More complex systems, such as 
those with active targeting moieties often have a lower drug loadings due to the 
multifunction and more complex nature of the drug delivery system312. 
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Establishing the entrapment efficiency enables the comparison of the uploading 
technique used for these nanogels compared to those reported in the literature. The 
drug entrapment efficiency can be calculated via equation 13. 
𝐸𝑛𝑡𝑟𝑎𝑝𝑚𝑒𝑛𝑡  𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 =    !"#$%&  !"#$  !"#$%$!!!"#!$%&'  !"#$  !"#$%$   𝑥  100    Equation 13 
Sun et al obtained a maximum entrapment efficiency of 84% when loading upto 0.14 
eq drug onto their nanoparticles313 and Tavassolian et al had a maximum entrapment 
efficiency of 79% when loading 0.5 eq of drug onto their micelles312. Yigitoglu et al 
managed to achieve exceptionally good results with their alginate polyvinylpyrrolidone 
copolymer beads with between 0.13 and 0.5 eq drug loadings and entrapment 
efficiencies of 92% and above.314  
To establish how much tamoxifen was successfully uploaded into the nanogels through 
molecular imprinting, the nanogels were analysed using HPLC (high performance liquid 
chromatography). The method involved dispersing the nanogels in a solvent, in this 
case ACN, where interactions between the drug and functional monomer were easily 
disrupted, but where the drug was highly soluble. This was followed by quantification of 
the drug in solution by HPLC. The optimal conditions for analysing tamoxifen in the 
Hichrom C18 25mm column were found to be 5:95 water acidified with 0.5% acetic acid 
to Acetonitrile at a flow rate of 1.5 ml/min, which gave a pressure of approximately 80 
bar.  This gave a peak at around 7 minutes. Initially a reference line of Tamoxifen, 
figure 59, in dissolved in ACN (acetonitrile) was established.  
 
Figure 59 –Calibration curve of the area under the curve obtained via HPLC against the 
concentration of tamoxifen injected. 20 μl were injections performed in acetonitrile measuring 
the absorbance at 291nm. Flow rater was 1.5 ml/min using 95% ACN, 5% water acidified with 
0.5% acetic acid. 
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Once the calibration curve was obtained the nanogels were dissolved in ACN (at 1 
mg/ml) and mixed for 5 minutes. This process was established as the best method to 
extract all the tamoxifen from the nanogels as the tamoxifen is highly soluble in ACN, 
whereas the nanogels are insoluble in ACN, disrupting the ionic interaction and the 
drug was released. After 5 minutes stirring the mixture was filtered with a 20 nm filter to 
remove the nanogel from the mixture and 20 µl were injected into the HPLC. The data 
can be seen in table 17. 
Nanogel Ratio 
Fm:Tam 
(by mols) 
TCA 
content 
(%) 
Entrapment 
efficiency (%)  
Final Ratio 
of drug to 
carrier  
 
NG1A 1:1 2.5 > 99.9 0.42:1 
NG1B 1:0.5 2.5 92 0.19:1 
NG2A 1:1 5 95 0.38:1 
NG2B 1:0.5 5 96 0.19:1 
Table 17 – The entrapment efficiency and final drug loadings of some of the molecularly 
imprinted nanogels prepared. MIP nanogels contained 20 % MBA and 10 % AA with the 
remained of the nanogels comprised of acrylamide. All nanogels were polymerised at 70 °C in 
DMSO with a CM of 0.5%, using AIBN at 2% of all double bonds by mol. Where TCA is 
trifluoromethyl coumarin acrylamide and Fm is functional monomer. 
A high drug loading of tamoxifen into the nanogels was achieved, with nearly 100% 
entrapment efficiency. In NG1A and NG2A with a 1:1 ratio of acrylic acid to tamoxifen, 
there are 0.42 equivalents of Tamoxifen to nanogel. This is a relatively high loading of 
drug for a drug delivery with excellent entrapment efficiencies of between 92 and > 
99% compared to those found in the literature.210, 313, 314 Having confirmed that 
molecular imprinting can be an efficient method for the uploading of tamoxifen onto the 
nanogels, an analysis of the pH-triggered release of the drug in vitro was the next 
investigation.  
4.3.3 Diffusion verses triggered release 
To assess the efficacy of these nanogels in terms of their qualities as potential drug 
carriers, in vitro analysis of the drug release was required, as mentioned above. The 
aim of this investigation was to minimise drug release via diffusion, and ensure that the 
drug release only occurs when an environment with reduced pH is encountered, in 
order to increase drug dosage at the required site (here, breast tumour cells) and 
reduce healthy cell exposure to the drug. At pH 3, below the pKa value of acrylic acid, 
which is 4.25, the acid is undissociated303 and therefore retains its hydrogen, and no 
longer maintains the ionic interaction with tamoxifen . This is on the assumption that 
the polymer matrix in water does not significantly alter the pKa values of the functional 
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monomer. Analysis of the nanogel tamoxifen content at pH 3 enabled evaluation of the 
maximum amount of drug available for release in an aqueous environment, giving the 
limit of the system. Although the maximum amount of tamoxifen loaded onto the 
nanogels was established, it is likely that some of the tamoxifen is imprinted deep into 
the core of the nanogel, which under physiological conditions would not be accessible 
for release. Therefore to determine the maximum drug available for release in an acidic 
aqueous environment the nanogels were exposed to aqueous solutions at pH 3.  
The nanogels were re-suspended in water acidified with HCl to pH=3 and dialysed for 2 
days, with 4 water exchanges (the final water exchange was with pH neutral water) and 
freeze dried once again. The nanogels were worked up in the same way as described 
previously, dissolved at 1mg/ml in ACN, stirred for 5 min, filtered and injected into the 
HPLC. The area under the curve was compared to that of the nanogel without the 
extraction process and the percentage of drug retained in the nanogel after pH reduced 
extraction was recorded in table 18. 
Nanogel Ratio 
Fm:T
am 
TCA 
(%) 
Entrapment 
efficiency 
(%) 
Tamoxifen retained 
by the nanogel in 
water at pH 3 (%) 
Ratio of drug to carrier 
available for release in 
aqueous conditions.  
NG1A 1:1 2.5 >99.9 20 0.34:1 
NG1B 1:0.5 2.5 92 5 0.17:1 
NG2A 1:1 5 95 4 0.35:1 
NG2B 1:0.5 5 96 7 0.17:1 
Table 18- Tamoxifen available for release in acidic aqueous environment from some of the 
molecularly imprinted nanogels. MIP nanogels contained 20 % MBA and 10 % AA with the 
remained of the nanogels comprised of acrylamide. All nanogels were polymerised at 70 °C in 
DMSO with a CM of 0.5%, using AIBN at 2% of all double bonds by mol. Where TCA is 
trifluoromethyl coumarin acrylamide and Fm is functional monomer. 
The amount of tamoxifen remaining in the nanogels is a very small percentage of 
between 4 and 7% for the majority of the nanogels (NG1B, NG2A and NG2B). NG1A 
had a larger proportion of loaded tamoxifen unavailable for release with 20% being 
retained in the polymer matrix, however due to the initial high loading of tamoxifen in 
the nanogel (0.42 eq) it maintained a comparatively high drug load which was available 
for release. Therefore NG1A effectively had a 0.35:1 drug (available for release) to 
nanogel ratio, higher than the majority reported in the literature.308, 312, 313 If both the 
entrapment efficiency and the drug available for release are considered, then between 
80 % (NG1A) and 91% (NG2A) of drug loaded onto the nanogels is available for 
release.  
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4.3.4 Drug release 
The data obtained so far clearly suggested that the molecular imprinting approach had 
allowed the upload of very good quantities of tamoxifen in the nanogels. This was the 
result of the combination of the imprinting approach together with the use of the acrylic 
acid as a functional monomer to specifically ‘anchor’ the drug to the polymeric matrix. 
The nature of this acid-base interaction could therefore be further exploited to induce a 
stimuli-controlled release of the drug. The next set of experiments focussed on 
measuring the impact of the pH in triggering the release of the drug from the tamoxifen-
loaded nanogels. 
Data in the literature report different values of pHs for tumorous cells, varying. from 6.8 
for extracellular tumour tissue pH, to pH 4.5 in some of cellular compartments (such as 
pH 6.5-5.0 in endosomes and pH 5.0-4.5 in lysosomes)315, 316. Breast tumour cells 
themselves vary in pH with drug resistant breast tumour tissues having lower pH than 
their non-resistant counter parts317. pH 5.5 is conventionally used when analysing novel 
materials as proof of principle256, 318-320. Therefore investigations into the release of 
tamoxifen from the nanogels were carried out at pH 5.5 to mimic tumour environments 
in general. 
In order to analyse the drug release from the nanogels, the nanoparticles loaded with 
tamoxifen were dissolved in the aqueous phase and dialysed against a buffer solution 
being stirred at 37 °C to mimic the dynamic equilibrium in vivo. In this way any drug 
released from the polymer would be removed from the carrier by passing through the 
dialysis membrane, as it would in the body, reducing the likelihood of rebinding and 
therefore allowing the evaluation of continued drug release. In a closed system 
whereby the carrier is simply dissolved in the relevant buffer and continually mixed, the 
carrier is in continual contact with any free drug which would not be the case in vivo, as 
the drug would be released and used for it’s intended purpose, preventing rebinding. 
The amount of drug released as a function of time was determined by quantification of 
the drug remaining incorporated in the nanogel. The first step involved analysing the 
drug release at pH 5.5 using 1mM acetate buffer. When the drug was removed during 
dialysis at pH 3 it was noticed that a significant increase in water solubility of the 
nanogel itself was obtained. This indicated that sedimentation at pH 5.5 was unlikely as 
the more drug was removed, the more soluble the nanogel became in water. Therefore 
NG1A (6 mg) was dissolved in buffer at 2 mg/ml and suspended on dialysis in acetate 
buffer (1 L, 1 mM) and at each time point the dialysis tube was inverted several times 
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to ensure a representative sample was removed. At the required time points 100 μl of 
the nanogel solution were removed, 100 μl of ACN were added to facilitate the release 
of the drug from the polymer matrix, the solution was vortexed for 30 seconds, filtered 
and injected (20 μl) into the HPLC. This allowed for many time points to be assessed. 
This was repeated in triplicate to obtain reliable data. The results can be seen in figure 
60. 
 
Figure 60 - Tamoxifen released from nanogel NG1A in acetate buffer (pH 5.5) over 7 hours. 
Analysis carried out using HPLC, eluent used was 95% acetonitrile to 5% water acidified with 
0.5% acetic acid at a flow rate of 1.5 ml/min. 
The data clearly indicated that the drug was released successfully at pH 5.5. A very 
rapid release was observed and the payload totally dispensed within the first 2 hours. 
This could be advantageous as depositing a high payload of drug, only at the site of the 
intended target could have a beneficial effect on preventing the rapid replication of 
breast tissue cells. As these nanogels are <200 nm in size they will be retained at the 
tumour site by the EPR effect (explained in section 4.2.1) and therefore the drug would 
theoretically be released over a 2 hour period only at the target site. However to 
establish that the drug was only released at acidified pH, analysis of tamoxifen release 
from the nanogels at physiological pH (pH 7.4295) was also evaluated. Leakage of the 
drug outside of its required location increases the systemic toxicity and reduces the 
appropriate bioavailability of the drug, as less accumulates at the lesion site285. 
To evaluate drug leakage at pH 7.4, NG1A was dissolved in water at 2 mg/ml and 
placed in 1000 dalton dialysis tubing. As mentioned above, NG1A was less soluble at 
higher concentrations; as such this was a cloudy solution. To prevent artefacts in the 
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data due to sedimentation of the nanogels, individual ‘parcels’ of nanogel containing 
500 μl of the nanogel solution were each put in a separate section of dialysis tube, but 
each parcel was placed in the same dialysis solution. In this case the dialysis solution 
was 1 litre of 1 mM PBS buffer, adjusted to pH 7.4. A parcel was removed at each 
relevant time point, all contents removed and diluted (to 1 mg/ml) with 500 μl of ACN, 
vortexed for 30 seconds, filtered using a 20nm PTFE filter and injected (20 μl) into the 
HPLC. This was carried out in triplicate for accuracy and the results are presented in 
figure 61.  
 
Figure 61 – Tamoxifen released from nanogel NG1A in PBS buffer (pH 7.4) over 7 hours. 
Analysis carried out using HPLC, eluent used was 95% acetonitrile to 5% water acidified with 
0.5% acetic acid at a flow rate of 1.5 ml/min.  
Figure 61 shows that less than 10 % of the drug was released in 7 hours. In the case of 
pH 5.5 80% of the drug was released, suggesting only a very small amount of drug 
would be leaked whilst the nanogel circulated inside the body. The data suggests that 
the nanogels have released the drug in high dosage at a pH of around 5.5 and retain 
the drug at physiological pH. This feature makes the nanogels attractive as a drug 
delivery system as it may significantly reduce side effects of the drug.  
The release response of the drug delivery carrier at reduced pH was rapid, releasing 
the majority of the payload within the first 2 hours. This would be beneficial for an 
immediate response for a growing tumour, however for prevention of breast cancer and 
a more sustained delivery of tamoxifen a slower more controlled release would be 
desirable. Several studies have attempted to show controlled release however when 
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the nanoparticles reach their trigger the tamoxifen payload is often released within the 
first 2-3hours, as with the nanogels under test321, 322. One study by Vivek et al has more 
successfully controlled the release of tamoxifen from the nanoparticles (with loadings of 
up to 28%) releasing steadily over 6 hours323. However more drug was released at pH 
7.4 (~20% within 6 hours) than the nanogels produced in this project. Moreover, at pH 
4 the reported maximum drug release was 68% and at pH 6 just 43% of the reported 
drug load was released by 48 hours323, whereas in the current study, the nanogels 
released >80% of the loaded drug.  To investigate whether a reduced payload would 
release more slowly, for a more controlled release, the nanogels previously prepared 
with varying loading (section 4.3.1) were analysed over a longer period of time for their 
drug release. 
To investigate the effect of reducing the loading of the drug in the nanogel on the 
release timescale NG1A, NG1B and NG1C were analysed for their release over a 48 
hour period. 
 
Figure 62 - Tamoxifen released from nanogel NG1A, NG1B and NG1C in PBS buffer (pH 7.4) 
over 7 hours. Analysis carried out using HPLC, eluent used was 95% acetonitrile to 5% water 
acidified with 0.5% acetic acid at a flow rate of 1.5 ml/min.  
As can be seen in figure 62, when the loading of tamoxifen is less (10 %, NG1C) a 
much slower release profile is seen, with tamoxifen being released more steadily and 
evenly over the 48 hour period. Even at double this drug loading as in JRP103 (20 % 
drug loading) the drug is steadily released over a 24 hour period. It follows that this 
system can be tailored for either a slower release of a drug at lower concentrations, 
which is ideal for preventative care, or for a faster release with a higher payload when 
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treating tumours. In all circumstances the payload is mainly released at reduced pH, 
targeting the specific target lesions and protecting healthy cells from substantial side 
effects.  As the in vitro studies have shown positive results with regard to the efficacy of 
these nanogels, an analysis in vivo, using a genetically modified line of zebrafish was 
carried out. 
4.4 In vivo drug release 
The in vitro release of the drug at pH 5.5 proved to be very successful. In the next 
section the data related to the testing of the release mechanism of the selected 
nanogels in vivo, using a transgenic line of zebrafish are presented, which demonstrate 
that the same release mechanism can be shown to occur in vivo. Zebrafish tamoxifen 
reporter line ubi:loxP-EGFP-loxP-mCherry (ubi:switch), acquired from University 
College London fish facility, were used for these studies. 
4.4.1 The LoxP-CreERT system 
An advantage of mice and zebrafish is the ability to generate transgenic reporter lines.  
One of the many reasons mice are often used as an in vivo model is the ability to 
create new mouse models due to better knowledge of their genome and transgenic 
technologies206. One such system that has been exploited in both mouse models and 
zebrafish is the loxP-creERT system. Using the loxP-creERT system DNA 
modifications can be made. For this project the loxP-creERT system has been 
exploited to visualise a colour change in zebrafish in presence of tamoxifen. Therefore 
when tamoxifen is not present the zebrafish fluoresce green (GFP) fluorescence. When 
tamoxifen is present, an enzyme (cre recombinase) is triggered and the fish DNA 
encoding for the green fluorescence is deleted and the fish instead produce red 
(mcherry) fluorescence.  
The cre/lox system is a well known biological process that has been used for the past 
15 years to artificially control gene expression (the process of reading the information 
of a gene and synthesising the gene product, which is normally a protein although can 
be the formation of functional RNA). Cyclization recombination (cre) is a gene that 
encodes site specific DNA recombinase, thus allowing recombination of specific DNA 
sites when the cre protein is present. The specific sites that the cre protein can cut, and 
then recombine the DNA surrounding it, is a ‘locus of-X over P1’ or loxP sequence. 
LoxP sequences are 34 base pairs long and from a bacterial virus, ‘P1 
bacteriophage’324, 325. The loxP DNA excised from the virus is not found in animals or 
plants. Therefore the loxP sequence can be artificially inserted into an animal or plants 
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DNA without the risk of excision of undesired areas of their genome. A representative 
diagram of how the cre/loxP system works can be seen in figure 63.309  
 
Figure 63- A systematic diagram of Cre mediated loxP recombination where the gene is only 
expressed when Cre recombinase is released and deletes the STOP coding. 
For a gene to be expressed, a promoter is required to initiate the multi-step process 
required for the protein production. To gain control over the expression of a particular 
gene/protein a STOP coding DNA sequence is surrounded by loxP sequences and 
inserted between the promoter and the gene. The promoter needs to be ‘ubiquitous’ to 
enable the switch to be present in all cells at all stages of development326. Only when 
the loxP sequences are cut, removing the stop coding, can the protein be produced 
and therefore gene expression occurs. 
To produce an in vivo model containing this gene control a transgenic line containing 
the cre recombinase and a separate transgenic line containing the loxP-flanked gene 
must be produced. In the resulting offspring, those that inherit both genes, the coding 
between the loxP sequences will be excised and no longer function, and gene 
expression will occur in tissues where cre is present327. However where cre is not 
No#cre,#the#gene#is#not#expressed#
Ubiquitous#promoter# STOP# gene#expressed#
loxP# loxP#
Ubiquitous#promoter# gene#expressed#
Ubiquitous#promoter# STOP# gene#expressed#
loxP# loxP#
Cre$
With#cre#the#gene#is#expressed#
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present and the code between loxP sites will remain and function as normal and in the 
gene would not be expressed.  
 
4.4.2 LoxP –creERT induced by tamoxifen zebrafish 
Work carried out in 2009 by Hans et al introduced a tamoxifen inducible creERT2 
mediated loxP recombination in zebrafish328.  They found loxP excision was dose 
dependant and occurred within 2-4 hours of administration of tamoxifen or its 4-
hydroxytamxifen metabolite when applied at mid-gastrulation period of development 
(~8 hpf). However Hans used EF1α promoter to drive the transgene expression, which 
was ubiquitous for zebrafish embryos during gastrulation (5½-10 hpf) and mid-
somitogenesis (10-24 hpf) stages. They found expression was only strongly retained in 
the retina and hindbrain beyond 24 hpf328.  It was Mosimann et al who used ubiquitin 
(ubi) as the promoter for the cre/loxP system in zebrafish326. They found that ubi 
promoter drove transgene expression ubiquitously in the vast majority of cells starting 
at mid-blastula (2-5 hpf) development and remaining through all stages of 
development. Therefore using ubi promoter Mosimann created a ubi:switch line of 
zebrafish which emitted GFP fluorescence. When their loxP flanked line were crossed 
with the creERT2 line and the resulting embryos were exposed to tamoxifen, mcherry 
(red) fluorescence was expressed326. A systematic diagram of the transgene 
expression can be seen in figure 64.  
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Figure 64 – A systematic diagram of tamoxifen induced creERT2 mediated loxP recombination 
where GFP fluorescence is seen in absence of tamoxifen, and mcherry fluorescence is seen in 
presence of tamoxifen. 
In this model two zebrafish lines are created, the first containing the loxP sequences, 
which emit GFP fluorescence ubiquitously from 24 hpf. The second line contains the 
cyclization recombinase and express GFP fluorescence in the heart at 48 hpf. It is 
possible to create homozygous cre and loxP containing zebrafish, by crossing two 
heterozygous zebrafish. From this two heterozygous offspring (+/-), and two 
homozygous offspring, one containing no cre recombinase or loxP (-/-) and one 
containing both genes of either cre or loxP (+/+), of which 3 will express GFP 
fluorescence, can be obtained. The one containing both alleles will emit slightly 
stronger GFP fluorescence, although this can be difficult to identify. By crossing a 
homozygous cre transgenic zebrafish with a homozygous loxP transgenic zebrafish all 
offspring produced would contain one loxP allele and one cre recombinase allele, 
therefore all offspring would contain the ubi:switch. However the fish obtained for this 
project were acquired from University College London’s fish facility, where the 
transgenic zebrafish is maintained as a heterozygous line. In practical terms, to avoid 
the need to put in place a breeding program over several generations(which itself is 
highly time consuming as zebrafish take 3 months to become sexually active) it was 
decided to use the heterozygous fish obtained.  
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loxP# loxP#
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Both genes generate visible fluorophores with a single allele and therefore fish used to 
create embryos containing the loxP/cre system were heterozygous (+/-), forming four 
different offspring (+/-, +/+, -/+, -/-), of which only one (+/+) will contain the ubi:switch 
mechanism required for detecting tamoxifen. At 24 hpf it is possible to isolate those 
embryos which have not inherited the loxP sequences (-/+, -/-), as they do not emit 
GFP fluorescence throughout their body and can therefore be remove from the sample. 
However only 50 % of the embryos that remain will contain the ubi:switch (+/+). 
Therefore when analysing effects of tamoxifen it is important to remember that not all 
embryos in a sample group will express mcherry fluorescence, even if tamoxifen is 
present. A schematic illustrating the generation of ubi:switch ubi:loxP-EGFP-loxP-
mCherry embryos can be seen in figure 65. 
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Figure 65 – Schematic of zebrafish embryos allele inheritance to form a ubi:switch transgenic 
zebrafish. A) hetro/homozygous embryo which has inherited loxP, showing all over GFP 
fluorescence at 24hpf. B) homozygous embryo which has not inherited loxP, showing no GFP 
fluorescence at 24hpf C) hetro/homozygous embryo which has inherited cre, showing GFP 
fluorescence ain the heart at 48hpf. B) homozygous embryo which has not inherited cre, 
showing no GFP fluorescence in the heart at 48hpf E) ubi:switch ubi:loxP-EGFP-loxP-mCherry 
zebrafish before exposure to tamoxifen (GFP fluorescence) F) ubi:switch ubi:loxP-EGFP-loxP-
mCherry zebrafish after exposure to tamoxifen (mcherry fluorescence). 
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4.4.3 Tamoxifen release studies in loxP zebrafish 
The development of the ‘ubi:switch transgenic zebrafish’ line enables reliable visual 
evaluation of the release of tamoxifen from the nanogels in vivo. Transgenic zebrafish 
have previously been used to establish preliminary efficacy of drug delivery systems. 
Lui et al found that piperlongumine loaded onto their polymer micelles inhibited tumour 
growth in transgenic zebrafish through inhibiting angiogenesis (prevention of forming 
new blood vessels)329. FLK-1 premoter EGFP transgenic zebrafish were used, whose 
blood vessels emit GFP fluorescence and hence allowed monitoring of intersegmental 
blood vessel growth. 
Mosimann had already shown that a short application (15 minutes) of tamoxifen was 
enough to induce the fluorescence change in the ubi:switch zebrafish, although it took 
3 days for results to be visually perceived. He also found the longer the fish were left to 
develop their colour, the more intense the fluorescence seen. However the age at 
which he was using the transgenic fish was much younger, 8 and 24 hpf326. To ensure 
the nanogels were entering the zebrafish, immersing them in the nanogel solutions 
beyond 5 dpf was preferable. At 24 hpf Mosimann found a higher intensity of 
fluorescence was seen with proportionately higher concentrations (1 μM compared to 5 
μM) of drug administered and that 10 μM was a lethal concentration, however he did 
not administer tamoxifen at later stages of development. Zebrafish are considerably 
bigger at 5 dpf compared to 24 hpf225 and therefore lethal concentrations of tamoxifen 
and concentrations high enough to trigger the cre recombinase in enough cells to 
visualise the colour change by microscope remained unobserved at 5 dpf and beyond. 
Investigations were required to use concentrations above and below 10 μM of 
tamoxifen, to ensure enough drug is present to visualise any release without 
administering a toxic dose.   
To evaluate the effect of the drug over different timescales and in varying 
concentrations, three different experiments were set up, each with distinct groups of 
zebrafish. The first group were fed tamoxifen-loaded nanogel NG1A (2.5% coumarin 
tag) at a concentration of 24 µg/ml, which contains tamoxifen at 10 µg/ml (27 μM), for 
30 minutes before returning to fresh fish water. The second group were fed NG1A at a 
concentration of 2.4 µg/ml, which contains tamoxifen at 1 µg/ml (2.7 μM), for 2 hours 
before returning to fresh fish water. And the final group were fed NG1A at a 
concentration of 0.24 µg/ml, which contains tamoxifen at 0.1 µg/ml (0.27 μM) for 12 
hours before returning to fresh fish water. Along side each of these groups, 3 control 
Judith Ray 2014  Chapter 4 
155 
 
groups were also maintained under the same conditions in 6 well plates. Firstly a 
parallel control group was placed in a tamoxifen citrate solution (effectively the free 
drug) of the same concentration of tamoxifen for the same length of time. The second 
control was non tamoxifen loaded nanogel, NG1 (Batch 2), at the same concentration 
of nanogel as NG1A. The final standard negative control were zebrafish in fresh fish 
water, the experiment set up can be seen in figure 66. Twelve 6 dpf ubi:switch 
zebrafish were placed in each solution, the fish were previously sorted for GFP 
fluorescence at 24 hours, removing any fish who did not inherit systemic fluorescence 
and therefore the loxP allele. Therefore the embryos that remained either contained the 
full loxP-creERT system, which turn mcherry on exposure to tamoxifen or just the loxP 
allele which would remain GFP fluorescent regardless of exposure to tamoxifen.  
Drug loaded nanogel 
NG1A (34 µg/ml) 
24 µg/ml nanogel 
10 µg/ml tamoxifen 
Free Drug 
Tamoxifen citrate  (15 µg/ml) 
10 µg/ml tamoxifen 
Treated for 30 minutes  
Controls  
in fish water 
Non-drug loaded nanogels 
NG1 (batch 2) (24 µg/ml) 
24 µg/ml nanogel 
 
 
Drug loaded nanogel 
NG1A (3.4 µg/ml) 
2.4 µg/ml nanogel 
1 µg/ml tamoxifen 
Free Drug 
Tamoxifen citrate  (1.5 µg/ml) 
1 µg/ml tamoxifen 
Treated for 2 hours 
Controls  
in fish water 
Non-drug loaded nanogels 
NG1 (batch 2) (2.4 µg/ml) 
2.4 µg/ml nanogel 
 
 
Drug loaded nanogel 
NG1A (0.34 µg/ml) 
0.24 µg/ml nanogel 
0.1 µg/ml tamoxifen 
Free Drug 
Tamoxifen citrate  (0.15 µg/ml) 
0.1 µg/ml tamoxifen 
Treated for 12 hours 
Controls  
in fish water 
Non-drug loaded nanogels 
NG1 (batch 2) (0.24 µg/ml)   
0.24 µg/ml nanogel 
 
Figure 66- Experiement layout for investigating the release of tamoxifen in juvenile ubi:switch 
zebrafish.  
After 24 hours one fish in the strongest solution of NG1A containing 10 µg/ml tamoxifen 
had died but otherwise all other fish were alive and well. However, no mcherry 
fluorescence could be seen in any of the zebrafish except for the remaining yolk which 
was fluorescing red in every fish at every timeframe. The single fish may have died due 
to a rapid and concentrated internal release of tamoxifen. The lack of mcherry 
fluorescence was not an immediate concern as Mosimann reported a time delay before 
detecting the fluorescence change and only presented images taken 3 days after 
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tamoxifen exposure326. After 48 hours still no mcherry fluorescence was seen in any of 
the samples. However 3 days after the initial exposure to tamoxifen all fish remaining 
were alive and well and 50 % of zebrafish exposed to tamoxifen citrate or NG1A 
contained varying degrees of mcherry fluorescence. This was expected as, statistically, 
half of the fish would have inherited both the cre and loxP alleles required. None of the 
fish exposed to the non-loaded nanogel were expressing mcherry fluorescence and 
neither were any of those maintained in fish water, except the yolk, which was 
fluorescing red in every fish at every timeframe. Images of the fish can be seen in 
figure 67 for the lower two concentrations of tamoxifen, and in figure 68 for the higher 
concentration. This experiement was not fully balanced as not all concentrations were 
administered for the all the timeframes (due to the project deadline) therefore further 
experiments would be required showing the effects of all the variables to fully validate 
these results.  In general fish in all three concentrations of the tamoxifen-loaded 
nanogel showed a stronger mcherry fluorescence than the fish exposed to the free 
tamoxifen citrate at equivalent concentrations. This suggests tamoxifen loaded 
nanogels had successfully triggered the cre recombinase release in the cells more 
successfully than the free drug, therefore improving its bioavailability and confirming it’s 
release. However what triggered the release of the tamoxifen was not clearly identified. 
It is possible that the tamoxifen was released when the nanogels reached the stomach 
of the zebrafish which itself may have a reduced pH, however no information could be 
retrieved on the pH of the stomach. (Although potential reduced pH of the stomach 
could be enabling release of the drug from the nanogels in this in vivo experiment, in 
final use of this nanogel delivery system, the nanogels would be required to be injected 
otherwise tamoxifen would be immediately released when the nanogels reached the 
stomach.) The pH of the zebrafish water was measured before, during and after the 
experiment, and it remained consistently at neutral pH. Zebrafish buffer their own pH to 
maintain neutral pH in cells330. To establish if tamoxifen was released in fish water 
solution, an in vitro experiment was carried out, suspending NG1A in fish water over a 
24 hour period.  
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Figure 67 - ubi:switch zebrafish treated for 12 hours at 0.1 µg/ml tamoxifen, viewed 3 days after 
exposure, A) control immersed in fish water, B) immersed in Tamoxifen citrate, C) immersed in 
NG1A, 0.1 µg/ml tamoxifen loaded nanogel. ubi:switch zebrafish treated for 2 hrs at 1 µg/ml 
tamoxifen, viewed 3 days after exposure, immersed in, D) fish water (control), E) tamoxifen 
citrate and F) NG1A tamoxifen (1 µg/ml) loaded nanogels. 
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Figure 68 – ubi:switch zebrafish treated for 30 minutes at 10 µg/ml tamoxifen citrate, viewed 3 
days after exposure, A and D) control,  no mcherry fluorescence seen  in the body or heart, B 
and E) Tamoxifen citrate, mcherry fluorescence seen everywhere including in the heart, C and 
F) NG1A tamoxifen loaded nanogels, mcherry fluorescence seen everywhere including in the 
heart as indicated by the arrows.  
A 
B 
C 
D E 
F 
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4.4.3.1 Release of tamoxifen from NG1A in fish water 
The preliminary data indicated that tamoxifen loaded nanogels were releasing the drug 
in transgenic zebrafish. However clearly establishing the release trigger required 
further investigation. To eliminate the water required for healthy fish survival as a 
potential release trigger and therefore to confirm that a mechanism operating inside the 
zebrafish was causing the release of the tamoxifen from the nanogel, the nanogel was 
suspended in fish water solution. Using the same method as studying the tamoxifen 
release at pH 7.4, ~6 mg nanogel was dissolved in fish water at 2 mg/ml, divided into 
500 μl dialysis parcels and placed in 1 l of fish water. At the relevant time point one 
parcel was removed, 500 μl ACN was added, the solution was vortexed for 30 seconds 
and 20 μl was injected into the HPLC using exactly the same conditions as before. The 
area under the peak was analysed according to the calibration curve (figure 58) 
obtained in section 4.3.2 and the data point plotted. This data is presented in figure 69. 
 
Figure 69 – Tamoxifen released from nanogel in fish water (0.75g sodium biocarbonate, 0.18g 
marine salts and 0.08g calcium sulphate per 10L water) over 7 hours. Analysis carried out using 
HPLC, eluent used was 95% acetonitrile to 5% water acidified with 0.5% acetic acid at a flow 
rate of 1.5 ml/min.  
This experiment showed no significant amount of tamoxifen being released in the fish 
water from the nanogel and therefore it confirmed that the drug was not being released 
before the nanogel entered the zebrafish. It remained to be investigated whether the 
(possibly) reduced pH in the stomach of the zebrafish, or enzymes in the zebrafish, 
caused release of the tamoxifen from the nanogel. In order to prove release and 
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accumulation of the drug at a target lesion site, the nanogels would need to be 
administered in a mouse model.  
4.4.4 Comparison of the therapeutic effect of tamoxifen loaded 
nanogels over the free drug 
Zebrafish have no breast tissue and therefore analysing real therapeutic effect is not 
possible. However, tamoxifen is lethal to zebrafish and monitoring the time it takes for a 
lethal dose of tamoxifen to cause signs of toxicity to the fish is a valid way to establish 
how quickly the tamoxifen is taken up by the zebrafish.  To analyse the potential 
bioavailability of tamoxifen when loaded onto the nanogels over the free drug in vivo, 
ubi:switch zebrafish were exposed to tamoxifen citrate and NG1A at a lethal 
concentration of tamoxifen (27 μM). For the test sample, NG1A (24 μg/ml, 2.5% 
coumarin tag) containing a 43% loading of tamoxifen, dosed at 10 μg/ml (27 μM) 
tamoxifen was used.  In the first control sample, tamoxifen citrate was used as a free 
drug dosed at 10 μg/ml (27 μM) of tamoxifen. A further control sample was devised, 
having the nanogel (not loaded with tamoxifen) NG1 (batch 2) (2.5% coumarin tag) at 
24 μg/ml.  
Twelve 7 dpf zebrafish were placed in each of the 4 solutions, including the controls, in 
a 6 well plate maintained at 28.5 °C and were monitored regularly under microscope, 
for conventional signs of toxicity such as lack of movement, lying on their side, lack of 
response to touch and death. After 1.5 hours the fish exposed to tamoxifen-loaded 
nanogel, NG1A, were all floating in their solution and were unresponsive to touch, 
showing severe signs of toxicity. Those in all other solutions including that of tamoxifen 
citrate were all healthy showing no signs of toxicity. It was not until 16 hours after 
immersion in the solutions that the fish in tamoxifen citrate showed the same reactions 
to toxicity as those after just 1.5 hours exposure in the tamoxifen-imprinted NG1A. All 
zebrafish in fresh fish water and control nanogel with no loaded tamoxifen, NG1 (batch 
2), were healthy, swimming and highly responsive to touch at 16 hours after exposure. 
These results potentially show that the imprinting of tamoxifen on the nanogel both 
increased the bioavailability (and subsequently, the therapeutic effect) of the drug and 
significantly decreased the lag time before such therapeutic effect was seen in the 
zebrafish. However uptake of the free drug and the nanogel bound drug may have 
been via different routes (and therefore having potentially different therapeutic effects.) 
Therefore although preliminary experiments seem promising, giving indication that 
these NPs should be taken on into further in depth mammalian studies, no final 
Judith Ray 2014  Chapter 4 
161 
 
conclusions on the drug carrier and its efficacy over the free drug can be made. If the 
increased bioavailablilty of the drug when bound to the nanogel is true, along side the 
pH stimulated release, this drug delivery system would provide more precise targeting 
of the drug, with reduced doses of drug required (when loaded onto the nanogels) in 
order for the same therapeutic effect to occur by comparison with larger doses 
conventionally used when administering the ‘free drug’. To pursue these investigations 
in greater depth, and with a closer analogue to human reaction, analysis of the effect of 
these loaded nanogels on both MFC-7 breast cancer cells in vitro and in a mouse 
model with breast tumour growth would be required.  
4.5 Final Conclusions and further work 
Acrylamide based nanogels were identified as a potential drug delivery system, with 
high dilution radical polymerisation giving a practical approach to their formation, in 
particular allowing control over particle size without the need for surfactants.  Evidence 
showed that trifluoromethyl coumarin acrylamide could be successfully incorporated in 
the acrylamide nanogels, giving good levels of fluorescence emission without having 
significant negative effects on particle size or water solubility. Acrylamide based water-
soluble nanogels containing a trifluoromethyl coumarin acrylamide with an average 
particle size of less than 200 nm were successfully synthesised.  
These nanogels were found to be not acutely toxic in keratinocyte cells using several 
different in vitro assays. Uptake of the nanogels into the skin cells was also seen 
visually using confocal microscopy alongside evidence given by flow cytometry. Further 
analysis of the nanogels in vivo in 48 hpf zebrafish embryos showed no acute toxicity 
when administered orally (up to 1mg/ml). Immersion of 2 hpf zebrafish embryos in 
nanogel solutions showed acute toxicity at 1 mg/ml, however this was demonstrably 
due to the high concentration of coumarin which showed acute toxicity to both 2 hpf 
and 48 hpf zebrafish embryos when the free tag was administered. At concentrations of 
0.075-0.025 mg/ml nanogel no acute toxicity was seen on the 2 hpf zebrafish embryos. 
Nanogel did not appear to pass through the lining of the intestine of the zebrafish when 
the immersion technique was applied, at either 2 hpf or 48 hpf. Therefore 36hpf 
zebrafish embryos were injected into the cardinal vein with a 10 mg/ml nanogel solution 
(54 ng per fish), which saw the nanogel circulating the bloodstream of the zebrafish 
before dispersing into the cells. 5 hours after injection the nanogels could be seen 
gathering in the hindbrain of the zebrafish, no nanogel could be seen circulating the 
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zebrafish 12 hours after injection and all fish were alive showing no evidence of acute 
toxicity 7 days after injection. 
Molecular imprinting was identified as a suitable method for the uploading of the drug 
onto the nanogels whilst maintaining control over its release. The ionic interaction 
introduced between tamoxifen and acrylic acid as the functional monomer, evaluated 
by 1H-NMR studies, allowed release of the drug at reduced pH. The drug was 
successfully loaded onto the nanogels with relatively high drug loadings of 19-42%, 
which had excellent encapsulation efficiencies of 92-99.5%. Little drug release from the 
loaded nanogels was observed at physiological pH (7.4 using PBS buffer) whilst 
excellent release was seen at pH 5.5 (in acetate buffer), enabling targeted release in 
tumour cells which have a similarly reduced pH. When the drug-loaded nanogels were 
administered orally to 6dpf transgenic ubi:switch zebrafish, drug release was seen by a 
colour change in fluorescence (from GFP to mcherry). The mechanism of release is not 
yet completely understood. However, release due to the fish water required for their 
survival was ruled out. Zebrafish showed signs of response to toxicity from the 
tamoxifen 14.5 hours sooner, when immersed in nanogel solutions loaded with 
tamoxifen than when the free drug was administered, showing a much faster response, 
and therefore a better therapeutic effect in zebrafish. Although these studies gave 
promising very preliminary results and showed the drug was released in zebrafish, this 
gives no real indication to the release of tamoxifen from the nanogels or the system’s 
therapeutic effect in humans. This system would need to be administered intravenously 
to ensure the nanogels bypassed the stomach (where they would be released 
immediately due to the low pH), therefore the next stage to asses release of the 
tamoxifen from the nanogels in a more in depth study would be to inject the nanogels 
into a mouse model. 
4.5.1 Further work 
The next step for these nanogels would be to carryout in vivo testing on a small 
mammal such as mice. As transgenic mice have also been developed with loxP-
creERT system228 this could prove useful in detecting tamoxifen release and identifying 
tissues in which the drug is released. Efficacy can also be further tested in mice as they 
have breast tissue. It would be possible to grow analogues of breast tumours on mice 
to see if the nanogels continued to show a significant advantage over the free drug in 
reducing the tumours and preventing further growth.  
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These preliminary studies have shown promising results, however there are some 
areas of the system that could be extended. The solubility of the nanogels with the drug 
loaded, is considerably less than those without. This issue needs to be addressed, 
possibly by adding more acetic acid or another highly soluble monomer. Core-shell 
nanogels have been formed using RAFT (reversible addition fragmentation chain 
transfer) polymerisation135, whereby macro chain transfer agents (CTA’s) are formed 
initially and then the macro-CTA’s are polymerised together using a cross-linker. This 
method could be used to load the drug in the centre of the nanogel and putting highly 
soluble groups on the shell aiding the overall solubility and potentially addressing the 
quick release of the drug at the same time. 
The nanogels should also be evaluated for their release at higher pH such as 6.8 for 
tumour cell extracellular environment and the pH’s consistent with both resistant and 
non-resistant breast cancer cells. At this higher pH the drug may also be released at a 
slower rate, giving greater control over its release and giving a more prolonged delivery 
of the drug. Not only this, the molecular imprinting technique could be exploited to 
develop a polymer which contains both a recognition site for a specific ligand or antigen 
which is coupled to an imprinted drug. This could actively target the drug delivery 
carrier to the target site and trigger the release more accurately. In doing this, it may 
also further help control and slow down the release of the drug, achieving a more 
sustained delivery. 
The initial intravenous zebrafish toxicity studies showed the nanogels gathering in the 
hindbrain of the zebrafish, further experiments should be carried out on the zebrafish at 
8 dpf as this is the age when the blood brain barrier is formed. Crossing the blood brain 
barrier is notoriously difficult and therefore, these nanogels could prove to be highly 
beneficial for delivery of drugs to the brain if they do indeed cross the blood brain 
barrier. 
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5. Materials and methods 
5.1 Materials 
5.1.1 Chemicals for the synthesis of dansyl amioethyl acrylamide 
Ethylene diamine (99%), Dansyl chloride (99%), triethylamine (99%) and acryloyl 
chloride (Fluka, 96%) were all purchased from Aldrich Chemical Co. (Gillingham, 
Dorset, UK). Dry Solvents dichloromethane (CH2Cl2) and tetrahydrofuran (THF) were 
supplied from MBRAUN MB SPS-800 solvent purification system. Reactions were 
carried out under an inert atmosphere of nitrogen, at the temperature stated. All 
glassware was oven dried and flamed prior to experimental use. Flash column 
chromatography was performed on reaction mixtures using Fluka silica gel 60 (220-240 
mesh) (Brockmann 2-3). Analytical thin layer chromatography (TLC) was carried out 
using pre-coated aluminium or glass backed plates with Merck Kieselgel 60 F254 and 
the plates were visualized under an ultraviolet lamp at λ = 254/365 nm. 
5.1.2 Chemicals and materials for nanogel synthesis and drug 
incorporated 
Ethylene bisacrylamide (99%), methylene bisacrylamide (99%), acrylamide (99%), and 
Acrylic acid (99%) were all purchased from Aldrich Chemical Co. (Gillingham, Dorset, 
UK). 2,2-azobisisobutyronitrile (AIBN, 98%) was purchased from Acros Fisher Scientific 
UK (Loughborough, Leicestershire) and recrystallized from methanol before use. 
Tamoxifen citrate (98%) was purchased from Cambridge Bioscience (Cambridge, UK). 
Dialysis membrane for nanogel isolation was purchased from Medicell International 
Ltd, 22 mm diameter and molecular cut off 3500 Daltons. Biotech CE membrane 
dialysis tubing used for drug release studies was purchased from VWR (Leicester, UK) 
with a diameter of 16 mm and molecular cut off of 550-1000 Daltons. 
5.1.3 Chemicals for interaction studies via 1H-NMR (400MHz) 
All deuterated solvents for NMR studies were purchased from Cambridge Isotope 
Laboratories Inc. All other solvents used for polymerisation and analytical experiments 
were of analytical grade.   
5.1.4 Chemicals and materials for the kinetic assays 
Anotop™ 10 Plus 0,02 µm syringe filter with a 10 mm diameter and water (HPLC 
grade, BDH Prolabo) were purchased from VWR. Acetonitrile (HPLC grade) was 
purchased from Acros Fischer Scientific UK (Loughborough, Leicestershire, UK).  
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5.1.5 Chemicals for the in vitro studies 
The DMEM/F12, Penicillin/streptomycin solution, FBS and Trypsin/EDTA cell culture 
were purchased from Acros Fisher Scientific UK (Loughborough, Leicestershire). 
Phosphate buffered saline solution, thiazolyl Blue Tertrazolium Bromide (98%), 
dimethyl sulfoxide (99.5%), Lactic Dehydrogenase in vitro toxicity assay kit and 
CellBLIND 96 well plates were all purchased from Aldrich Chemical Co. (Gillingham, 
Dorset, UK). Trypan Blue Stain (0.4%) and Countless Cell counting Chamber Slides 
were purchased from Invitrogen (paisley, UK). 
5.1.6 Chemicals for the in vivo studies 
Sodium bicarbonate and calcium sulphate were purchased from VWR (Leicester, UK). 
Marine salts were purchased from MBK installations limited. PTU, Tricaine 
methanesulfonate (MS-222) and methyl cellulose were all purchased from Aldrich 
Chemical Co. (Gillingham, Dorset, UK). 
5.1.7 Micros-pipettes/ Hamilton syringes: 
Eppendorf micropipettes with volumes ranging from 2-20 μl, 10-200 μl, 100-1000 μl, 1-
5 ml and 1-10 ml were used for forming nanogel solutions for DLS analysis and for fish 
experiments. The accuracy of the volume measured was verified by weight and found 
to be ±1%. Hamilton syringes of 1-10 μl, 5-50 μl, 10-100 μl, 20-250 μl and 50-500 μl 
were used for forming solutions for UV-VIS and Fluorescent spectroscopy experiments 
and used for measuring volumes for drug upload and release studies.  
5.1.8 Instruments 
5.1.8.1 NMR Spectroscopy: 
1H and 13C NMR spectra were recorded on a Bruker AV400 NMR spectrometer. 
Chemical shifts in NMR spectra are reported in δ (ppm) relative to residual solvent 
signals: CDCl3 δH = 7.26 ppm; δc = 77.23 ppm or d6-DMSO δH = 2.50; δc = 39.51. 
H1NMR peak multiplicity were reported as follows = singlet, d = doublet, t = triplet, q = 
quartet, m = multiplet). Coupling constants (J) were measured in hertz. NMR data are 
presented as follows: chemical shift δ (in parts per million (ppm)) integration, 
multiplicity, coupling constant J (in Hz) and assignment. 
5.1.8.2 UV-VIS Spectroscopy: 
UV-Vis samples were analysed using Varian Cary 300 BIO UV_Vis 
Spectrophotometer, equipped with an internal thermostat. 
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5.1.8.3 Fluorescent Spectroscopy: 
All fluorescence data was accomplished on a Flouromax-3. 
5.1.8.4 Zetasizer (Dynamic light scattering): 
DLS measurements were performed in Queen Mary’s School of Materials and 
Engineering on a Malvern Zetersizer Nano ZS. 
5.1.8.5 Freeze-dryer: 
Two freeze-dryers were used, Edwards, super Modulyo and Labcoco FreeZone 6 Litre 
Benchtop Freeze Dry System. 
5.1.8.6 High performance liquid chromatography (HPLC): 
All data was recorded on a manual injector Aglient Technologies 1220 Infinity LC fitted 
with a Hichrom 5 C18 250 x 4.6mm column.  
5.1.8.7 Confocal Microscope: 
Leica SP5 confocal laser scanning microscope 
 
5.2 Methods 
5.2.1 Synthesis of dansyl amino ethyl amine  
 
11 ml (0.16 mol) of ethylene diamine was dissolved in 30 ml of dry THF and stirred. 
1.1g (3.7 mmols) of Dansyl chloride was dissolved in approximately 15 ml of dry 
dichloromethane and added to the mixture drop wise over 1 hour at 0ºC (ice bath). The 
reaction mixture was left stirring at room temperature. TLC monitoring (DCM/Acetone: 
8/2) showed the reaction to be complete after 2 hours. 10 ml of saturated NaCl solution 
was added to the mixture and the majority of the THF was evaporated at reduced 
pressure. The mixture was neutralised with HCl, before being extracted with DCM (3 x 
10ml) The combined organic layers were dried of MgSO4, filtered and evaporated 
under reduced pressure which gave 0.97g of product (solid, pale yellow) (JR_S_07) 
with a yield of 89%. 
(5a) 
Judith Ray 2014  References 
168 
 
C14H19N3O2S 
1H-NMR (CDCl3, 400MHz) δ(ppm), J(Hz):8.47 (d, J=8Hz, 1H, ArH), 8.23 (d, J=12Hz, 
1H, ArH), 8.19 (d, J=8Hz, 1H, ArH), 7.50 (t, J=16, 8Hz, 2H, ArH), 7.45 (t, J=16, 8Hz, 
1H, ArH), 2.85 (t, J=12, 8Hz 2H, -CH2CH2NH2), 2.82  (s, 6H N(CH3)2 , 2.62 (t, 2H J=8, 
12Hz, 2H, -CH2CH2NH2). 
13C-NMR (CDCL3, 100Hz) δ (ppm) 156.53, 140.59, 134.70, 134.53, 134.35, 133.58, 
132.74, 127.97, 123.99, 119.90 (Napthalenyl), 50.85 (-NHCH2CH2NHS-), 50.14 (-
N(CH3)2), 46.22 (-NHCH2CH2NHS-). 
5.2.2 Synthesis of dansyl amino ethyl acrylamide 
  
0.4g (1.37 mmols) of Dansyl amino ethyl amine (2) and 0.21 ml (1.50 mmols, 1.1 eq.) 
of triethylamine were dissolved in 40 ml of dry DCM and stirred. 0.12 ml (1.50 mmols, 
1.1 eq.) of acryloyl chloride was dissolved in approximately 10 ml of dry 
dichloromethane and added to the mixture drop wise over 1 hour at 0ºC (ice bath). The 
reaction mixture was left stirring at room temperature overnight, after which TLC 
monitoring (DCM/Acetone: 8/2) showed the reaction to be complete. The DCM was 
evaporated at reduced pressure and the product was purified by flash chromatography 
(EtOAc/hex: 1/1) which gave 0.3g of product (solid, pale green/yellow) (3) with a yield 
of 65%. 
C17H21N3O3S 
1H-NMR (CDCl3, 400MHz) δ(ppm), J(Hz):8.47 (d, J=12Hz, 1H, ArH), 8.28 (t, J=16, 8.0 
Hz, 2H, ArH), 7.61 (t, J=16, 8Hz, 1H, ArH), 7.56 (t, J=12, 4Hz, 1H, ArH), 7.23 (d, 
J=4Hz, 1H, ArH), 6.22 (d, J=16Hz, 1H, -COCH=CH2), 5.95 (d, J=12Hz, 1H, -
COCH=CH2cis), 5.91 (d, J=12Hz, 1H, CONH), 5.62 (d, J=8Hz, 1H, -COCH=CH2trans), 
5.36 (s, J=12Hz, 1H, SO2NH), 3.41 (dd, J=8, 12Hz, 2H, -CH2CH2NHCO) 3.11 (dd, J=8, 
12Hz, 2H, -CH2CH2NHCO) and N(CH3)2 , 2.97 (s, 6H, N(CH3)2). 
(5) 
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13C-NMR (CDCL3, 100Hz) δ (ppm) 166.22 (-COCH=CH2), 152.20, 134.21, 130.78, 
130.03, 130.00, 129.83, 129.49, 128.68, 126.84, 123.21, 118.50, 115.33 (Napthalenyl, 
- COCH=CH2), 45.41 (-NHCH2CH2NHS-), 43.19 (-N(CH3)2), 39.38 (-NHCH2CH2NHS-). 
13C-NMR (CDCL3,100Hz) δ(ppm): 166.26, 166.06 ((-COCH=CH2)2), 152.28, 134.11, 
131.96, 131.80, 130.75, 130.39, 130.02, 129.47, 129.04, 128.57, 126.53, 123.03, 
117.80, 115.61 (Napthalenyl, (-COCH=CH2)2), 45.61(-NHCH2CH2NHS-), 45.38 (-
N(CH3)2), 39.42 (-NHCH2CH2NHS-). 
5.2.3 General procedure of the nanogel synthesis 
The standard protocol of high dilution radical polymerization was used to prepare 
Tamoxifen imprinted (MIP) and non-imprinted (NIP) nanogels. Both nanogels were 
systhesised using the same conditions. However, polymerization of imprinted nanogels 
took place in the presence of the drug, and the non-imprinted without it. The 
concentration of monomers (CM) was fixed at 0.5% and the percentage of initiatior, 
AIBN, at 2% of the number of moles of double bonds in the polymerization solution. 
The percentage of cross-linker was set at 20 % and acrylic acid at 10 % and TCA at 
2.5 or 5% of the total monomers in the prepolymerisation mixture, with the shortfall 
made up with acrylamide. Tamoxifen (53mg, 1.4x10-4 mol, 1 eq.) acryllic acid (10 mg, 
1.4x10-4 mol, 1 eq.), TCA (20 mg, 7.1x10-5 mol), acrylamide (176 mg, 2.5x10-3 mol), 
MBA (98mg, 6.4x10-4 mol) and AIBN (13 mg, 7.9x10-5 mol) were dissolved in dry 
DMSO (60 g, 54 ml) in a 100 ml Wheaton glass serum bottle. The solution was flushed 
with nitrogen and heated at 70°C for 2 days. (where eq. = equivalent). 
5.2.3.1 nanogel recovery 
After polymerisation the nanogel solution was dialysed against non-distilled water for 
two days, with 2 water exchanges per day unless complete template removal was 
desired at which point the nanogel was dialysed against non-distilled water acidified to 
pH 3 with HCl, the last water exchange was with non-distilled water at normal pH). The 
dialysis membrane used had a pore size of 3500 Daltons. On completion of dialysis the 
solutions were frozen in liquid nitrogen and freeze-dried. Dry, off white to pale yellow, 
very lightweight powders were obtained. 
5.2.4 Nanogel characterization general procedures 
5.2.4.1 Zetasizer  
All fluorescein tagged Nanogels were prepared as 0.1 mg/ml solutions in 1% DMSO 
99% water, all the dansyl tagged nanogels were prepared as 0.1 mg/ml solutions in 
Judith Ray 2014  References 
170 
 
100 % DMSO due to the solubility issue. All coumarin tagged nanogels were prepared 
as 0.1 mg/ml solutions in 100 % water where possible, those unsoluble in water were 
measured in 1% DMSO 99% water. Many samples were measured both with filtration 
(450 nm pore size PTFE filter) and without, however no difference in size was seen. 
Size distribution of the light intensity was calculated using the refractive index of the 
solvents (DMSO nD25 and water nD25 1.33). Volume and number distributions were 
extrapolated from the intensity by adding the refractive index of polymethacrylate 
selected as a reference from the literature (nD25 1.4914 and dn/dλ 0.0575). 
5.2.4.2 TEM 
A 1 mg/ml nanogel solution was prepared to which a 4% OsO4 solution was added at a 
ratio of 4:1 respectively. The combined solution was allowed to rest for 1 hour before 
being dialysed overnight against distilled water. to prevent interference during imaging 
by the presence of excess oxidant. The final solution was diluted 1 in 10 and a drop 
deposited on the 300 mesh carbon coated copper grid and left to dry. Images were 
obtained using a JEOL 1200EX (120kV) with the beam at 90°.  
5.2.4.3 Fluorometer  
For fluorescence analysis of the nanogels, the nanogels were dissolved in different 
solvents. The fluorescein containing nanogels were dissolved in 10 % ethanol and 90 
% distilled water at 0.01 mg/ml. The dansyl containing nanogels were dissolved in 100 
% ethanol at 0.01 mg/ml. The coumarin containing nanogel were all formed with 100 % 
DMSO at 1 mg/ml and 0.1 mg/ml. 2 ml of each solution was placed in a 4 sided quartz 
cuvette and measured for fluorescence intensity using their excitation wavelengths of 
307 nm for dansyl, 490 nm for fluorescein and 345 nm for the coumarin tag. The 
emission of the nanogels were read at 470, 516 and 460 nm respectively. 
 
5.2.5 Fluorescent tag incorporation studies 
5.2.5.1 Calibration curves 
Incorporation of fluorescent tags into the nanogels were evaluated by mean of 
calibration curves obtained via UV-Vis spectroscopy. Three stock solutions of 
dansylaminoethylamine, Fluorescein-0-methacrylate and trifluoromethyl coumarin 
amine were prepared independently by weight in DMSO. The three stock solutions 
were then cross-diluted to create 9 solutions of varying concentrations with a UV-Vis 
absorption range between 0 and 1. The absorption maximum of 1 ml (maximum 
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volume inside the spectrophotometric cuvette) of each solution was measured by UV-
VIS spectrometry at 339 nm for dansylaminoethylamine solutions, 490 nm Fluorescein-
0-methacrylate solutions and 386 nm for trifluoromethyl coumarin solutions. The 
absorptions were plotted against their relevant concentrations and where possible the 
data was fitted to a linear regression passing through the origin using sigma plot 8.0. 
The determination of the molar absorption coefficient εmax at pH 14 was determined 
using the Beer-Lambert Law, defined by the following equation: 
 
A = ι ε c   Equation 1 
Where A is the absorption maximum, ε  is the molar absorption coefficient, l is the 
length of the cuvette (1 cm) and c is the concentration inside the cuvette. The molar 
absorption coefficient for each fluorophore was determined via the slope of the linear 
curve obtained.  
 
To establish the incorporation of fluorescent tag into the nanogel, nanogels were 
weighed accurately at 0.35 mg and dissolved in 2 mls DMSO. 3 dilutions of the stock 
solution were formed and the maximum absorption were read at the same wavelength 
as at their respective fluophore’s calibration curve (339, 490 or 386 nm). The extention 
coefficient from the reference curve of the relevant fluorophore was compared to the 
concentration of nanogel prepared in mg/ml, to establish the mole/mg of tag in the 
nanogel (equations 15 and 16). The theoretical value of moles of tag per mg of 
nanogel, if 100% incorporation had been achieved, was also calculated taking into 
consideration both the chemical and percentage yield (equation 17).  The final 
incorporation of tag into the nanogel was achieved by comparing the two results 
(equation 18). At least 3 different samples of each nanogel were analysed and the 
average incorporation was reported.  
	  !!"!" 𝑜𝑓  𝑛𝑎𝑛𝑜𝑔𝑒𝑙  𝑠𝑜𝑙𝑢𝑡𝑖𝑜𝑛 = !!" 𝑥10!!  Equation 14 
	  
	  𝑐!"(!"#) = !!"/!"!!"/!"    Equation 15 
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𝑐!"(!!!") = !!"×  %  !"#$%  !!"!#$%     Equation 16 
 
	  %  𝑖𝑛𝑐𝑜𝑟𝑝𝑜𝑟𝑎𝑡𝑖𝑜𝑛 =    !!"(!"#)!!"(!!!")   ×100  Equation 17 
	  
where	  nFM	  =	  no.	  of	  moles	  of	  functional	  monomer,	  mFM	  =	  mass	  of	  functional	  monomer,	  CFM(exp)	  =	  
concentration	  of	  functional	  monomer	  determined	  experiementally,	  CFM(theo)	  =	  concentration	  of	  
functional	  monomer	  determined	  theoretically,	  mnanogel	  =	  final	  mass	  of	  nanogel	  obtained	  and	  %	  
yield	  =	  final	  percentage	  yield	  obtained	  of	  the	  nanogel.	  
 
5.2.6 Tamoxifen acetic acid interaction studies via 1H-NMR 
Proton, 1H-NMR, spectra were record at 400MHz on a Bruker	  AV400	  NMR	  spectrometer.	  
A	   stock	   solution	  of	  Tamoxifen	  was	  prepared	   in	  d6-­‐DMSO	  at	  a	   concentration	  of	  7.1x10-­‐2	  mM.	  
Increasing	   quantities	   of	   acetic	   acid	   were	   added	   to	   the	   tamoxifen	   solution	   from	   0	   to	   128	  
equivalents	  recording	  the	  spectra	  after	  each	  addition.	  The	  variation	  in	  chemical	  shift	  ΔδHta	  of	  
the	  protons	  of	  the	  two	  methyl	  groups	  bound	  to	  the	  nitrogen	  in	  tamoxifen	  was	  calculated	  and	  
plotted	  against	  acetic	  acid	  concentration.	  The	  data	  obtained	  was	  fitted	  into	  a	  hyperbola	  curve	  
using	   sigma	   plot	   8.0	   software	   and	   the	   binding	   constant	   was	   determined	   using	   the	   ligand	  
binding	  equation	  as	  follows:	  
	  
Δ𝛿!"# = !∗!!!!∗!    Equation 18 
	  
Where	  ΔδHta	  is	  the	  variation	  of	  chemical	  shift	  of	  the	  methyl	  hydrogens	  adjacent	  to	  the	  nitrogen	  
on	  tamoxifen,	  x	  is	  the	  concentration	  of	  acetic	  acid,	  B	  is	  the	  association	  constant	  of	  the	  complex	  
formation	  and	  A	  is	  a	  constant.	  	  
 
5.2.7 Drug upload and release experiments  
5.2.7.1 Tamoxifen calibration curve achieved via HPLC 
Concentrations of tamoxifen uploaded onto the nanogels was evaluated by means of 
calibration curve established using HPLC. Three stock solutions of tamoxifen at 
different concentrations were prepared independently by weight in acetonitrile. The 
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solutions were cross diluted to generate 9 solutions with different concentrations 
ranging from 0.1 to 1 mM. 20 µl of each solution was injected into the HPLC using an 
eluent of 95:5 acetonitrile to water acidified at 0.5% (v/v) with acetic acid at a flow rate 
of 1.5 ml/min (creating a pressure of approximately 86 bar). Tamoxifen eluted at 
approximately 7 minutes and the area under the curve was plotted against 
concentration to form a reference curve. Thus obtaining a value for b in the equation: 
 
 y=bx+c     Equation 19 
Where	  y=	  area	  under	  the	  curve,	  x	  =	  concentration,	  b	  =	  slope	  of	  the	  curve	  and	  due	  to	  the	  curve	  
passing	  through	  the	  origin	  c=0.	  	  
5.2.7.2 Determination of tamoxifen loading 
The nanogel was dissolved in acetonitrile to release the drug from the drug delivery 
system at a concentration of 1 mg/ml of nanogel. The solution was stirred rapidly for 5 
minutes before being filtered through a 20 nm PTFE filter to remove the nanogel. 20 μl 
of the solution was injected into the HPLC using the same eluent and flow rate as used 
to obtained the calibration curve. This was carried out in triplicate with three 
independent samples. The area under the curve gave a value for Y in equation 19 and 
b could be substituted from the slope of the calibration curve hence giving the 
concentration of tamoxifen present in the sample.  
5.2.7.3 Tamoxifen release studies  
5.2.7.3.1 Establishing maximum drug release at pH 3 
Drug loaded nanogels were dialysed for 2 days in water acidified to pH 3 with HCL with 
water exchanged 4 times within that period. The final water exchange was with distilled 
water at neutral pH. The nanogels were frozen in liquid nitrogen and freeze-dried. The 
newly isolated nanogels were dissolved in acetonitrile at 1mg/ml and stirred rapidly for 
5 minutes before being filtered through a 20 nm PTFE filter and 20 µl was injected into 
the HPLC using the same eluent and flow rate as before. The area under the curve 
was once again compared to the slope of the calibration curve to give the concentration 
of tamoxifen that remained in the nanogels. 
5.2.7.3.2 Establishing drug release at pH 5.5 in acetate buffer 
643 ml sodium acetate trihydrate solution (1.36 g in 1 L, 0.01 M) was added to 357 ml 
acetic acid (0.01 M), diluted 1 in 10 and brought to pH 5.5 with NaOH (0.01 M) to 
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create a 1 mM acetate buffer solution. 1 L of the 1 mM buffer solution was heated to 37 
°C. Approximately accurately 6 mg nanogel was dissolved in the buffer at a 
concentration of 2 mg/ml, the mixture was stirred for 30 seconds. 100 µl of the mixture 
was immediately removed and 100 µl of acetonitrile was added, vortexed for 30 
seconds and filtered through a 20 nm PTFE filter. 20 µl was injected into the HPLC 
using the same eluent and flow rate as the calibration curve achieved. The remaining 
nanogel was placed on dialysis (tubing was 500-1000 Daltons cut off) in the heated 
buffer solution with samples being taken and treated in the same way as the sample 
taken immediately (time 0 hr) at time 20, 30 and 45 minutes and 1, 2, 3, 5 and 7 hours.  
Dialysis buffer was exchanged for fresh heated buffer at 4 hours. The dialysis bag was 
inverted several times before each sample was taken to ensure a representative 
sample was analysed. This was carried out in triplicate with three independent samples 
of each nanogel.  
 
5.2.7.3.3 Establishing drug release at pH 7.4 in phosphate buffer 
Potassium chloride (0.2 g) disodium hydrogen phosphate (1.44 g) and potassium 
dihydrogen phosphate (0.24 g) were dissolved in 1 L distilled water to form a 10 mM 
solution. The buffer was diluted 1 in 10 and brought to pH 7.4 with NaOH (0.01 M) to 
create a 1mM phosphate buffer solution. 1 L of the 1 mM buffer solution was heated to 
and maintained at 37°C. Approximately accurately 6 mg nanogel was dissolved in the 
buffer at a concentration of 2 mg/ml, the mixture was stirred for 30 seconds before 
being divided into 500 µl volumes and each being added to a separate length of 
dialysis tubing (500-1000 Daltons), all ‘parcels’ were added to the same heated buffer 
solution (except sample for time 0). At relevant time points, one ‘parcel’ of 500 µl of the 
mixture was removed and 500 µl of acetonitrile was added, vortexed for 30 seconds 
and filtered through a 20 nm PTFE filter. 20 µl was injected into the HPLC using the 
same eluent and flow rate as the calibration curve achieved. Samples were removed at 
time 0, 20, 30 and 45 minutes and 1, 2, 3, 5 and 7 hours.  Dialysis buffer was 
exchanged for fresh heated buffer at 4 hours. This was carried out in triplicate with 
three independent samples of each nanogel.  
 
5.2.7.3.4 Establishing drug release in fish water 
Fish water, comprised of sodium bicarbonate (75 mg/L), marine salts (18 mg/L) and 
calcium sulphate (8.4 mg/L) in reverse osmosis (R/O) purified water, was formed and 1 
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L was heated to 37 °C. Approximately accurately 6 mg nanogel was dissolved in the 
fish water at a concentration of 2 mg/ml, the mixture was stirred for 30 seconds before 
being divided into 500 µl volumes and each being added to a separate length of 
dialysis tubing (500-1000 Daltons). All ‘parcels’ were added to the same heated buffer 
solution (except sample for time 0). At relevant time points one ‘parcel’ of 500 µl of the 
mixture was removed and 500 µl of acetonitrile was added, vortexed for 30 seconds 
and filtered through a 20 nm PTFE filter.20 µl was injected into the HPLC using the 
same eluent and flow rate as the calibration curve achieved. Samples were removed at 
time 0, 20, 30 and 45 minutes and 1, 2, 3, 5 and 7 hours.  
5.2.8 In vitro assays 
All the experiments were performed in triplicates. 
5.2.8.1 Alamer blue assay 
The immortalized human keratinocyte cell line N/Tert-1 was used as model to test the 
cytotoxity and the cellular uptake of JR P240 nanogel. To test the cell viability the 
sample P240 cells was dispersed in medium (DMEM-F12 modified) at  5, 10, 20, 40, 
50 µg/ml and used to treat a minimum of 2x105 cells/well previously seeded in 12-well 
plates. After 24, 48 and 96 hours at 37 °C  AlamarBlue Assay was performed. The 
reagent, an oxidative-reductive indicator that fluoresces or changes colour as a result 
of cells growth, was added to treated and untreated cells and incubated for a minimum 
of 2 hours at a concentration as suggested by the vendor. The change from oxidized 
(non-fluorescent, blue) form to reduced (fluorescent, red) form of the indicator 
was monitored at 530-560 nm excitation wavelength and 590 nm emission wavelength 
and the results were reported as the percentages of viable cells respect to the negative 
control.  
5.2.8.2 MTT assay 
To test cell viability each sample (NG1(batch1) and NG2(batch1)) was dispersed in 
medium at 10, 25, 50, 100, 200 µg/ml and used to treat a minimum of 3000 cells/well 
previously seeded in 96-well plates. After 24, 48 and 72 hours MTT test was performed 
using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide to treat the cells for 
2 hours at room temperature. The reaction was stopped using Dimethyl Sulfoxide and 
each assay plate was read at Thermo Scientific Varioskan Flash Multimode Reader at 
570 nm. Tested samples were compared to negative controls and reported as a 
percentage of the negative control.  
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5.2.8.3 LDH assay 
Membrane damage was measured at 10, 25, 50, 100, 200 µg/ml of nanogel 
(NG1(batch1) and NG2(batch1)) dispersed in medium which was applied to a minimum 
of 3000 cells/well previously seeded in 96-well plates. After 4, 8, 24, 48 and 72 hours 
supernatant aliquots from previously treated 96-well plates were transferred to new 
plates, centrifuged and used to perform Lactate Dehydogenase Assay. The samples 
were incubated at room temperature for 20 minutes, then emission was recorded 
Thermo Scientific Varioskan Flask Multimode Reader at 690 nm (background reading) 
and 490 nm (sample reading). Tested samples were compared to emission of negative 
control and reported as a percentage of emission of negative control. 
5.2.8.4 Cellular uptake 
The cellular uptake was observed by confocal microscopy of the fluorescent nanogels 
and FACS. At a concentration of 200 ug/mL, the nanogels were detected in the 
cytoplasm of the N/Tert keratinocytes after 2 hours of incubation in DMEM/F12 media 
(without phenol red present). The cells were washed with PBS before being fixed for 
FACS analysis, for which the Pacific blue channel (corresponding to 405 nm excitation 
and 455 nm emission) was used. 
For confocal microscopy after 2 hours incubation and washing, the cells were seeded 
on cover slips in 12 well plates for confocal imaging. When the cells were 60-70% 
confluent, fluorescent nanogels (NG1(batch2) and NG2(batch2)) were added to the 
media and incubated for 2 hours. Cells were then washed with PBS and fixed with 4% 
paraformaldehyde and confocal microscopy imaging (Zeiss 510) was performed at 405 
nm and emission read at 450 nm.  
	  
5.2.9 In Vivo experiements 
All fish were maintained at 28.5 °C in ‘fish water’ which is a salt water solution 
comprised of sodium bicarbonate, marine salts and calcium sulphate in a ratio of 
7.5:1.8:0.84 g in 100 L of reverse osmosis (R/O) purified water. All test solutions were 
formed using fish water. Adult fish were maintained on a 14 hr / 10 hr light dark cycle 
following standard husbandry protocols. Embryos/larvae used for in vivo nanogel 
analysis were maintained at 28.5 °C in the dark. Casper Fish were bred in-house and 
were generated from established casper breeders in our facility. Ubi:switch transgenic 
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zebrafish were acquired from University College London fish facility and quarantined 
for one month prior to use. For breeding fish were housed in pairs (1 L tanks) overnight 
with a clear divider separating tank-mates to facilitate identification. Embryos were 
collected within 2 hpf and placed in separate petri-dishes (n*40/dish). All groups were 
age and sex matched before testing. During this time, fish from each treatment group 
were housed in groups of ~10 per tank (5 L). All procedures were carried out under the 
Animals (Scientific Procedures) Act, 1986, and under local ethical guidelines (Queen 
Mary, University of London). 
5.2.9.1 Immersion administration 
For toxicity assessment Casper embryos were collected and sorted at 2 hpf. 
5.2.9.1.1 Experiements carried out at 2 hpf 
2 hpf casper embryos were placed in 2ml of test solution in a 24 well plate (one embryo 
per well). The embryos were monitored for signs of nanogel up take (via fluorescent 
microscope) and for signs of acute toxicity (such as oedema or curvature of the 
notochord) or death every 24 hours. The embryos were exposed to the required 
solutions for 24 hours (unless otherwise stated) before being returned to fresh fish 
water. 
5.2.9.1.2  Experiments carried out at 48hpf 
48 hpf casper embryos were placed in 10ml of test solution in a 6 well plate (6 embryos 
per well). The embryos were monitored for signs of nanogel up take (via fluorescent 
microscope) and for signs of acute toxicity (such as oedema or curvature of the 
notochord) or death every 24 hours. The embryos were exposed to the required 
solutions for 7 days (unless otherwise stated) before being returned to fresh fish water. 
When sufficient up take of the nanogels was seen, the fish were analysed live, whilst 
anesthetized using MS222, via confocal microscopy. 
5.2.9.1.3 Fluorescence quenching studies in 36 hpf Casper embryos 
100μl of 10mg/ml solutions of nanogels (NG1(batch2) and NG2(batch2)) were added to 
20 homogenized 36hpf Casper zebrafish embryos in a 96 well plate, with 5 repetitions 
for each nanogel. The fluorescence was measured on the plate reader. After 24 hours 
maintained at 28.5°C the fluorescence was measured again.  
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5.2.9.2 Intravenous administration 
Casper embryos were maintained in a petri dish until 36 hpf. The embryos were then 
anesthetised with MS222 and dechorionated. The embryos were immobilized on a 
microscope slide using a 5% methyl cellulose and injected with a 10mg/ml solution of 
JRP240 into the cardinal vein blood pool just above the heart using the fluorescent 
microscope fitted with the micro injector. The fish were monitored for the first 30 
minutes using the fluorescent microscope. The fish were monitored for nanogel 
distribution under the confocal microscope at 1, 2.5, 4, 5, 6, 12, 18, 24 hours after 
injection and every 24 hours after that until the experiment was terminated at 7 days 
after injection. During observation under the confocal microscope, fish were 
anesthetised with MS222 and immobilized using methyl cellulose where necessary.  
 
Injection concentration was calculated by measuring droplet size produced by the glass 
needle inserted in the micro-injector using a grid embedded in the eyepiece of the 
microscope. Under the same magnification a ruler was placed under the microscope to 
measure the size of the grids, which can then be used to calculate the radius of the 
droplet. The volume of the droplet could be determined using volume of a sphere: 
 
!!𝜋𝑟!     Equation 20 
 
where	  r	  =	  the	  radius	  of	  the	  droplet.	  
The mass of nanogel can then be calculated using the volume and concentration of the 
solution injected. 
5.2.9.3 Drug release studies in transgenic zebrafish 
A heterogeneous loxP (-Tg(3.5ubb:loxP-EGFP-loxP-mcherry) adult zebrafish was 
crossed with a heterogenous creERT2 (-Tg(3.5ubb:creERT2,my17:EGFP) zebrafish to 
produce ubi:switch embryos in a 1 L tank with a clear divider, removed immediately 
prior to the start of the light cycle. Embryos were collected, sorted and maintained at 28 
°C. At 24 hpf fish who did not show all over GFP fluorescence were removed from the 
test sample. 6 dpf ubi:switch embryos were placed in 10ml of test solution in a 6 well 
plate (12 embryos per well). The three solutions used for analysis were nanogel NG1A 
(34 μg/ml, 10 μg/ml tamoxifen, 24 μg/ml nanogel), NG1 (24 μg/ml) and tamoxifen 
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citrate (15 μg/ml, 10 μg/ml tamoxifen). Where 29% of NG1A (by weight) was 
tamoxifen, 71% was nanogel. These were all formed in fish water and diluted with fish 
water to gain lower concentrations where necessary. The embryos were monitored for 
signs of tamoxifen exposure (via fluorescent microscope) and for signs of acute toxicity 
(such as oedema or curvature of the notochord) or death every 24 hours. The embryos 
were exposed to the required solutions for 30 minutes, 2 hours or 12 hours according 
to the strength of solution they were exposed to, before being returned to fresh fish 
water.  
5.2.10 Isolation of tamoxifen from it’s citrate salt  
Tamoxifen citrate (2 g) was ‘dissolved’ in a sodium carbonate solution (160 ml, 10 mM) 
and extracted with chloroform (3x120 ml). The extracts were dried over MgSO4 and 
evaporated to dryness.  
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